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Immunoglobulin G1 monoclonal antibodies (IgG1-mAbs) are one of the most important 
and fastest growing class of biotherapeutic agents. These mAbs are being used to treat a wide range 
of medical conditions such as cancer, macular degeneration, autoimmune diseases, rheumatoid 
arthritis, etc. Antibodies are dynamic molecules and their dynamic nature governs their 
physiological and biological functions. Antibodies are protein based drugs and are prone to both 
physical and chemical degradation in vitro. The biggest concerns related to IgGs mAb stability is 
their propensity to form protein aggregates (at low and high protein concentrations) and transient 
protein-protein interactions at high protein concentrations leading to dramatic increase in solution 
viscosity. Predicting protein stability and mapping protein interactions at high protein 
concentrations remains some of the most desirable long term goals of protein formulation 
development. 
 This dissertation’s second chapter focused on exploring the utility of hydrogen exchange 
mass spectrometry (HX-MS) in predicting stability profile of an IgG1 mAb, mAb-4, upon addition 
of various destabilizing phenolic antimicrobial preservatives (APs). The trends in mAb-4’s 
physical stability measurements using differential scanning calorimetry and extrinsic fluorescence 
spectroscopy (thermal stability) and size exclusion chromatography (aggregation propensity) 
showed correlations with significant increases in local flexibility of the aggregation hot-spot 
peptide segment in the CH2 domain of mAb-J (HC 237-254) upon addition of APs. Most 
hydrophobic AP (m-cresol) caused the greatest decrease in physical stability of mAb-4 and also 
the biggest increase in the local flexibility of CH2 domain peptide hot-spot of the antibody. Global 
deuterium uptake by mAb-4 was also highest in the presence of m-cresol, followed by phenol, 
phenoxyethanol and benzyl alcohol.  
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In the third and fourth chapter, the effect of different solution and environmental variables 
on viscoelastic behavior and propensity of concentration-dependent self-association of two IgG1 
mAbs was tested. One of the IgG1 mAbs, mAb-C showed a primarily hydrophobic interaction 
driven protein association behavior, however, the other IgG1 mAb, mAb-J, showed a distinct 
association mechanism where the antibody monomers associated through electrostatic attractive 
interactions. A novel HX-MS methodology was developed to map protein-protein interaction 
interfaces of transient intermolecular antibody associations at high protein concentrations. 
Antibody solutions of low (non-associating) and high protein concentrations (associating) were 
lyophilized and reconstituted directly in D2O solutions to initiate HX process directly at target 
concentrations.  
Protein interface of mAb-C reversible self-association was confined in the relatively 
hydrophobic VH and VL domains of the antibody that spanned its CDR2H and CDR2L loops, 
indicating towards a Fab-Fab interaction drive association event. HX-MS also revealed distant 
dynamic coupling effects of mAb-C association in the form of significant increases in local 
flexibility of certain peptide segments in the VH and CH2 domains of the antibody. HX-MS analysis 
of mAb-J reversible self-association revealed one of the interfaces in the VH and VL domain 
(positively charged, spanning CDR3H and CDR2L) and other interface in the CH3 domain of the 
antibody (negatively charged). Hence, HX-MS can provide a robust solution to protein physical 
stability prediction for rational design of protein formulation strategies and high-resolution 
protein-protein interaction interface mapping at high protein concentrations for engineering mutant 
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Intermolecular protein-protein interactions can play a key role in determining both the efficacy 
and safety of biopharmaceutical candidates. Reversible self-associations and irreversible 
aggregation of biotherapeutic agents can present serious challenges related to product formulation 
development, process control and regulatory concerns regarding safety and immunogenicity of the 
product1,2. The work presented in this thesis will primarily focus on one subclass of biotherapeutic 
protein drugs, immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs). Monoclonal antibodies 
are one of the fastest growing class of biotherapeutic drug products with the greatest number of 
potential candidates in a clinical phase3. Monoclonal antibodies are produced from the 
immortalized clones of single B plasma immune cells. Due to the nature of their origin, mAbs 
exhibit mono-specificity towards their targets and this property is exploited to develop highly 
potent and efficacious antibody based therapies for cancer, autoimmune, inflammatory and 
metabolic conditions.  
The first segment of this introductory chapter will focus on the underlying mechanisms of 
protein-protein interactions and the fundamental physical underpinnings responsible for such 
phenomenon. Emphasis will be given to the effect of conformational dynamics, colloidal 
interactions, surface exposure and distribution of charged and apolar residues, protein 
concentration and solution environment on the nature and extent of protein-protein interactions. In 
the second section we will discuss the role of protein-protein interactions in governing protein 
stability from a pharmaceutical perspective. Particular emphasis will be given to high protein 
concentration solutions of mAbs and factors that negatively impact protein production and 
formulation development under crowded environments. Finally, traditional and novel/emerging 
analytical tools used for characterization of protein-protein interactions at high protein 
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concentrations will be discussed. In addition, basics of hydrogen exchange mass spectrometry 
(HX-MS) will be briefly explained with a focus on the utility of a novel lyo/recon HX-MS method 
in mapping interfaces of transient protein-protein interactions under crowded solution conditions 
(high protein concentration). 
 
1.2 Intermolecular Protein-Protein Interactions 
 Protein-protein interactions are integral to many biochemical processes in vivo. Intra and 
extracellular functions are usually carried out by large molecular machineries composed of several 
protein partners organized through protein-protein interactions4. These interactions between 
proteins are usually specific in nature and culminate into a form exhibiting a specific biological 
function. Such contacts are also known as functional contacts5,6. These intermolecular interactions 
however, are not always beneficial and productive for a biological system. Many protein-protein 
interaction events in vivo are deleterious and aberrant. Such abnormal intermolecular interactions 
are either a consequence of protein complex formation at an improper time and location or due to 
non-specific interactions between misfolded/conformationally distorted sub-fractions of 
functional proteins, invoking either an immune response from the body or discontinuing important 
biological processes like signal transduction7. Unwanted protein-protein interaction events are the 
basis of a multitude of diseases including but not limited to Alzheimer’s disease, Huntington’s 
disease and prion disease. Protein-protein interactions can follow multiple pathways and can be 
categorized based on their strength, nature of interaction partners and nature of non-covalent 





1.2.1 Classification of Protein-Protein Interactions 
1.2.1.1 Homo-Oligomers vs. Hetero-Oligomers 
 Protein complexes that involve only one type of monomeric unit are classified as homo-
oligomers. Hetero-oligomers consist of non-identical members which can either be monomers or 
oligomers of a different protein molecule. Depending upon the nature of the protein interaction 
interface, homo-oligomers can be further sub-categorized into isologous oligomers and 
heterologous oligomers. Isologous homo-oligomers involve identical protein interfaces between 
every interacting partner. Isologous associations generally give rise to defined complexes of finite 
members. Heterologous associations although they involve the same class of protein monomers, 
do not share the same protein interface. Such associations, if lack cyclical symmetry, may give 
rise to isodesmic association.  
 
1.2.1.2 Transient vs. Permanent Associations 
 Protein-protein interactions can also be categorized based on the time-scale of association. 
Permanent associations, as the name suggests, have very high binding affinities and appear to be 
irreversible over the entire experimental time-scale. Rate of association (kon) for permanent 
interactions is significantly higher compared to rate of dissociation (koff). Transient associations, 
however, are weaker and thus can dissociate at a much faster rate. The rate of association and 
dissociation can change upon application of an external stress (or other trigger) that affects 
association equilibrium7. Transient protein-protein interactions can further be subdivided into 
weak and strong interactions. Transient interactions, which are also the main focus of this thesis, 
exhibit dynamic equilibrium in solution. The direction of the equilibrium depends upon many 
factors including protein conformation, global/local dynamics, physiochemical properties of the 
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protein, as well as, solution variables such as pH, temperature and ionic strength. The interaction 
interface of weak transient protein-protein interactions tend to be smaller and have fewer contact 
points9-11. Strong transient protein-protein interactions also are present in an equilibrated state, 
however, an external molecular trigger needs to be introduced to the system to shift the equilibrium 
towards the dissociated, monomeric state. Strong transient associations usually involve larger 
conformational changes in the protein structure and may elicit biological processes like signal 
transduction.  
 
1.2.1.3 Native vs. Non-Native Associations 
 Protein conformation is a significant driver of protein-protein interactions. Proteins can 
associate in both native and non-native states. Amino acid content, chemical nature of surface 
exposed residues, solution properties and external stresses dictate the association route that the 
protein will undertake, especially for in vitro studies in various solutions12. Both native and non-
native associations can be reversible or irreversible in nature. Hemoglobin, a tetramer, is an 
example of native association of very high affinity, in which the protein remains in its complexed 
form under a wide range of solution conditions and effectively appears irreversible except at very 
low concentrations. Antibodies, on the other hand, can undergo reversible oligomerization in their 
native form, and such associations are weak and can disrupt upon changes in protein concentration 
and solution properties13-17.  
Proteins are dynamic in nature undergoing continued breathing motions and global/local dynamic 
changes in flexibility. Due to sub-molecular dynamical motions, the solvent accessibility of apolar 
residues (which are primarily buried in the core of proteins) increases. The amount of time these 
apolar residues spend exposed to the solvent under native conditions is relatively slight, however, 
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under stressed conditions, this time-span can increase, leading to non-native contacts between 
protein molecules in solution18. Such complexes can be reversible or irreversible. Strong contacts 
between apolar residues between molecules can also lead to further distortion of the 
conformational integrity of the protein structure which leads to formation of nuclei and eventually 
to generation of extensive levels of non-native irreversible oligomerization18-21. 
 
1.2.1.4 Covalent vs. Non-Covalent Associations 
 Protein intermolecular interactions can also be distinguished based on the nature of the 
interactions that exist at the interface of association. Native and non-native interactions between 
protein partners can be established by both covalent bonds and non-covalent interactions. Covalent 
interactions between protein molecules are rare in nature, except for disulfide bonds. They do 
however, play an important role in biological functions such as post-translational modifications 
(ubiquitination and SUMOylation etc.). Certain covalent bond formations can also lead to protein 
aggregation and degradation. Under alkaline conditions and reducing environments, disulfide 
bonds are labile and can degrade to give rise to deprotonated free thiols. Direct attack of hydroxyl 
anions on sulfur can degrade disulfide bonds to form thiolate anions which eventually attack 
another disulfide bond to form non-native thiolate dimers22. The presence of free thiols under 
native, oxidative environments can lead to the formation of non-native intermolecular disulfide 
bonds, causing covalent oligomerization of protein molecules, via mixed disulfide exchange 
reactions.23 
 Non-covalent interactions between and within protein molecules (i.e., inter and 
intramolecular protein associations) are weak in nature (1-5 kcal/mol). They are widely prevalent 
in biology. For example, their formation assists in protein folding and function24,25. Depending 
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upon amino acid variability, surface distribution, chemical nature of the amino-acids and solvent 
exposure, folded protein molecules can associate with each other through a number of different 
types of non-covalent interactions26. Protein concentration also plays a significant role in 
determining the extent and kinetics of non-covalent associations. Protein-protein interactions 
initiated by non-covalent interactions are usually transient and are disrupted upon dilution or upon 
varying the solution conditions (depending upon the nature of non-covalent interactions)27. In the 
subsequent section of this introduction, various type of non-covalent interactions that initiate and 
stabilize protein-protein interactions will be briefly discussed. 
 
1.2.2 Types of Non-Covalent Interactions   
1.2.2.1 Electrostatic Interactions 
 Electrostatic interactions exist between and among cations and anions which are species 
with integral charge. These type of forces can be attractive or repulsive depending upon the nature 
of the charge on the interacting partners. Electrostatic attractive interactions play an important role 
in protein folding and biochemical processes involving intermolecular protein associations where 
oppositely charged amino acid side chains form salt bridges. 
 Electrostatic potential or electrostatic force is formally given by Coulomb’s law28: 
                                                                𝐹𝐸 =
𝑘𝑒𝑞1𝑞2
𝜀𝑟2
                                                              (1.1) 
Where FE is the electrostatic force, measured in Newtons, q1 and q2 are two formal point charges 
in solution, measured in Coulombs, ke is the Coulomb’s constant (9.0 x 10
9 N m2/C2), r is the 
distance between the charges in meters and ε is the dielectric constant of the solution in which the 
two charges are placed. FE, electrostatic force is thus defined as an interaction between charges 
that are paired or pairwise interaction
29. Dielectric constant reflects the tendency of the solution to 
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reduce the coulombic force between the point charges relative to a vacuum. The dielectric constant 
of a vacuum is 1 and that of water is 78.3 at 25°C, measured in Farads per meter (F/m)30. Compared 
to vacuum, water is very efficient at shielding and reducing the force between point charges. Since 
the interior of a protein is relatively apolar, the dielectric constant of the interior of a protein is 
relatively low compared to water and though to ranges from 1 to 20 F/m31. In biological systems 
where the proteins are present in crowded environments, it is extremely difficult to accurately 
determine the dielectric constant of the solution in the immediate vicinity or within a protein. 
Dielectric constants of micro-environments are variable and accurately modelling such values for 
molecular mechanics force fields is an active area of investigation32. 
 
1.2.2.2 Dipolar Interactions 
 Dipole formation is based on the concept of separation of charge. Electronegativity is a 
measure of dipole strength which is simply defined as the tendency of an atom to attract electrons 
towards itself. In a molecule containing atoms of varying values of electronegativity, atoms with 
higher electronegativity carry a partial negative charge and other atoms of lower electronegativities 
carry a partial positive charge. This separation of charges within a molecule makes the bond 
between the atoms, polar. The magnitude of the polarity of a molecule is given by its dipole 
moment, which depends upon the distance of charge separation as well as the magnitude of the 
partial charges. The unit of dipole moment is Debye. The potential energy for dipolar interactions 
is given by equation 1.229.  
                                                               𝑉 = −
2𝜇1𝜇2
4𝜋𝜀𝑟3
                                                           (1.2) 
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Where V is the potential energy associated with a dipolar interaction, measure in Joules, μ1 and μ2 
are the dipole moments of each interacting molecule, ε is the dielectric constant of the solution and 
r is the distance between the interacting partners separated by a straight line in space.  
In proteins, oxygen is the most electronegative atom and carries a partially negative charge. 
High electronegativity of oxygen imparts a dipole moment to the amide bond (3.7 Debye). The 
large dipole moment of backbone amide bonds play an important role in protein folding (in the 
form of hydrogen bonding; see below) and maintaining the structural and conformational integrity 
of proteins. In addition to the attractive interactions between opposite poles of two dipoles (dipole-
dipole interactions), they also exert potential over neighboring charges and partial charges. 
Attractive or repulsive interactions between dipoles and neighboring charged ions are called ion-
dipole interactions. Since dipoles carry an electrostatic field around them, this electrostatic field 
interacts with electron clouds around neighboring molecules. This interaction shifts the electron 
cloud densities over molecules, thus inducing a dipole or polarization. Aromatic amino acids 
containing π electron clouds such as, phenylalanine, tyrosine and tryptophan are more polarizable 
than their aliphatic counterparts and interact with dipoles to a much greater extent. Such dipolar 
interactions are known as dipole-induced dipole interactions. 
 
1.2.2.3 London Dispersion or van der Waals Interactions  
 Even neutral molecules attract each other. Electron densities of each atom fluctuate to some 
extent based on the natural resonant frequency of that atom33. These short lived fluctuations or 
imbalance in electron density create a temporary dipole. To reduce charge-charge repulsions, this 
temporary dipole polarizes and thus induces an oppositely aligned dipole in the neighboring atom. 
This resulting interaction is called induced dipole-induced dipole attractive interaction, or London 
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dispersion forces34. London dispersion forces are short range forces and can significantly affect 
protein-protein interactions in crowded solutions as well as within molecules. 
 
1.2.2.4 Hydrogen Bonding 
 Hydrogen bonds are one of the most important determinants of protein folding and 
conformational stability35. These bonds involve a Lewis base with lone pair of electrons (hydrogen 
bond acceptor), and an electronegative atom attached to the hydrogen (hydrogen bond donor). A 
strong electronegative donor pulls the electrons away from the hydrogen, thus imparting a partial 
positive charge on the hydrogen atom. Hydrogen atoms do not have non-bonding inner shell 
electrons that shield the nucleus, therefore its positively charged nucleus gets exposed which in 
turn attracts the hydrogen bond donor that carries a net negative charge due to the lone pair of 
electrons36. Although hydrogen bond acceptor (Lewis base) attracts the hydrogen towards itself, 
the covalent bond between hydrogen and electronegative hydrogen bond donor never breaks and 
remains intact, therefore, hydrogen bonds can essentially be categorized as dipole-dipole 
interactions. Hydrogen bonds play an essential role in the formation of stabilizing secondary, 
tertiary, and if applicable, quaternary structures of proteins36.  
The strength of hydrogen bonds varies greatly depending upon the chemical nature of the 
donor and acceptor atoms. If the hydrogen bond forms between charged atoms, then the strength 
of such bonds ranges from 2-4 kcal/mol. The most common type of hydrogen bond is of moderate 
strength and are formed between neutral donors and acceptors. Strength of such bonds lies between 
3-12 kcal/mol37. Most of the intramolecular hydrogen bonds as well as hydrogen bonds between 
amino-acid side chains and water fall into the moderate strength category and as mentioned above 
play a key role in protein structure formation and stabilization. Hydrogen bonds also are a key 
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player in establishing intermolecular protein-protein interactions. Interactions between the oxygen 
of the carbonyl group and backbone amide hydrogens present at the protein interfaces often play 
a key role in establishing strong intermolecular associations. 
 
1.2.2.5 Hydrophobic Interactions/Apolar Interactions 
 Hydrophobic or apolar interactions within biological systems such as proteins can be 
effectively explained with a thermodynamic basis. Protein molecules contain both hydrophilic and 
hydrophobic amino-acid residues. As the name suggests, hydrophobic resides do not interact 
favorably with water molecules. Due to this thermodynamically unfavorable interaction, water 
molecules arrange around the hydrophobic molecules creating an aqueous shell which causes 
disruption of hydrogen bonding network in the 3 dimensional space of the system. Creation of 
multiple aqueous shells around the hydrophobic residues produce a large entropic penalty in the 
system. To reduce this unfavorable entropic cost due to reduction in both rotational and 
translational entropy, the hydrophobic residues forced inside the protein core. This in turn lets the 
water molecules form favorable hydrogen bonds with each other, thus decreasing the free energy 
of the system.  
The hydrophobic effect (in addition to hydrogen bonding) plays a crucial role in 
determining the folded native state and stability of a protein molecule. It also plays a significant 
role in protein-protein interactions. Partially disrupted protein conformers or highly dynamic local 
regions in a protein tend to occasionally expose the hydrophobic cores to their aqueous 
surroundings. Such partially distorted conformers and local fluctuations are short lived, and 
therefore, do not necessarily affect protein stability. Under stressed conditions, however, the life-
span of such partially distorted conformers can increase causing water molecules to push exposed 
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hydrophobic patches on neighboring molecules together thus initiating protein associations. 
Interestingly, the nature of non-covalent interactions that promote protein folding within a protein 
molecule is same as those that promote non-native protein-protein interactions between protein 
molecules.  
1.3 Monoclonal Antibody Structure 
Monoclonal antibodies are one of the most important classes of biotherapeutic agents3. In this 
thesis, we specifically focus on the role of protein-protein interactions in governing the behavior 
of monoclonal antibodies in solution. The next section briefly describes the salient features of IgG1 
antibody structure. Following this section, we will review impacts of protein-protein interactions 
on monoclonal antibody structure and stability and methods to qualitatively and quantitatively 
study such interacting systems. 
Monoclonal antibodies (mAbs) are Y-shaped glycoproteins of the immunoglobulin class, 
where the Fab region (antigen binding domain) forms the “V” and Fc (crystallizable fragment) 
forms the stem of the molecule. Both of these fragments carry different biological functions. The 
Fab fragment is primarily responsible for antigen recognition, whereas, the Fc fragment binds to 





Figure 1.1: Structure of a human monoclonal IgG1 antibody38. (Figure reproduced with 
permission from Dove Press).  
 
The primary structure of mAbs can broadly be subdivided into two identical heavy and two 
identical light chains. Each heavy chain contains four domains and each light chain forms into two 
similar domains.  These chains are held together by inter and intra-chain disulfide linkages and 
non-covalent interactions, therefore the antibody structure can also be called a “dimer of dimers” 
or homodimer. While each domain contains one intramolecular disulfide bond, the number of 
disulfide bonds linking the heavy chains (intermolecular disulfide bonds) varies between different 
classes and sub-classes of antibodies39.  
The first 100 to 110 amino-acids towards the N-terminus of the antibody constitute the variable 
domain (V region). This domain spans both the light chain and heavy chain (VL and VH). As the 
name suggests, the amino-acid makeup in this domain is variable and determines the specificity of 
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the antibody towards an antigen. These differences within the variable domain are found within 
areas called complementarity-determining regions (CDRs)39. These CDRs (both in variable light 
and variable heavy chain) constitute the antigen binding interface of the antibody. The amino-acid 
content and sequence of rest of the antibody is relatively conserved and very few differences are 
seen in the rest of the molecule. Therefore, this region is called the “constant domain” (CL and 
CH). Antibodies can further be classified on the basis of various classes of light and heavy chains. 
Monoclonal antibodies have two variations of light chains, kappa (κ) and lambda (λ). In humans 
60% of the antibodies have kappa light chains. In contrast, in mice 95% of the antibodies contain 
the kappa sub-type of light chain. The heavy chains also possess sub-types. Based on amino-acid 
sequence patterns the heavy chain can be subdivided into five different sub-types, μ, δ ,γ, ε and α. 
Based on the subtype of heavy chain, immunoglobulins are classified as IgA (α), IgG (γ), IgM (μ), 
IgD (γ) and IgE (ε). Minor differences in the amino-acid sequences within IgA and IgG sub-types 
lead to further classifications into subisotypes. In humans, there are two subisotypes of IgA, IgA1 
and IgA2, whereas, IgG has four subisotypes, IgG1, IgG2, IgG3 and IgG4. In this thesis we focus 
primarily on the IgG1 sub-class of an IgG monoclonal antibody39. Immunoglobulin G1 (IgG1), is 
a ~150 kDa molecular weight protein with 4 inter and 12 intra-chain disulfide bonds. 
IgG1antibodies, like other subclasses and subisotypes of mAbs, is variably glycosylated, with an 
N-linked glycosylation site at Asn 297 in the CH2 domain of the heavy chain
40-42. 
 
1.4 Pharmaceutically Relevant Challenges Triggered by Colloidal and Conformational 
Destabilization of Monoclonal Antibodies 
Both colloidal and conformational destabilization of antibodies can result in non-native, 
irreversible aggregation. Such an outcome is highly undesirable for antibodies since aggregation 
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impacts their developability, viability and safety as potential drug candidates43,44. Both of these 
pathways of destabilization act together to cause increases in protein aggregation. Depending upon 
the environmental/solution variables (e.g. temperature, additives, ionic strength and pH) and 
physiochemical properties of protein molecules (morphology, chemical nature of exposed amino 
acids, isoelectric point, etc.), either conformational destabilization or colloidal destabilization can 
be the dominant form of the aggregation pathway.  
Various formulation approaches can be used to address issues related to conformational 
and colloidal destabilization. Global and local charge on the surface of macromolecules including 
antibodies govern their colloidal stability. In a colloidally stable solution, individual molecules of 
proteins carry nearly equivalent net charge and thus experience an overall repulsive interaction 
from neighboring monomers. Any change in solution properties like pH relative to the isoelectric 
point of the protein molecules can affect the colloidal stability of proteins. At isoelectric point (pI), 
protein molecules carry a net zero charge. Under such conditions due to reduction in overall 
repulsive interactions, asymmetrically charged patches of amino-acids on the surface of proteins 
start reorienting the molecules to establish favorable long-range intermolecular electrostatic 
attractive interactions. In addition to charge heterogeneity, patches of exposed hydrophobic amino-
acids can also initiate such protein-protein interactions. As mentioned above, exposed hydrophobic 
patches from the interior of a protein molecule are thermodynamically unfavorable. Therefore, 
water molecules under crowded conditions can be viewed as pushing the protein molecules 
together to exclude such amino acid side-chains from the surface, thus initiating non-native 
protein-protein interactions. Changing solution pH so that protein molecules carry a net negative 
or positive charge helps to increase the colloidal stability of the molecule. Site-specific 
mutagenesis can be used to target asymmetric charge patches on the surface of a protein. However, 
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this approach can also potentially effect protein potency and structural integrity. Addition of 
charged excipients (e.g., salts, charged amino acids) can break salt-bridges between protein 
molecules and can be used to increase the colloidal stability of proteins. 
Conformational destabilization pertains to structural integrity and overall folding of the 
protein molecules. Proteins are dynamic entities with both large scale global and localized dynamic 
motions45,46. As mentioned above, hydrophobic residues are buried inside the core of the natively 
folded protein. Due to such dynamic motions in protein structure, however, these hydrophobic 
patches are transiently exposed to the solution for a relatively very short time span47. Such changes 
in protein dynamics can be reversible and might not affect the overall average folded state of the 
protein. Environmental and solution variables like pH, temperature and mechanical stresses affect 
the magnitude and kinetics of dynamic motions and in turn can affect the overall conformational 
integrity of the protein48,49. Changes in protein conformation and generation of partially perturbed 
conformers with exposed hydrophobic aggregation prone amino acid sequences can lead to the 
formation of irreversibly associated oligomers of protein molecules. Several formulation strategies 
can be followed to minimize protein aggregation initiated by conformational distortion in solution. 
Various stabilizing excipients can be used to enhance the conformational stability of the proteins. 
Sucrose is one of such stabilizer. Due to its thermodynamically unfavorable interactions with the 
unfolded state of the protein, sucrose gets preferentially excluded from the protein surface leaving 
water molecules to populate around the proteins. This causes a thermodynamically unfavorable 
increase in the system’s chemical potential. To minimize thermodynamically unfavorable 
interactions between water molecules and surface exposed apolar residues, preferential exclusion 
causes protein surface area to decrease which in turn favors the native fold (lowest surface area) 
and stabilizes the native protein conformation50-54. In addition to sucrose, other sugars and small 
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molecules can also be used to exhibit similar behavior. Kosmotropic salts like sodium sulfate have 
been shown to stabilize protein conformation through favorable interactions with positively 
charged amino-acids (stabilization of native-fold) and preferential exclusion mechanisms55-58.  
In subsequent sections, we will discuss various protein association events with 
pharmaceutical implications such as protein aggregation, concentration dependent transient 
reversible self-association and phase separation of protein solutions. Mechanisms behind such 
phenomenon will be briefly discussed followed by approaches to minimize their occurrence in 
protein formulations. 
 
1.4.1 Protein Aggregation: Mechanisms, Challenges and Solutions 
Protein aggregation is one of the greatest pharmaceutical challenges faced by protein 
formulation development scientists. To mitigate protein aggregation, it is essential to understand 
the underlying mechanisms and variables that affect this process. This section will only briefly 
cover protein aggregation mechanisms and preventative measures. Protein aggregation is a 
complicated phenomenon and to discuss every aspect and mechanism leading to aggregation is 
beyond the scope of this chapter.  Extensive reviews have appeared to provide more detailed 
information18,21,48. 
Protein aggregation has been classically explained using the Lumry-Eyring model of 
aggregation (Equation 1.03) 21,59. According to this scheme, proteins in their native state first form 
a reversible partially perturbed intermediate conformer “U”. As explained above this partially 
unfolded conformer can then undergo an irreversible step where these conformers come together 
to form an irreversible aggregate “A”.  
                                                     2𝑁
𝐾𝑢𝑛𝑓
↔  𝑈 + 𝑈
𝑘𝑎𝑔𝑔
→  𝐴2                                                               (1.3) 
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where N is the natively folded monomer, U is the partially unfolded intermediate and A2 represents 
an irreversible dimer. Kunf is the equilibrium constant of the change from N to U, whereas kagg 
represents the kinetics of association of two molecules of partially unfolded conformer “U” to form 
an irreversible dimer “A2”. Thermodynamic underpinnings of this aggregation model can be 
understood using a reaction energetics diagram (Figure 1.2). Protein aggregation can be modulated 
both by thermodynamic as well as kinetic controls. As mentioned above, one way to control protein 
aggregation is to increase the activation free energy of formation of the partially unfolded 
conformer “U”. Pharmaceutical excipients like sucrose and kosmotropic salts that directly affect 
the partially unfolded conformer can be used to stabilize the native conformer through the 
preferential exclusion principle. 
 
 
Figure 1.2: Schematic theoretical reaction coordinate diagram conceptualizing protein 




 In addition to thermodynamic control of protein aggregation, kinetic stabilization can also 
be achieved by increasing the activation energy of the association step of the aggregation process. 
The theory of slow agglomeration explains in detail, how altering the potential of mean force 
(PMF) of protein solution perturbs the kinetics of protein aggregation60-62. 
 The Lumry-Eyring model helps to lay the foundation for building a better understanding 
of protein aggregation. Protein aggregation is at times, however, not so straightforward. Protein 
aggregation in practice can be affected by a number of variables and the actual mechanisms of 
protein aggregation is a complex interplay between various different competing pathways like 
conformational distortion63, chemical degradation64, native transient associations65,66 and protein 
adsorption to various types of interfaces67-71. Antibody aggregation in bulk solution is a complex 
process that includes many pathways and steps. A modification of the classical Lumry-Eyring 
model was proposed by Roberts et al72. Figure 1.3 shows various pathways and steps of antibody 
aggregation. As shown in the figure, antibody aggregation can be initiated by either protein 
oligomerization of native conformers or through partial disruption of protein structure leading to 
weak protein oligomerization of structurally disrupted sub-populations. Protein associations of 
native and distorted conformers are reversible in nature and under stabilizing solution conditions 
usually return back to their monomeric forms. However, under destabilizing solution conditions 
(exposed hydrophobic aggregation hot-spots) the transient oligomers could undergo an irreversible 
change to form nuclei. Nuclei are the smallest form of an irreversible aggregate. After generation 
of nuclei the protein molecules involved do not generally return to the original native 
conformation. Nuclei can grow through different pathways such as monomer-monomer addition, 
monomer-aggregate addition or aggregate-aggregate addition to form smaller or bigger aggregates 
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which eventually form particles, under certain conditions phase separation can also occur (Figure 
1.3). 
 
Figure 1.3: Schematic representation of monoclonal antibody multi-step non-native aggregation 
process in bulk solution72. (Image reproduced with permission from Elsevier). 
  
  If the net charge on the partially distorted conformer and nuclei is high (e.g., solution pH 
below or above the pI of the protein) and the charge screening length is short (low ionic strength 
solution conditions) then the nuclei undergo minimal growth and small aggregates are formed. 
However, if the net charge on the nuclei are low (e.g., solution pH approaching the pI of the 
protein) and charge screening length is long (high ionic strength solution conditions), then the 
nuclei experience either monomer-aggregate addition or aggregate-aggregate addition, both of 





Figure 1.4: Effect of solution conditions and physiochemical nature of mAb molecule on the 
mechanism/pathway of protein aggregation72. (Image reproduced with permission from 
Elsevier). 
 
1.4.2 Concentration Dependent Reversible Self-Association of Proteins 
 Reversible self-association (RSA) or reversible oligomerization is a concentration dependent 
process in which there exists an equilibrium between the native monomeric and oligomeric state. 
This type of association between protein molecules is ubiquitous in nature, especially 
intracellularly where protein concentrations can reach up to 300 mg/mL and intermolecular 
distances between protein molecules are very small73-76. The subcutaneous delivery of 
biopharmaceuticals is gaining interest over the past few years due to reasons related to patient 
compliance and self-administration of doses. The subcutaneous space, however, does not allow 
high volume injections and restricts pharmaceutical dosage forms to only 1-2 mL to deliver 
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relatively high doses of protein drugs. Due to this restriction, protein drugs for subcutaneous 
delivery are formulated at very high protein concentrations (above 100 mg/mL)77,78. At such high 
concentrations, the intermolecular distances between protein monomers decrease significantly 
causing them to initiate specific and non-specific protein-protein interactions thus causing the 
solution to deviate from ideality79-82. In this introduction we will focus on specific intermolecular 
interactions between protein partners at high protein concentrations.  
 Reversible self-association can be mathematically defined by the equations given below: 
                                                        nM ↔ Mn                                                                (1.4) 
where n is the number of monomeric units involved in self-association and M is the native 
monomer. Equation 1.483, shows the interrelationship between critical parameters like the 
association rate constant, ka and dissociation rate constant, kd of protein association. One of the 
most important parameter by which the self-association process can be efficiently described is the 
association constant, Ka and dissociation constant, Kd which is reciprocal of Ka (Kd = 1/Ka). Ka 
can be calculated using the concentrations of the product and reactants of the association 
equilibrium (Eq. 1.5)83 
                                                                   Ka =
Mn
[M]n
                                                                (1.5) 
Reversible oligomerization of proteins at high protein concentrations depends on the amino acid 
makeup and surface exposure of electrostatic and hydrophobic amino acid residues. Structural 
morphology also plays a crucial role in determining the strength and stoichiometry of protein 
association process. This process can also involve multiple oligomerization equilibrium states such 
as monomer-dimer, monomer-trimer, monomer-trimer-hexamer, monomer-dimer-tetramer etc. 
Although rare, association of protein molecules at high protein concentrations can also follow an 
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isodesmic distribution or monomer addition mechanism. In this system a single molecule of native 
monomer associates through monomer addition to a growing oligomeric chain in every step84-86.  
 Various mechanisms of antibody self-associations have been studied and described 
previously. Two of the prevalent mechanisms are associations initiated by enthalpically driven 
electrostatic interactions and entropically driven hydrophobic interactions between native 
monomeric species of antibodies. Anisotropically distributed patches on an antibody surfaces 
initiate either long range electrostatic attractive interactions or hydrophobic interactions driven by 
the solvent. For both of these processes, overall electrostatic repulsive interactions between the 
mAb molecules should be at its minimum. At a solution pH where overall repulsive interactions 
between the protein molecules reach a minimum, self-association may be initiated. First, the 
monomeric molecules reorient themselves based on their reactive centers (electrostatic anisotropy 
or hydrophobic heterogeneity). Then, based on the nature of the non-covalent interactions and 
surface area of the interface of interactions, protein monomers undergo multiple collisions before 
a successful association event occurs. Although electrostatic attractive interactions and 
hydrophobic interactions appear to be the main drivers of self-association, a reversible 
oligomerization process is often the outcome of a balance between various types of non-covalent 
interactions including van der Waals, hydrophobic, dipolar, hydrogen bonding and electrostatic 
interactions82.  
Reversible self-association of mAbs presents several challenges towards their 
pharmaceutical development. Protein-protein interactions directly affect solution dynamic 
viscosity. The modified Mooney’s equation provides an expression for protein solution viscosity 
(Eq. 1.06)80 






]                                              (1.6) 
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where, η represents solution dynamic viscosity, ηo represents solvent viscosity, C signifies protein 
concentration, [η] is the intrinsic viscosity in mL/g and ν is the Simha shape parameter (molecular 
orientation and morphology)87. The modified Mooney’s equation also takes into account the first 
order interaction parameter (κ) or the crowding factor at high protein concentrations. Protein 
solution viscosity, according to this equation, depends on the effective volume as well as 
shape/morphology of the protein species and crowding of the solution. However, contributions 
from specific (e.g., overall charge, electrostatics) and non-specific (e.g., ion-pairs, anisotropic 
charge distributions) effects should also be considered. The modified Mooney’s equation does not 
consider contributions from such forces. Deviations from a purely excluded volume effect have 
been previously reported and can only be explained when contributions from the above mentioned 
forces are considered as significant87. Therefore, it can be concluded that long and short ranged 
non-covalent interactions modulate protein-protein interactions and can impact protein solution 
viscosity.  
Large protein complexes result in significant increases the shear modulus of the solution15. 
This increase in shear modulus or modulus of rigidity results in a dramatic increases in solution 
viscosity at higher concentration 88,89. Figure 1.5 and equation 1.790 show how protein-protein 
interactions affect shear modulus (G) by increasing the amount of displacement force (F) to 
maintain the same displacement (u) of the solution column of height (H). Shear modulus is directly 
proportional to the dynamic viscosity of the solution (η) 






                                                                 (1.7) 
 





Figure 1.5: (A) Non-associating antibody solution displacement upon application of force, F. (B) 
Self-associating antibody slows down the displacement of the solution column upon application 
of the equivalent force applied in case (A) demonstrating greater viscosity in case (B). 
 
Significant increases in solution viscosity imposes various pharmaceutical development 
and engineering challenges related to product filtration, pumping and syringeability. Due to high 
viscosity, a self-associating antibody solutions at high protein concentrations often cannot be 
delivered employing regularly used needles91. Due to high backpressure issues, wide gauge 
needles will need to be utilized that may cause painful injections. This effect decreases patient 
acceptability and compliance. Transient protein-protein interactions have also been shown to lead 
to irreversible aggregate formation which causes issues related to immunogenicity and loss of 
product viability and potency92. Depending upon the dissociation rate of oligomers, self-associated 
antibodies can exhibit aberrant pharmacokinetic profiles after subcutaneous injection93. Extensive 
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self-association may also lead to phase separation and increases in solution turbidity causing 
protein destabilization and patient acceptance issues94.  
Reversible self-association, depending upon the nature of the non-covalent interactions, 
can be disrupted by addition of appropriate formulation excipients and/or by applying changes to 
the solution conditions. For systems that associate through either electrostatic or hydrophobic 
interactions, formulating antibodies at pH values below their pI value, where they carry a net 
positive charge, increases their colloidal stability by initiating overall electrostatic repulsive 
interactions between mAb monomers in bulk solution. In the case in which protein associations 
are primarily driven by electrostatic attractive interactions, addition of charged excipients such as 
salts and charged amino-acids can shield the surface exposed point charges on the antibody thereby 
disrupting any pairwise interactions between interacting partners. Apart from formulation 
strategies, high resolution analytical characterization and interfacial mapping of RSA in 
conjunction with site-specific mutagenesis at the interface has been successful in designing more 
stable mAb mutants with enhanced physiochemical properties and low viscosities at high protein 
concentrations17,95. Figure 1.6 describes the antibody self-association phenomenon and factors that 




Figure 1.6: Pictorial representation of reversible self-association (RSA) of antibodies. Factors 
affecting the extent of reversible self-association are listed in the lower left corner of the figure. 
 Due to the inherent non-ideality in high protein concentration solutions, many analytical 
tools used to study protein-protein interactions in dilute solutions fail to produce reliable and 
reproducible data at high protein concentrations. Analytical characterization is of great importance 
and necessity to better understand protein self-association at high protein concentrations96. In the 
subsequent section of the introduction we will briefly discuss various biophysical and analytical 
tools that can be used to study self-association of proteins at both lower and higher resolutions. 
We will also discuss a novel hydrogen exchange mass spectrometry method developed by our lab 
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as part of this thesis work to map protein interfaces of these transient associations at peptide level 
resolution, directly at high protein concentrations. 
 
1.5 Analytical and Biophysical Tools to Characterize Reversible Self-Association of Proteins  
1.5.1 Dynamic Light Scattering (DLS) 
 DLS is one of the most widely used analytical techniques to measure protein-protein 
interactions in solution. This technique can be used both in a batch mode and high throughput 
microplate format which makes it an important tool for early developability studies. DLS 
measurements are based on the fluctuations of intensity of the light scattered by the particles 
undergoing constant Brownian motions. In bulk solution, protein molecules are constantly 
bombarded by neighboring water molecules, due to the kinetic energy of the smaller water 
molecules. Transfer of kinetic energy from water molecules to protein molecules cause a 
randomness in motion of the protein molecules and the frequency of this randomness forms the 
basis of size determination by DLS.  Particles of different sizes show either fast Brownian motions 
(smaller particle sizes) or slow motions (larger particle sizes). Based on the frequent change in 
Brownian motion, protein particles impart a randomness to the phase of the scattered light which 
in turn introduces intensity fluctuations that are time-dependent (fast vs. slow fluctuations) and 
can be tracked using a light scattering detector to determine the size of the particle. These 
fluctuations are a direct function of the diffusional property of the particle through which the 
hydrodynamic size of the particle is measured. Phase transitions in the scattered light are fitted to 
a second order intensity correlation function (Eq. 1.8)97 






∫ I(t)I(t + τ)dt
T
−T
                                (1.8) 
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where g2(τ) is the second order correlation function, I(t) is the intensity of the scattered light at 
time t and I(t+τ) is the intensity of scattered light shifted in time by a small time interval τ and T 
is the infinite time limit. The correlation function correlates the intensity decay after time t to t+τ. 
The diffusion coefficient is calculated from the correlation function fits. The Stokes-Einstein 
equation (Eq. 1.9)97 describes the relationship between diffusion coefficient (Dt) and 
hydrodynamic radius (RH) of particles undergoing Brownian motion in an ideal solution with no 
intermolecular interactions. 
                                                Dt =
kBT
6πηRH
                                                     (1.9) 
 In equation 1.997 kB is Boltzmann’s constant, T is the temperature and η is the viscosity of the 
solution. Attractive intermolecular interactions such as reversible self-association between 
antibody monomers can lower the translational diffusion coefficient which is reflected by an 
increase in the average hydrodynamic diameter 77,98. 
The mutual diffusion constant is measured as a function of protein concentration. A linear 
fit of mutual diffusion constant vs. concentration data to equation 1.1015 enables calculation of kD. 
                                                              Dm = Do(1 + kDC)                                                     (1.10) 
where, Dm represents the mutual diffusion coefficient, Do is the self-diffusion coefficient, kD is the 
diffusion interaction parameter and C is protein concentration. Value of kD indirectly measures 
self-association phenomenon since it contains contributions from both hydrodynamic and 
thermodynamic processes15,99. A positive value of kD represent overall repulsive interactions 
between protein monomers and a negative value net attractive interactions in solution. Although 
kD is not a direct measure of protein-protein interactions, several studies have shown good 
agreement between kD and second virial coefficient values which is another measure of colloidal 
stability81,100,101. Despite the ease of use and high throughput of the DLS platform, this technique 
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fails to provide reliable and reproducible data above a protein concentration of 20 mg/mL due to 
physical processes like multiple scattering and non-ideal behavior due to non-specific protein-
protein interactions at high protein concentrations. However, DLS still remains one of the most 
utilized analytical technique to measure strong protein-protein interactions and aggregation in the 
dilute concentration regime with attempts to extrapolate the experimental results to high protein 
concentration solutions still under active investigation. 
 
1.5.2 Multi-Angle Light Scattering (MALS) 
As the name suggests, in MALS measurements light scattering from a particle is measured 
at multiple angles using multiple detectors. The fundamental quantity that is measured in these 
experiments is the excess Rayleigh ratio (R(θ,c)) as a function of protein concentration and 
scattering angle. The measured quantity is related to the scattering angle and protein concentration 
(c), in addition or in excess of the scattering of the solvent devoid of any solute, i.e. scattering 
contributions from the pure solvent. The Zimm equation (Eq. 1.11)97 describes the interplay 
between excess Rayleigh ratio, weight averaged molecular mass M, apparent second virial 
coefficient A2 and the protein concentration, c, of the species present in the solution. 
                                               R(θ, c) = K∗McP(θ)[1 − 2A2McP(θ)]                                      (1.11) 
where,  





2                                                    (1.12) 
where, no represents the refractive index of the solvent, NA is the Avogadro’s number, (dn/dc)
2 is 
the incremental increase in refractive index with increasing protein concentration and λo is the 
wavelength of the incidental wavelength in a vacuum. The apparent second virial coefficient A2, 
similar to the diffusion interaction parameter kD discussed above, is a measure of the colloidal 
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stability of protein solutions. Positive value of A2 represents an overall repulsive interactions 
between solute particles, whereas, negative values indicate a destabilizing solution condition with 
net attractive interactions between solute or protein monomers102,103. Therefore, A2 can be used to 
screen multiple solution conditions for their effect on the colloidal stability of a protein molecule, 
making MALS an extremely useful technique in formulation development for protein 
therapeutics104-106. Variations of classical multi-angle light scattering are also being used to 
qualitatively and quantitatively characterize transient protein-protein interactions in dilute to high 
protein concentration solution conditions.  
Composition-gradient multi-angle light scattering (CG-MALS) involves stop-flow 
injections of a series of dilution/concentrations of an associating system that allows true 
equilibration at each step. To analyze specific, reversible self-association protein molecules in the 
ideal limit, a modification of the Zimm equation is used (Eq. 1.13) to measure the light scattering 
of two components A and B. Equations of mass action (Eq. 1.14) and conservation of mass (Eq. 
1.15)97 are used to estimate the stoichiometry of protein association along with mole fraction of 
each component107. 
                                                           
𝑅
𝐾∗
= Σ𝑖,𝑗(i𝑀𝐴 + 𝑗𝑀𝐵)
2[𝐴𝑖𝐵𝑗]                                          (1.13) 
with mass action 
                                                                        𝐾𝑖𝑗 =
[𝐴𝑖𝐵𝑗]
[𝐴]𝑖[𝐵]𝑗
                                                         (1.14) 
and conservation of mass 
                                          [𝐴]𝑡𝑜𝑡𝑎𝑙 = ∑ 𝑖𝑖,𝑗 [𝐴𝑖𝐵𝑗],        [𝐵]𝑡𝑜𝑡𝑎𝑙 = ∑ 𝑗𝑖,𝑗 [𝐴𝑖𝐵𝑗]                       (1.15)  
Ma and Mb represent molar masses of system components A and B, i and j represent stoichiometric 
distribution of A and B in complex AiBj. 
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Although MALS provides a thorough characterization of reversible-self association and 
protein-protein interactions, experimental A2 values are only reliable within the ideal limit (dilute 
solutions). CG-MALS equations (given above) can be used to fit the Rayleigh scattering data to 
various association models and through this fitted apparent second virial coefficients can be 
estimated at high protein concentrations. Another limitation of this technique is the experimental 
throughput. CG-MALS experiments can only be done in batch mode and pumps attached to the 
experimental system can only withstand low levels of backpressure. At high protein 
concentrations, where the extent of self-association is high, pumps installed in the CG-MALS 
setup may fail to inject, forcing the user to manually inject samples. 
 
1.5.3 Viscosity Measurements   
 As mentioned above, transient protein-protein interactions can dramatically affect the 
viscosity of a protein solution. Associating systems show significantly higher viscosities when 
compared to non-associating systems at high protein concentrations. This outcome is exploited by 
formulation developmental scientists to characterize various solution conditions and excipient 
combinations while formulating proteins at high concentrations108,109. Solution viscosity can be 
presented as a virial expansion of a polynomial (Eq. 1.16)80 
                                                𝜂 = 𝜂𝑜(1 + 𝑘1𝐶 + 𝑘2𝐶
2 + 𝑘3𝐶
3 +⋯)                                      (1.16) 
where η is dynamic viscosity of the solution, ηo represents the viscosity of pure solvent, C is the 
protein concentration and k1, k2 and k3 are the first, second and third virial coefficients
80. 
Contributions from the second virial and third virial coefficients are negligible under dilute 
conditions which permits 1.16 to be simplified to equation 1.1792: 





) = 𝑘1 + 𝑘2𝐶                                                  (1.17) 
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where, ηred represents reduced solution viscosity which provides a measure of intrinsic viscosity 
(k1) at infinite dilution. As the protein concentration is increased, contributions from the second 
and third virial coefficients (pair-wise interactions and higher-order intermolecular interactions) 
become significant and cause the solution behavior to deviate from Newtonian to non-Newtonian 
which can be qualitatively assessed by shear ramping experiments using viscometers110. While the 
above mentioned light scattering techniques struggle to provide reliable screening data of protein 
solutions at high protein concentrations, rheometers or viscometers provide an excellent 
opportunity to screen various formulation combinations at high protein concentrations in a 
relatively high throughput manner. 
 
1.5.4 Sedimentation Velocity Analytical Ultra-Centrifugation (SV-AUC)   
 Sedimentation velocity analytical ultra-centrifugation (SV-AUC) is a classic technique used 
to characterize reversible as well as irreversible protein oligomerization. Samples containing 
protein oligomers are subjected to very high centrifugal force. This causes the individual 
constituents of the sample to sediment to the bottom of the cell over time. The sedimentation rate 
of these constituents and factors that affect this sedimentation rate are given by equation 1.18111: 









                                          (1.18) 
 where s is the sedimentation coefficient, u is the radial velocity, ω represents the angular velocity 
of the rotor and r is the radial position. The product of the square of angular velocity and radial 
position ω2r is the angular momentum. M represents the molar mass of the species, ν is the partial 
specific volume and ρ represents the density of the solvent, NA is the Avogadro’s number and f is 
the frictional coefficient. The diffusional coefficient is represented by D and R is the gas constant. 




The Stoke’s equation can be used to calculate frictional coefficient for a uniform sphere (Eq. 
1.19)111 
                                                                        fo = 6πηRo                                                             (1.19) 
where fo represents the frictional coefficient of a regular sphere and Ro is the radius of that sphere. 
η represents the dynamic viscosity of the solution. A combination of equation 1.17 and 1.18 gives 
equation 1.20, i.e., the sedimentation coefficient of a sphere. 






1/3                                                     (1.20) 
Some of the values in equation 1.20 are known constants and can be replaced by their values at 
20°C. This provides a simpler, modified equation 1.21111: 
                                                            ssphere = 0.012
𝑀2/3(1−νρ)
ν−1/3
                                                  (1.21) 
Equation 1.19 represents the sedimentation coefficient in terms of M, ν and ρ and can be used to 
calculate sedimentation coefficients for a spherical protein in water at 20°C111.  
SV-AUC utilizes two different types of optics to measure the radial concentration 
distributions, absorbance and interference optics. This technique can be used to measure the size 
and obtain information on the shape of the molecule with little to no restrictions on the nature of 
the solvent that can be used112. The sample for analysis should have some distinguishing optical 
property (should be compatible with either of the two optical systems) and should be highly 
purified with only a few distinct components. Purity of the sample can affect the reliability of the 
measurements. SV-AUC is considered as an orthogonal technique to size exclusion 
chromatography (SEC), but in some ways is superior because the samples do not interact with any 
external matrix and the dynamic range of SV-AUC is much larger than SEC113. SV-AUC’s biggest 
drawback is its low throughput and limitation on protein concentration. Since the most widely used 
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optical property is absorbance, this limits protein concentration between absorbance values of 0.2-
1.0 OD at the chosen wavelength. The protein concentration limit can be pushed slightly using 
narrower path length cells and the interference optical system, however, it still does not allow 
protein concentrations to exceed ~10 mg/mL. This limitation restricts SV-AUC’s ability to use for 
analysis of high protein concentration systems.  
 
1.5.5 Affinity Capture Self-Interaction Nanoparticle Spectroscopy (AC-SINS) 
 AC-SINS is a promising and novel technique in the field of protein-protein interaction 
assessment114,115. This technique involves decorating the surfaces of gold-nanoparticles with 
varying ratios of capture antibodies (e.g., specific polyclonal, goat anti-human) and non-capture 
antibodies (e.g., non-specific polyclonal). These gold-nanoparticles are then introduced in dilute 
solutions (0.001-0.05 mg/mL) of the antibody of interest. Capture antibodies on the surface of the 
nanoparticles immobilize the antibody of interest on the surface of the nanoparticles. 
Agglomeration/colloidal stability of gold-nanoparticles after their introduction in the mAb solution 
is governed by the immobilized mAb’s self-association potential. Reduction in the inter-particle 
distance between the nanoparticles or their aggregation causes a red-shift in the wavelength of the 
absorbance maximum. AC-SINS holds promise because of its ability to quantitatively assess 
protein self-association in very dilute solutions. This technique can also analyze impure solutions 
of antibodies because the capture antibodies have specific affinities.  
 
1.5.6 Hydrogen Exchange Mass Spectrometry (HX-MS) 
 Hydrogen exchange (HX) is a classic tool to study protein backbone dynamics and protein-
protein interactions. HX coupled to mass spectrometry (HX-MS) provides an excellent opportunity 
36 
 
to extend its utility to larger, more complex macromolecules such as monoclonal antibodies. HX-
MS has a rich experimental history and a wide spectrum of applicability. The subsequent section 
briefly explains the basics of hydrogen exchange process and how it can be used to measure 
backbone amide flexibility of macromolecules. More detailed descriptions of various aspects of 
this technique have been published recently116.  
 Protein molecules are dynamic entities with motions ranging from femtoseconds to seconds 
time-scale117. Various techniques can be utilized to capture protein dynamics corresponding to 
various time-scales. Motions ranging from picoseconds to seconds can be tracked using nuclear 
magnetic resonance (NMR), whereas X-ray diffraction cannot be used to track protein motions. 
Although these two techniques are the well-established and widely employed to study protein 
structure and protein-protein interactions at very high resolution118-121, they find relatively little 
applicability in pharmaceutical development of formulated protein drugs, especially analysis of 
local dynamics or protein-protein interactions of entire monoclonal antibody molecules. On the 
contrary, HX-MS has recently found utility in measuring local flexibility and probing protein-
protein interactions of large multi-domain macromolecules such as antibodies.  
 
1.5.6.1 Basics of Hydrogen Exchange 
 Labile hydrogens in the amino-acids when introduced in an aqueous environment constantly 
exchange with the hydrogens in the solvent. Not all hydrogens in protein structure are labile, 
hydrogens attached to the electronegative heteroatoms (oxygen, nitrogen and sulfur) exchange at 
a measurable time-scale. Hydrogens attached to the carbon atoms do not exchange with the 
solvent. When solvent is changed from H2O to D2O, labile hydrogens attached to the above-
mentioned heteroatoms start exchanging with deuterium atoms in the solvent. Hydrogens bonded 
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to heteroatoms in the side-chains of amino-acids undergo essentially instantaneous exchange with 
the solvent, and due to the reversible nature of the process, revert back to hydrogen once exposed 
to H2O during liquid chromatography (LC) step of the experiment. Therefore, such hydrogens 
cannot be utilized for any practical purposes.  
 In contrast, the exchange rate of hydrogens bonded to the backbone amide depends upon the 
folded state of the protein and stability of intramolecular hydrogen bonding122-125. Backbone 
hydrogens that are involved in secondary structure of the protein (i.e., α-helices and β-sheets) are 
significantly shielded from the solvent and form stable hydrogen bonds with neighboring H-bond 
acceptors (e.g., carbonyl group of amide bonds). Therefore, these hydrogens exchange at a much 
slower rate compared to hydrogens from a region of the protein that are solvent exposed and form 
weak intramolecular H-bonds (e.g., unstructured loops, CDRs of mAbs). Kinetics of deuterium 
uptake correspond to the stability of hydrogen bonding between backbone amide hydrogens in any 
particular location. Regions of proteins that are well structured, stable and solvent protected like 
the β-sandwich domains of the antibody, show very slow backbone exchange kinetics (from hours 
to months), however, unstructured and solvent exposed regions of the protein exchange very 
quickly (within milliseconds of initial exposure to D2O)
126.  
 By tracking and comparing the kinetics of deuterium uptake of different locations of the 
protein between various solution conditions, one can retrieve useful information concerning the 
local flexibility of the protein molecule and external factors that affect the local flexibility. The 
same fundamentals can be applied while mapping the interface of protein-protein interactions. 
Various non-covalent interactions specifically or non-specifically initiate intermolecular 
associations, these associations in addition to other non-covalent interactions also form as a 
consequence of intermolecular H-bonding between interacting protein partners. When kinetics of 
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deuterium in associating and non-associating conditions are compared, valuable information about 
the protein interface of protein-protein interactions can be retrieved using hydrogen exchange 
methodology17,127. However, one should be cautious while interpreting results of such HX-MS 
experiments as changes in HX kinetics due to allosteric effects of protein-protein interactions can 
make data interpretation challenging. 
 Amide backbone hydrogen exchange rate in a protein is a combination of two factors, 
chemistry and structure. Peptide segments even in an unstructured state (i.e., devoid of any higher 
order structure) exchange at a kinetic rate. This exchange rate of unstructured peptide is referred 
to as chemical exchange. This chemical exchange process includes contributions from acid 
catalysis, base catalysis and a minor contribution from water catalysis (Eq. 1.22)116,128 
                                      𝑘𝑐ℎ = 𝑘𝑖𝑛𝑡,𝐻[𝐻
+] + 𝑘𝑖𝑛𝑡,𝑂𝐻[𝑂𝐻
−] + 𝑘𝑖𝑛𝑡,𝑤𝑎𝑡𝑒𝑟[𝐻2𝑂]                              (1.22) 
where kint, H, kint, OH and kint, water represent rate constants of acid catalysis, base catalysis and water 
catalysis of HX process. HX kinetic rate shows a strong dependence on pH. Figure 1.7 shows the 




Figure 1.7: pH rate profile showing dependence of HX chemical exchange rate (kch) on solution 
pH of an amide hydrogen in a random coil poly-DL-alanine peptide at 20°C. Adapted from Ref. 
[31] 
 
 Above pH 3, the HX process is primarily catalyzed through base catalysis. The rate of the 
reaction reaches at its minimum around pH 2.5, and below pH 2.5, the rate of HX primarily is 
driven by acid catalysis. Above pH 4, the rate of chemical exchange shows a 10-fold increase in 
rate with every pH unit increase. Other solution variables such as ionic strength and temperature 
and neighboring amino acids also modulate chemical exchange rate126,129.  
 Proteins in their native state remain as an ensemble of various different conformers of nearly 
similar ground state free energy. Native state conformation is an average structure of all the 
different ground state conformers. However, protein does not stay in one conformation and spans 
different native conformations at any given time. This behavior is translated as global and local 
dynamics and proteins appear to be in a constant state of flux117,130,131. Due to the inherent fluidity 
of protein structures, the H-bonds that hold them together also break and reform. The kinetics of 
H-bond breaking and reforming depends upon the local dynamics of the region of interest in a 
protein structure. HX process in folded, dynamic proteins can be explained using the Linderstrom-
Lang model of exchange132. Based on the location of the backbone amide, high energy local 
fluctuations that are part of the transition states between natively folded structures can temporarily 
disrupt intramolecular H-bond network, thus enabling the backbone amide to engage in H-bonding 
with the solvent instead. The Linderstrom-Lang model conceptualizes exchange process from 










                                                   NHcl ⇌ NHop → NDop ⇌ NDcl                                                 (1.23) 
 where NHcl represent natively folded conformation of the protein also called the exchange 
incompetent state. As the protein undergoes local fluctuations, NHcl changes to NHop which is the 
locally perturbed, exchange competent state with a disrupted intermolecular H-bond. k1 and k-1 
represent rates of opening and closing of intermolecular backbone amide H-bonds.  
 In an exchange competent state, if the protein is introduced into D2O, the backbone amides 
start forming H bonds with the deuterium atoms in the solution. Protein molecules in their ground 
state are present both in exchange competent and incompetent states, these forms are 
interchangeable and protein spends time in both the states. Depending upon external stress 
conditions, the time spent in one particular state can change in relation to other, which reflects the 
change in local flexibility. Therefore, the HX process depends upon the structural flexibility of the 
protein molecule as well as the chemical exchange rate (kch). From equation 1.21, expression for 
HX rate can be derived (Eq. 1.24)116 
                                                            kHX =
kop×kch
kop+kcl+kch
                                                         (1.24) 
kHX is the rate of hydrogen exchange or isotopic exchange rate. Normally, protein conformation 
does not deviate too far from the average conformer and under native state proteins return to their 
folded state very rapidly. Therefore, it can be safely assumed that rate of H-bond closing is much 
greater than their opening rates under native state conditions (kcl >> kop). This assumption modifies 
equation 1.24 to equation 1.25116. 
                                                                  kHX =
kop×kch
kcl+kch
                                                            (1.25) 
Depending upon the rate of closing and opening of hydrogen bonds, two extreme conditions can 
be envisioned. The unfolded intermediates that populate the transition states are usually short lived. 
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However, due to external stress and other environmental variables the life-span of such local 
unfolded intermediates can lengthen, allowing enough time for HX process to finish at all possible 
positions in that particular peptide segment. Under such conditions where kcl is much slower than 
the chemical exchange, kch of the peptide segment, chemical exchange rate becomes the rate 
limiting step and equation 1.25 gets modified to equation 1.26116:  
                                                                    kHX,obs = kop                                                             (1.26) 
 This mechanism is known as EX1 limit where the observed rate constant for HX is equal to 
the rate of opening of backbone amide H-bonds. EX1 limit is often regarded as evidence for the 
presence of global unfolding or large domain unfolding events that drive the exchange process. 
EX1 mechanism of HX is rarely seen in folded proteins under native conditions.  
 Most of the proteins under stable native conditions follow EX2 kinetics of HX. In this case 
with most folded proteins, the rate of refolding is much greater than the chemical exchange rate 
kch (kcl >> kch) and the probability of a successful exchange event is low, which means that the 
hydrogen bond opening and closing occur multiple times before a successful HX event. In EX2 
limit rate of HX can be redefined as equation 1.27:    
                                                      𝑘𝐻𝑋,𝑜𝑏𝑠 =
𝑘𝑜𝑝
𝑘𝑐𝑙
× 𝑘𝑐ℎ = 𝐾𝑜𝑝 × 𝑘𝑐ℎ                                                   (1.27) 
 
 As mentioned above HX coupled to MS has recently found applicability in protein 
formulation development and early stage developability efforts for pharmaceutically relevant 
proteins like antibodies133-135. Past studies have shown correlations between HX data and long term 
stability of monoclonal antibodies136-139. In another study (also discussed here in later chapters), 
practical limits of HX-MS methodology was stretched to include high protein concentration 
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regime. Transient protein-protein interactions were studied and mapped using a novel HX-MS 
methodology. 
 In this thesis, at first we will present applicability of HX-MS in identifying local 
perturbations in antibody structure upon introduction of various antimicrobial preservatives 
(conformational destabilizers) to the antibody solutions. Correlation between the degree of local 
fluctuations in flexibility with global, low resolution measures of physical stability such as thermal 
melting temperatures and protein aggregation propensity of an IgG1 monoclonal antibody will be 
presented. In later chapters, we will present a novel HX-MS methodology developed in our lab 
which is geared towards identifying and mapping protein-protein interaction interfaces of transient 
RSA of monoclonal antibodies at high protein concentrations. This work involved examining two 
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Chapter 2  
Correlating the effects of antimicrobial preservatives on conformational stability, aggregation 




















  Multi-dose formulations constitute approximately one-third of all parenteral formulations1. 
Multi-dose formulations offer multiple advantages over single use formulations, including: (1) 
product wastage is minimized, since different sized doses can be drawn overtime from the same 
container, (2) product efficacy and safety is maintained in an opened container over a longer period 
of time due to inhibition of microbial growth, and (3) product packaging is minimized which is 
beneficial from economic and patient compliance perspective1. One challenge in the development 
of multi-dose injectable formulations is to inhibit microbial growth unintentionally introduced into 
the containers during multiple drawings. For this reason, antimicrobial preservatives (APs) are 
added to multi-dose formulations to inhibit microbial growth during storage and administration2. 
Despite the benefit that APs offer, they have been shown to cause physical instability when added 
to formulations of protein-based drugs via protein structural alterations and aggregation3-7. Heljo 
et al linked peptide-preservative interactions to a decrease in the antimicrobial efficacy of APs and 
an increase in peptide self-interactions. Using NMR, they determined that the extent to which 
phenolic APs bind/interact to the peptides follows the order of their cLogP (calculated value of the 
octanol-water partition coefficient) values (more hydrophobic APs bound more strongly showed 
greater binding)8. To better understand how APs interact with, and potentially destabilize, more 
complex proteins such as mAbs, we have examined the effects of four different commonly-used 
pharmaceutical phenolic APs, m-cresol, phenol, phenoxyethanol and benzyl alcohol, with different 
hydrophobicities on an immunoglobulin G1 (IgG1) monoclonal antibody (mAb) as a model multi-
domain therapeutic protein. 
  IgG1 mAbs are one the most important and successful classes of biotherapeutic agents. 
Due to their specificity, affinity and avidity, ~40 monoclonal antibodies have now been approved 
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by regulatory agencies and scores of mAbs are currently being researched for treatment of a wide 
spectrum of human diseases9. IgG1 antibodies are multi-domain, glycosylated proteins containing 
four polypeptide chains (two heavy and two light chains) connected by inter and intramolecular 
disulfide bond linkages. The structure of IgG1 mAbs can further be classified into Fab (antigen 
binding fragment) and Fc (crystallizable fragment). These two fragments (Fab and Fc) contain 
constant (CL and CH1) and variable domains (VL and VH) in the Fab and constant domains in the 
Fc fragment (CH2 and CH3)
10. The Fab and Fc fragments are joined by a proline-rich, unstructured 
and highly dynamic hinge11,12. The hinge region imparts structural independence to the Fab and 
Fc fragments, enabling the antibody domains to exhibit a wide-range of global and local dynamical 
motions relative to each other13.  
  Similar to other protein-based therapeutics, antibodies are susceptible to structural 
destabilization and aggregation upon exposure to external environmental stresses during 
manufacturing, product storage, and administration 9,14,15. Covalent and non-covalent protein-
protein interactions that lead to irreversible protein aggregation can be triggered by changes in 
solution conditions (e.g., pH and addition of cosolutes) or external stresses (e.g., agitation, 
temperature, freeze-thaw, interface exposure, etc.). Conformational integrity of protein molecules 
and colloidal stability of their interactions both can play a role in the protein aggregation potential 
of proteins. For example, antibodies can undergo significant conformation changes that cause 
hydrophobic patches from the core of the antibody structure to become solvent exposed. These 
surface exposed patches of hydrophobic residues can then initiate intermolecular contacts, or in 
contrast, the nature of charge-charge interactions can alter causing a decrease in antibody colloidal 
stability16.  protein aggregation induced by Conformational perturbation occurs through generation 
of a partially unfolded conformer of the monomeric species16. The population of the partially 
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perturbed conformer dictates the extent of protein aggregation and subsequent generation of 
protein particles. Previous studies have emphasized the importance of the stability of the protein 
aggregation hotspots (aggregation-prone motifs) in governing protein aggregation and physical 
stability17,18. Previously, we have highlighted the utility of studying changes in local flexibility of 
protein aggregation hotspots in response to external stresses and solution conditions using 
hydrogen exchange-mass spectrometry (HX-MS) 19,20. Developing a deeper understanding of 
protein aggregation pathways and particle formation is of great importance as protein aggregates 
can illicit unwanted immune responses in patients that may reduce the efficacy and safety of 
antibody therapy21. 
 Protein flexibility has a complex relationship with the overall physical stability of proteins, 
especially from a pharmaceutical point of view22. Lower-resolution biophysical techniques like 
red-edge excitation shift fluorescence and ultrasonic spectroscopy that measure global dynamics 
of proteins were used by Thakkar et al to imply a direct relationship between mAb global dynamics 
and physical stability23.  In the present study, in addition to developing a better understanding of 
how APs affect mAb conformational stability and aggregation profiles, we also expand on our 
previous research to draw correlations between mAb local backbone flexibility, conformational 
stability (DSC and extrinsic fluorescence) and aggregation propensity (SEC). Interestingly, the 
phenolic APs tested in this study affect local flexibility of the same protein aggregation hot-spot 
in the CH2 domain of this IgG1 mAb (mAb-4) that was strongly correlated with physical stability 
profiles of other mAbs 19,20,24,25. We also determined that the extent of change in the local flexibility 
of the CH2 protein aggregation hot-spot, conformational instability and increased aggregation 
propensity of mAb-4 correlate well with the hydrophobicity of the phenolic APs. based on the 
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calculated log of the octanol-water partition coefficient (cLogP, see Table 1), an established 
measure of its hydrophobicity. Higher values of cLogP indicate higher hydrophobicity.  
 
2.2 Materials and Methods  
2.2.1 Materials 
A highly purified IgG1 monoclonal antibody, mAb-4, was obtained from Janssen Biotech Inc. 
(Horsham, PA) at a stock concentration of approximately 40 mg/mL. LC-MS grade water, 2-
propanol, LC-MS grade water containing 0.1% formic acid, citric acid monohydrate, dibasic 
anhydrous sodium phosphate and sodium chloride were obtained from Fisher Scientific (Fair 
Lawn, NJ). Liquid chromatography grade acetic acid and phosphoric acid were obtained from 
Fluka (Saint Louis, MO). LC-MS grade acetonitrile containing 0.1% formic acid was purchased 
from Honeywell (Morristown, NJ). Porcine pepsin, tris (2-caboxyethyl) phosphine hydrochloride 
(TCEP), guanidine hydrochloride, deuterium oxide (99.9% D), m-cresol (99%), GC grade phenol 
(≥99.5%), 2-phenoxyethanol (≥99%) and benzyl alcohol (≥99%) were purchased from Sigma-
Aldrich (Saint Louis, MO) 
 
2.2.2 Sample Preparation 
All samples of mAb-4 were prepared by dialyzing the mAb stock solution against the indicated 
corresponding buffer using 3500 kDa molecular-weight cutoff membranes (Slide-A-Lyzer, 




2.2.3 Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) thermograms were obtained on a Microcal VP-Capillary 
DSC with autosampler (MicroCal, Northampton, MA), over a temperature range of 10 - 90°C at a 
scan rate of 60°C/hour. All samples of mAb-4, at a concentration of 1 mg/mL, were prepared in 
20 mM citrate-phosphate buffer (pH 6.0) containing 100 mM NaCl with or without 53 mM m-
cresol, phenol, phenoxyethanol or benzyl alcohol (mAb-4 to AP ratio was kept at 1:8000, 
therefore, 53 mM AP was added to a solution of 1 mg/mL mAb-4). Thermograms of mAb-4 at a 
concentration of 1 mg/mL in the presence of 100 mM NaCl alone (control) or containing 53 mM 
APs were compared to the reference thermograms of corresponding buffers containing no protein. 
Data were analyzed using Origin 7.0 software package with MicroCal LLC DSC plug-in. Thermal 
melting (Tm) values were obtained by iteratively fitting the thermograms to a non-two-state model 
for unfolding. Onset temperature for unfolding (Tonset) values were determined using a procedure 
described by Manikwar et al 20. 
 
2.2.4 8-Anilino-1-Napthalene Sulfonate (ANS) Extrinsic fluorescence 
Unfolding of mAb-4 with increase in temperature in the presence of preservatives was also 
monitored by measuring fluorescence emission of 8-anilino-1-napthalene sulfonate (ANS) using 
a QM-40 spectrofluorometer (Photon Technology International (PTI), Inc., Birmingham, NJ) 
equipped with a four position cell holder and Peltier temperature control device (Quantum 
Northwest). ANS was added to the protein solution at a 20-fold molar excess and excited at 375 
nm. Excitation and emission slits were set at 4 nm. Emission spectra were collected from 400 to 
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600 nm (step size 1 nm) at an interval of 2.5°C, over a temperature range of 10-87.5°C. Emission 
peak intensity was monitored at 475 nm.  
 
2.2.5 Accelerated Storage Stability Study 
Samples of mAb-4 in 20 mM citrate-phosphate buffer (pH 6.0), containing 100 mM NaCl in the 
absence of preservatives (control), or containing 53 mM of m-cresol, phenol, phenoxyethanol or 
benzyl alcohol were prepared at a protein concentration of 1 mg/mL. These samples were sterile 
filtered through a 0.22 μm filter (Millipore, Billerica, MA) and 1 mL aliquots were dispensed into 
2 mL borosilicate glass type I vials (West Pharmaceutical Services, Exton, PA). Vials containing 
mAb-4 samples were then stored in triplicate at 50°C for 2, 4, 14 and 28 days. 
 
2.2.6 Size Exclusion High-Performance Liquid Chromatography 
To analyze mAb-4 samples, a Shimadzu high performance liquid-chromatography system 
equipped with a photodiode array detector. A 7.8 mm × 30 cm Tosoh TSK-Gel BioAssist G3SWxL 
(TOSOH Biosciences, King of Prussia, PA) and a corresponding guard column were 
preconditioned and calibrated using gel-filtration molecular weight standards (Bio-Rad, Hercules, 
CA). All samples of mAb-4 control and with preservatives, were centrifuged at 14000×g for 5 
minutes to remove any insoluble aggregates. a mobile phase containing 0.2 M sodium phosphate, 
pH 6.8 at a flowrate of 0.7 mL min-1 was used to separate mAb-4 species based on their 
hydrodynamic size. A dual wavelength quantification method described by Bond et al26 was used 
to quantify the amounts of various species (soluble aggregates, monomer and fragments) of mAb-
4. To quantify the amount of insoluble aggregates, the total area (sum of all SEC peaks) of mAb-
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4 chromatogram at each time point was subtracted from its corresponding time zero sample. This 
difference was defined as the total amount of insoluble aggregates present in than sample. The 
percentage of insoluble aggregates, soluble aggregates and monomer loss in mAb-4 samples are 
reported as described in Manikwar et al20. 
 
2.2.7 Hydrogen Exchange-Mass Spectrometry 
The stock solution of mAb-4 was diluted to a final concentration of 20 mg/mL using 20 mM 
citrate-phosphate buffer containing 100 mM NaCl at pH 6.0. For sample handling, preparation and 
injection an H/DX PAL robot (LEAP Technologies, Carrboro, NC) was used. To initiate the 
hydrogen exchange process, 2 μL of protein stock (at 20 mg/mL) was diluted in a 1:20 ratio with 
38 μL of labelling buffers (20 mM citrate-phosphate containing 100 mM NaCl at pH 6.0) 
containing either no preservatives (control) or 53 mM of m-cresol, phenol, phenoxyethanol or 
benzyl alcohol prepared in deuterium oxide. Thereafter, the reaction mixture was incubated at 
25°C for four exchange time-points, 30, 150, 1000 and 10000 seconds prepared in triplicate. 
Hydrogen exchange was quenched by 1:1 dilution with 0.2 M phosphate buffer at pH 2.5 
containing 0.5 M TCEP and 4 M guanidine HCl in H2O to stop the hydrogen exchange process. 
During the deuterium labeling and quenching steps, labeling buffers and quench buffer were 
maintained at 25°C and 1°C respectively using temperature controlled drawers of the H/DX PAL 
robot. Subsequent to the quench step, samples were loaded into the sample loop of the refrigerated 
column compartment containing connected to an Agilent 1260 infinity series LC (Agilent 
Technologies, Santa Clara, CA), an immobilized pepsin column, a peptide desalting trap and a 
C18 column. The temperature of the refrigerated LC compartment was maintained at 1°C to reduce 
the extent of back-exchange. Mobile phase A containing 0.1% formic acid was used to for protein 
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digestion and desalting. A combination of mobile phase A and mobile phase B (90% acetonitrile 
+ 10% water and 0.1% formic acid) was used to elute the peptides19,27. To minimize the carry-over 
of peptides from the previous runs, immobilized pepsin column was washed between each HX run 
using a procedure described previously22,27. The level of deuteration in each peptide was measured 
using an Agilent 6530 quadrupole-time of flight mass spectrometer (Agilent Technologies, Santa 
Clara, CA), equipped with a standard electrospray ionization source operated in positive mode. 
 
2.2.8 Mass Spectrometry data analysis 
Accurate mass measurements in combination with collision induced dissociation with 
tandem MS on an Agilent 6530 quadrupole-time of flight mass spectrometer was used to identify 
mAb-4 peptides. A total of 140 unique mAb-4 peptides covering approximately 92% of the 
primary sequence were identified and utilized for subsequent hydrogen exchange (HX) analysis. 
HDExaminer 2.0 software package (Sierra Analytics, Modesto, CA) was used to analyze the HX 
data and an R-script developed in-house was used to generate deuterium uptake plots with average 
deuterium uptake values and standard deviations for triplicate HX runs for each peptide of mAb-
4. To identify statistically significant differences between mAb-4 control sample (no 
preservatives) and samples containing preservatives, a 99% confidence interval value for the entire 
dataset was calculated and established as ± 0.18 Da using a method described by Houde et al24. 
Differences in HX crossing the 99% confidence limit were deemed significant and were displayed 
on the homology model of mAb-4 based on crystal structure of an isolated Fc fragment28 and the 





2.3.1 Antimicrobial preservatives decrease the thermal stability of mAb-4 
  A combination of differential scanning calorimetry (DSC) and extrinsic fluorescence 
spectroscopy was utilized to probe the effects of antimicrobial preservatives (APs) on the overall 
thermal stability of mAb-4. Four different APs commonly used as pharmaceutical agents were 
chosen in this study based on differences in their physical properties such as cLogP values (see 
Table 1). Figure 1a-d shows representative DSC thermograms of mAb-4 in the presence of each 
of the four APs while Table 2 summarizes the Tonset and the two Tm values from triplicate runs. 
Two distinct thermal unfolding events were observed in the thermograms of mAb-4 at pH 6.0. 
Based on previously reported DSC analyses with other of IgG1 mAbs,30,31 the first thermal 
transition likely represents unfolding of the CH2 and Fab domains (labeled Tm1/Tm2) while the 
second transition is the unfolding of Fc domain (labeled Tm3). Each of the APs destabilized mAb-
4 indicated by decreases in the thermal transition values (Tonset and Tm) compared to the mAb in 
the absence of APs. Interestingly, the ranking of decreased thermal stability is the same as the 
ranking of cLogP, with the most hydrophobic AP causing the greatest destabilization as 
represented by ΔTonset and ΔTm values (Table 2). 
  To further assess the destabilizing effect of APs on mAb-4 conformational stability, 
extrinsic fluorescence spectroscopy experiments using ANS as an extrinsic probe were conducted. 
Figure 2 shows the change in ANS emission peak intensity (wavelength 475 nm) of mAb-4 
samples with increasing temperature in the presence of the various APs tested. Onset temperature 
for unfolding of mAb-4 in the presence of APs was measured and compared to the control as 
shown in Table 3. The magnitude of destabilization of mAb-4 conformational integrity in the 
presence of the various APs followed the same trend seen in DSC experiments. In summary, both 
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DSC and extrinsic fluorescence spectroscopy analyses demonstrated that antimicrobial 
preservatives cause a decrease in mAb-4 overall conformational stability where the most 
hydrophobic AP caused the biggest destabilization followed by APs with decreasing cLogP values 
(table 2 and 3). 
 
2.3.2 Antimicrobial preservatives decrease the stability of mAb-4 under accelerated 
conditions 
  To assess the effect of APs on accelerated storage stability profiles, mAb-4 samples were 
stored at 50°C for up to 28 days. Size exclusion chromatography (SEC) was utilized to compare 
the monomer, aggregate and fragment content in mAb-4 samples in the presence of selected APs 
compared to the control (no preservatives) at day zero and over time. Overlaid SEC 
chromatographic profiles of these samples are shown in dotted lines in Supplemental Figure S1. 
No noticeable change was observed between chromatographic profiles of mAb-4 samples at time 
zero. Supplemental Figure S1 also shows overlaid chromatographic profiles of mAb-4 samples 
with preservatives after 28 days of storage at 50°C in which significant increases in the peak areas 
of multimeric protein complexes and fragments (solid lines, peak assignments based on 
comparison to molecular weight standards) were observed. The effects of the preservatives on 
mAb-4 stability in terms of percent loss in monomer content and percent increase in soluble and 
insoluble aggregates during accelerated storage are summarized in Figure 3 (monomer loss in Fig 
3A, and increase in soluble aggregates and insoluble aggregates in Figs 3B and Fig3C, 
respectively). Samples of mAb-4 containing APs showed elevated soluble (dimers and multimers) 
and insoluble aggregates at during storage at 50°C. Moreover, as shown in Figure 3D, m-cresol 
caused largest increase in total aggregates after 28 days (14.5%) followed by the addition of phenol 
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(9%), phenoxyethanol (5.5%) and benzyl alcohol (4.3%). In summary, the trend in the increase in 
aggregation propensity of mAb-4 in the presence of APs follows the rank order of AP 
hydrophobicity, where the most hydrophobic AP caused the greatest increase in mAb-4 
aggregation. 
            
2.3.3 Backbone flexibility of mAb-4 in control buffer (No Preservatives) 
Interrelationship between intrinsic protein dynamics and aggregation propensity has been 
a continuous topic of interest32,33. Here, hydrogen exchange mass spectrometry was utilized to 
measure relative backbone flexibility of mAb-4 in control buffer conditions (20 mM citrate-
phosphate, 100 mM NaCl, pH 6.0). A total of 140 mAb-4 peptides covering 90% of the primary 
sequence were identified. Deuterium uptake at 30 seconds for all mAb-4 peptides in the presence 
of 100 mM NaCl was measured and used to calculate percent flexibility as described by Majumdar 
et al19 using equation 1:  
                                                Flexibility (%) =
∆m30s
Nf
× 100%                                         (1) 
where Δm30s denotes the mass increase after 30 seconds of exchange, N is the number of 
exchangeable backbone protons conditions (all non-proline residues starting from position 3 of 
every peptide segment34) and f denotes the mole fraction of deuterium available for exchange under 
chosen labeling (f = 0.99). The distribution of percent flexibility for every mAb-4 segment is given 
in Supplemental Figure S2A. Peptide segments of mAB-4 that are in the lowest quartile of 
flexibility are classified as rigid, while the peptides in the top quartile are classified as flexible and 
segments in the middle 50% as intermediate. Regions where overlapping peptides showed 
conflicting results, flexible or rigid categories took priority over intermediate category and rigid 
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category took priority over flexible category. Figure S2B shows the flexibility categories mapped 
onto a homology model of mAb-4 (Supplemental Figure S2B). Several surface exposed secondary 
structural elements within mAb-4 (loops and β-strands in the Fab and CH3 domains), were highly 
flexible (colored in yellow) while most of CH2 domain and buried β-strands and loops in other 
domains of mAb-4 had lower flexibility (lowest quartile, colored in blue). No apparent correlation 
between mAb-4 flexibilities and segment-averaged B factor values obtained from the crystal 
structure of the antibody for peptides with identical sequences from the constant domains of the 
two mAbs (data not shown)28. The effect of APs on the relative local flexibility these domain 
regions in mAb-4 are addressed in the following section. 
 
2.3.4 Antimicrobial preservatives affect the local backbone flexibility of mAb-4 
To measure the effect of antimicrobial preservatives on mAb-4 local backbone flexibility, 
mAb samples were labeled by hydrogen exchange in deuterated solutions containing 20 mM citrate 
phosphate buffer (pH 6.0) containing 100 mM NaCl and 53 mM of each antimicrobial 
preservatives, m-cresol, phenol, phenoxyethanol and benzyl alcohol at 25°C. To identify localized 
effects of APs on mAb-4’s backbone flexibility, hydrogen exchange profiles of each of the 140 
peptide segments from mAb-4 was measured for up to 10000 seconds) in the presence of each of 
the APs and compared to the mAb-4 control (no APs). Figure 4 shows hydrogen exchange kinetics 
of six representative peptides from mAb-4 for the antibody in control buffer and in the presence 
of each of the four APs. Local flexibility of several regions within mAb-4 did not change upon 
addition of APs, while for other for other regions changed significantly (99% confidence interval, 
0.18 Da). For example, local flexibility of peptide region HC 237-254 in the CH2 domain of the 
antibody increased upon addition of all APs tested (two representative peptides from this region 
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shown in Figure 4), and these trends in the increase in local flexibility of this peptide segment, 
primarily at 1000 and 10000 seconds, correlates with the decrease in mAb-4 conformational 
stability and protein aggregation induced by APs described above.  
 Difference plots for all the 140 peptides within mAb-4 present a global comparison of their 
deuterium uptake values between mAb-4 in control buffer containing APs vs. mAb-4 in the control 
buffer alone (Figure 5). Relative mass differences (Δm, equation 2) for mAb-4 peptides are plotted 
on the vertical axis and peptide number is plotted on the horizontal of the plot. 
                                                    ∆𝑚 = 𝑚AP −𝑚control                                                  (2) 
 A positive value for Δm signifies an increase in the HX rate of the mAb segment in the presence 
of Aps implying an increase in flexibility while and a negative value indicates that the rate of HX 
is slower implying that APs decrease the flexibility of that peptide segment.  
 A nearly global increase in mAb-4 backbone flexibility was observed in the presence of 
APs (majority of individual changes were not significant at the 99% confidence limit of the 
dataset). The values for backbone flexibility for peptide segments were added together and 
subtracted from the control (no AP) to get a value for global flexibility change (Δmglobal, table 4). 
Increase in global flexibility in the presence of APs followed their hydrophobicity rank order, 
where the most hydrophobic AP (m-cresol) showed the biggest increase in global flexibility. Local 
flexibility of peptides covering HC 182-254 (peptides 42 to 57) spanning parts of both CH1 and 
CH2 domains of mAb-4 increased significantly at 150 second time-point upon addition of m-cresol 
and phenol. Although this increase was significant, its magnitude of increase over the significance 
limit was small. For the later time points, 1000 and 10000 seconds, local flexibility of peptides 
covering segment HC 237-254 (peptides 50 to 57) increased significantly upon addition of all APs, 
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however, the magnitude of this increase was much greater in comparison to 150 second time-point 
and also correlated with physical stability measurements. Backbone flexibility of overlapping 
peptides covering LC 183-215 (peptides 131 to 140) significantly increased (150, 1000 and 10000 
second time-points) upon addition of phenoxyethanol and benzyl alcohol and to a lesser extent in 
m-cresol and phenol, however, no direct correlation was apparent between flexibility increase in 
this segment and mAb-4 physical stability trends.  
 Not all peptides became more flexible in the presence of APs. Segment HC 50-59 (peptide 
12) in the VH domain became significantly more rigid in the presence of m-cresol and 
phenoxyethanol at 10000 second time-point. Backbone flexibility of HC 147-160 (CH1 domain, 
peptide 32) significantly decreased at 150 and 1000 second time-points upon addition of phenol. 
All the significant changes in local backbone flexibility (increases or decreases) observed above 
were mapped onto the homology model of mAb-4 (Figure 6). Regions (peptide segments) with 
increased or decreased local flexibility are colored in magenta and blue, respectively. In addition, 
peptide region HC 237-254 (peptides 50 to 57) in the CH2 domain of the antibody, where strong 
correlations between changes in local flexibility and mAb-4 physical stability were observed, is 
colored yellow in Figure 6 and labelled as the “primary effect”. 
 
2.4 Discussion  
 Antimicrobial preservatives are used in multi-dose parenteral formulations to inhibit and 
prevent inadvertent microbial growth during repeated drawing of drug dosage over time1,35. In 
addition to APs desirable inhibitory effect on microbial growth, however, APs have been shown 
to decrease physical stability and promote protein aggregation4,36,37. In the present work we use an 
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IgG1 monoclonal antibody to elucidate mechanistic insights into the destabilizing effects of four 
phenolic APs commonly used in pharmaceutical formulations. HX-MS is utilized to probe the 
effect of APs on the local flexibility of various peptide segments across the twelve Ig domains of 
the IgG1 mAb, and the findings are examined in comparison to the conformational stability and 
accelerated storage stability of the antibody in the presence of APs. This result demonstrates 
correlations between high resolution HX-MS characterization of mAb local flexibility in the 
presence of destabilizing APs and protein conformational stability/aggregation propensity. Several 
studies have identified such correlations between the local flexibility of CH2 domain peptide 
segments covering the region HC 237-254 and changes in the conformational stability and 
aggregation propensity of antibodies19,20,25,38,39. The present study provides additional data in 
support of HX-MS as a useful analytical tool for reliable monitoring of altered HX of aggregation 
hot-spots in the presence excipients thus, can be utilized for formulation development of mAbs. 
 Four APs that are commonly used in multi-dose formulations of protein therapeutics were 
chosen for this study, m-cresol, phenol, phenoxyethanol and benzyl alcohol. These APs are 
phenolic compounds and span a wide range of hydrophobicity (cLogP). The decrease in mAb 
conformational stability and increase in its aggregation propensity in the presence of APs followed 
their hydrophobicity rank ordering (table 1). The most hydrophobic AP of the four, m-cresol, 
caused the biggest conformational destabilization (measured by DSC and extrinsic fluorescence) 
and increase in aggregation propensity/kinetics (measured by SEC), followed by phenol, then 
phenoxyethanol and the least destabilizing benzyl alcohol (rank ordered in table 2 and 3). Several 
studies probed the effect of phenolic APs on smaller proteins and had similar observations. Maa 
and Hsu tested the effects of several phenolic APs (including m-cresol, phenol and benzyl alcohol) 
on physical stability and aggregation propensity of human growth hormone. They found that 
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among the three overlapping APs tested, m-cresol was the most destabilizing followed by phenol 
and then the least destabilizing, benzyl alcohol36. Gupta and Kaisheva probed the effect of these 
APs on aggregation propensity of an antibody under isothermal incubation conditions, they 
reached similar conclusions where more hydrophobic APs, m-cresol followed by phenol caused 
more aggregation when compared to less hydrophobic benzyl alcohol3. Decrease in 
conformational stability and increase in aggregation propensity of interleukin-1 receptor in the 
presence m-cresol, phenol and benzyl alcohol also correlated with their hydrophobicity rank 
ordering40. Heljo et al extended this research to peptides and probed the effect of APs on peptide 
stability, reaching the same conclusion where more hydrophobic m-cresol caused greater peptide 
destabilization followed by phenol which was followed by benzyl alcohol8. However, in another 
study, Bis et al and Hutchings et al probed the effect of phenolic APs on the physical stability and 
aggregation propensity of cytochrome c and interferon-α-2a. For both of these proteins, they 
demonstrated that although m-cresol was the most destabilizing AP followed by phenol, benzyl 
alcohol caused more protein aggregation than phenoxyethanol2,37. This behavior is opposite to 
what we have reported in this study: phenoxyethanol is more destabilizing than benzyl alcohol for 
mAb-4 which can be attributed to the differences in the proteins and/or possibly solution 
conditions. 
 Hydrogen exchange mass spectrometry was used in this study to probe the effects of the 
four phenolic APs on the local flexibility of mAb-4. HX-MS provides an excellent opportunity to 
examine changes in local flexibility of proteins upon changes in external environment or solution 
conditions. Correlation between changes in local flexibility in protein segments and global stability 
is of great interest to pharmaceutical scientists as it can shed light on to the mechanisms by which 
protein structure gets destabilized which eventually leads to protein aggregation. Two notable 
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effects were noted in this study in terms effects of phenolic APs on local flexibility of mAb-4.  
First, a nearly global increase in local flexibility was observed for mAb-4 peptides in the presence 
of all APs at 1000 and 10000 second time-point, although most of these differences were not 
statistically significant (Δm < 0.18 Da). This observation correlates very well with the DSC data 
(figure 1, table 2) that showed a decrease in all thermal transitions (Tm1/Tm2 and Tm3) 
corresponding to CH2, Fab and CH3 domains of mAb-4 in the presence of APs. Second, local 
flexibility of peptide segments in region HC 237-254 in the CH2 domain increased significantly 
upon addition of APs to mAb-4, and this increase was more pronounced than changes in local 
flexibility of other peptide segments.  This trend follows the rank ordering of hydrophobicity 
values of the APs which correlates well with the trends observed for physical stability and 
aggregation propensity of mAb-4 in the presence of APs (table 2 and 3). 
 Phenolic compounds have been previously used as solution additives to screen various 
physical properties of solvents that affect protein stability41,42. Addition of phenolic compounds 
can affect local hydrophobic contacts within the protein structure causing local 
unfolding/increased flexibility events as seen in the CH2 domain segment of mAb-4
41,43.  
Thirumangalathu et al hypothesized that phenolic compounds increase the amount of aggregation-
prone protein molecules with partially perturbed tertiary structure/ increased local flexibility in 
solution thereby increasing the extent of overall non-native aggregation6. It has been found in 
previous studies that cosolvents that enhance the aggregation potential of proteins, do so by 
shifting the equilibrium towards the partially unfolded conformation of the protein structure. For 
example, aggregation potential of IgG light chain variable domains increase upon addition of 
Congo red that shifts the equilibrium towards the partially unfolded conformer of the protein44. 
This behavior can potentially be explained by the Wyman Linkage function45. According to this 
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mechanism, aggregation-inducing ligands such as phenolic APs stabilize the aggregation-prone 
partially unfolded form of the protein, thereby, stabilizing these species through hydrophobic 
interactions and pairwise π-π and cation-π interactions that result in increase in the amount of 
partially perturbed conforms5. The difference in destabilization potential of the APs tested can 
potentially be explained by the differences in the extent of stabilization of aggregation-prone 
partially unfolded conformers (i.e., the primary effect in the CH2 domain) of mAb-4. This is further 
supported by both extrinsic fluorescence spectroscopy and HX-MS results. Lower onset 
temperature for tertiary structure unfolding measured by extrinsic fluorescence signifies loosely 
packed structure of mAb-4 in the presence of APs, where m-cresol being the most hydrophobic 
AP results in greater stabilization of partially perturbed conformers of mAb-4 followed by phenol, 
phenoxyethanol and benzyl alcohol. 
 Excellent correlation was observed between preservative-induced physical destabilization 
of mAb-4 and increase in local flexibility of HC 237-254 in the mAb CH2 domain. Both of these 
observations further correlated with the rank ordering of APs based on their hydrophobicity values. 
Previous studies conducted in our laboratories examined the effect of stabilizing and destabilizing 
excipients (chaotropic and kosmotropic salts, arginine and sucrose) on mAb physical stability, 
aggregation propensity and local flexibility of a different IgG1 mAb. A substantial increase in 
flexibility of two regions in the CH2 domain of the antibody was observed in the presence of 
arginine and chaotropic salts. This increase in local flexibility was then associated with decrease 
in conformational stability and increase in aggregation propensity of mAb in the presence of those 
cosolvents. No such effect was observed in the presence of sucrose and kosmotropic salts 19,20. In 
a follow up study, the authors probed the effect of distal, destabilizing mutations on the local 
flexibility of mAb domains. The same region in the CH2 domain of the antibody showed significant 
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increase in local flexibility in destabilized mutant mAb molecule46. Two other studies also reported 
this peptide segment in the CH2 domain of mAbs to be the least stable and most aggregation prone 
region  of theprotein25,47. One study found this CH2 peptide segment (HC 243-247) to be more 
flexible in both oxidized and deglycosylated IgG molecules which also had lower physical 
stabilty25. In the other study, insertion of an engineered disulfide bond in the same peptide segment 
of the CH2 domain increased the thermal stability of the isolated CH2 domain of an antibody by 
about 20°C48. One of the two cysteines in the engineered antibody was inserted at (L242C), which 
lies in the same CH2 domain aggregation hot-spot peptide segment. Engineered disulfides have 
been known to decrease local flexibility of the molecules through direct and allosteric effects49,50. 
All these studies together support the assertion that the changes in the local flexibility of peptide 
segment HC 237-254 in the CH2 domain of the IgG1 antibody strongly correlate with the changes 
in global physical stability and aggregation propensity of the same antibody molecule. 
 Peptide segment HC 237-254 in the CH2 domain contains two phenylalanine residues and 
several aliphatic residues that pack next to the glycans51. Phenolic APs may have direct or allosteric 
interactions with the mAb structure which can cause an increase in the local flexibility of the 
hydrophobic aggregation “hot-spot” region. This increased local flexibility could further cause 
increase in surface exposure of apolar residues ultimately resulting in intermolecular interactions 
with neighboring antibody molecules and formation of seed nuclei for future aggregation52,53. 
WaterLOGSY NMR and other binding studies between mAb and APs can help fully elucidating 
the actual mechanism of AP induced mAb destabilization (direct binding or indirect interactions). 
Such experiments are currently underway in our laboratories. The results in this study with a series 
of antimicrobial agents and an IgG1 mAb provide another example that demonstrates the utility of 
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HX-MS as an important analytical tool to identify stabilizing and destabilizing excipients for mAb 
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2.6 Tables and Figures 
Table 2.1 


















Structure and clogP (calculated log of partition coefficient, a measure of hydrophobicity of a 





Tm and Tonset for mAb4 in presence of different preservatives as measured by DSC 
mAb-4 in 20 mM citrate-







Mean ΔTonset Mean ΔTm1/2 Mean ΔTm3 
m-Cresol 1.98 52.6 -7.7 66.4 -5.6 78.1 -5.3 
Phenol 1.48 55.7 -4.6 68.4 -3.5 79.8 -3.6 
Phenoxyethanol 1.2 57.1 -3.3 68.4 -3.5 79.9 -3.5 
Benzyl alcohol 1.05 57.6 -2.8 69.4 -2.5 80.8 -2.7 
No Preservatives (Control) - 60.3 - 71.9 - 83.4 - 
n=3, Standard Deviation = ≥ 0.1, ≤ 0.8 
Effects of antimicrobial preservatives on thermal melting temperature (Tm) and thermal onset 
temperature (Tonset) values for mAb-4 as measured by DSC. All mAb samples were prepared in 20 
mM citrate-phosphate buffer (6.0) containing 100 mM NaCl with or without 53 mM APs. Range 













Tonset for mAb4 in presence of different preservatives as measured by DSC 
mAb-4 in 20 mM citrate-phosphate, 





m-Cresol 1.98 56.0 -7.9 
Phenol 1.48 58.4 -5.5 
Phenoxyethanol 1.2 59.8 -4.1 
Benzyl alcohol 1.05 61.1 -2.8 
No Preservatives (Control) - 63.9 - 
                             n=3, Standard Deviation = ≥ 0.1, ≤ 0.4 
Thermal onset temperature (Tonset) values for mAb-4 unfolding in the presence of antimicrobial 
preservatives as measured by extrinsic fluorescence. All samples of mAb-4 were prepared in 20 
mM citrate-phosphate buffer (pH 6.0) containing 100 mM NaCl with or without 53 mM APs. 












Δmglobal for mAb4 in presence of different preservatives as measured by HX-MS 
                 mAb-4 in 20 mM citrate-
phosphate, 100 mM, NaCl, pH 6.0 
containing 
LogP Δmglobal 
m-Cresol 1.98 37.5 
Phenol 1.48 33.2 
Phenoxyethanol 1.2 27.9 
Benzyl alcohol 1.05 19.7 
n=3, Standard Deviation ≤ 0.7 
Global flexibility change (Δmglobal) of mAb-4 in the presence of APs as measured by HX-MS. All 
samples of mAb-4 were prepared in deuterated solution of 20 mM citrate-phosphate buffer (pH 














Peptide number Peptide ID 
1 Heavy 4-22 (VH) 
2 Heavy 4-23 (VH) 
3 Heavy 5-26 (VH) 
4 Heavy 27-34 (VH) 
5 Heavy 27-36 (VH) 
6 Heavy 28-34 (VH) 
7 Heavy 30-34 (VH) 
8 Heavy 35-46 (VH) 
9 Heavy 35-49 (VH) 
10 Heavy 35-50 (VH) 
11 Heavy 37-50 (VH) 
12 Heavy 50-59 (VH) 
13 Heavy 51-59 (VH) 
14 Heavy 60-68 (VH) 
15 Heavy 69-78 (VH) 
16 Heavy 69-79 (VH) 
17 Heavy 69-80 (VH) 
18 Heavy 69-81 (VH) 
19 Heavy 80-86 (VH) 
20 Heavy 81-86 (VH) 
21 Heavy 84-93 (VH) 
22 Heavy 87-93 (VH) 
23 Heavy 91-126 (VH) 
24 Heavy 105-114 (VH) 
25 Heavy 106-114 (VH) 
26 Heavy 106-116 (VH) 
27 Heavy 107-114 (VH) 
28 Heavy 115-128 (VH) 
29 Heavy 115-134 (VH) 
30 Heavy 117-128 (VH) 
31 Heavy 147-160 (CH1) 
32 Heavy 147-176 (CH1) 
33 Heavy 148-160 (CH1) 
34 Heavy 148-176 (CH1) 
35 Heavy 158-165 (CH1) 
36 Heavy 158-176 (CH1) 
37 Heavy 161-176 (CH1) 
38 Heavy 165-176 (CH1) 
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39 Heavy 166-176 (CH1) 
40 Heavy 169-176 (CH1) 
41 Heavy 170-176 (CH1) 
42 Heavy 182-187 (CH1) 
43 Heavy 182-199 (CH1) 
44 Heavy 185-199 (CH1) 
45 Heavy 186-199 (CH1) 
46 Heavy 187-195 (CH1) 
47 Heavy 187-199 (CH1) 
48 Heavy 188-199 (CH1) 
49 Heavy 207-234 (CH1) 
50 Heavy 237-243 (CH2) 
51 Heavy 237-253 (CH2) 
52 Heavy 237-254 (CH2) 
53 Heavy 243-253 (CH2) 
54 Heavy 243-254 (CH2) 
55 Heavy 244-253 (CH2) 
56 Heavy 244-254 (CH2) 
57 Heavy 255-263 (CH2) 
58 Heavy 264-279 (CH2) 
59 Heavy 265-279 (CH2) 
60 Heavy 268-277 (CH2) 
61 Heavy 268-279 (CH2) 
62 Heavy 280-295 (CH2) 
63 Heavy 302-308 (CH2) 
64 Heavy 303-308 (CH2) 
65 Heavy 309-315 (CH2) 
66 Heavy 309-316 (CH2) 
67 Heavy 309-320 (CH2) 
68 Heavy 321-350 (CH2) 
69 Heavy 328-335 (CH3) 
70 Heavy 336-350 (CH3) 
71 Heavy 338-350 (CH3) 
72 Heavy 351-358 (CH3) 
73 Heavy 351-360 (CH3) 
74 Heavy 359-367 (CH3) 
75 Heavy 361-367 (CH3) 
76 Heavy 368-378 (CH3) 
77 Heavy 371-378 (CH3) 
78 Heavy 371-380 (CH3) 
79 Heavy 371-381 (CH3) 
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80 Heavy 371-382 (CH3) 
81 Heavy 379-392 (CH3) 
82 Heavy 379-400 (CH3) 
83 Heavy 381-400 (CH3) 
84 Heavy 382-400 (CH3) 
85 Heavy 383-392 (CH3) 
86 Heavy 383-400 (CH3) 
87 Heavy 392-400 (CH3) 
88 Heavy 393-400 (CH3) 
89 Heavy 394-400 (CH3) 
90 Heavy 407-412 (CH3) 
91 Heavy 408-412 (CH3) 
92 Heavy 413-425 (CH3) 
93 Heavy 429-448 (CH3) 
94 Heavy 431-448 (CH3) 
95 Heavy 433-448 (CH3) 
96 Heavy 435-448 (CH3) 
97 Heavy 435-449 (CH3) 
98 Heavy 443-449 (CH3) 
99 Light 1-10 (VL) 
100 Light 5-10 (VL) 
101 Light 12-19 (VL) 
102 Light 12-21 (VL) 
103 Light 19-30 (VL) 
104 Light 32-46 (VL) 
105 Light 33-46 (VL) 
106 Light 33-48 (VL) 
107 Light 36-46 (VL) 
108 Light 47-53 (VL) 
109 Light 47-70 (VL) 
110 Light 47-71 (VL) 
111 Light 54-62 (VL) 
112 Light 54-70 (VL) 
113 Light 71-82 (VL) 
114 Light 71-83 (VL) 
115 Light 75-82 (VL) 
116 Light 83-92 (VL) 
117 Light 97-104 (VL) 
118 Light 117-123 (CL) 
119 Light 117-126 (CL) 
120 Light 117-132 (CL) 
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121 Light 118-123 (CL) 
122 Light 118-126 (CL) 
123 Light 118-131 (CL) 
124 Light 118-133 (CL) 
125 Light 127-144 (CL) 
126 Light 137-144 (CL) 
127 Light 145-149 (CL) 
128 Light 154-162 (CL) 
129 Light 156-173 (CL) 
130 Light 161-173 (CL) 
131 Light 163-173 (CL) 
132 Light 163-174 (CL) 
133 Light 163-176 (CL) 
134 Light 163-180 (CL) 
135 Light 163-182 (CL) 
136 Light 174-182 (CL) 
137 Light 181-193 (CL) 
138 Light 183-196 (CL) 
139 Light 197-207 (CL) 
140 Light 197-215 (CL) 
 
Peptic peptides of mAb-4 with their location on the primary structure and sequential peptide 












Representative DSC thermograms of mAb-4 in the presence and absence (control) of antimicrobial 
preservatives (APs).  Samples contained 1 mg/mL protein in 20 mM citrate-phosphate buffer (pH 
6.0) containing 100 mM NaCl with and without 53 mM of indicated antimicrobial preservative. 
Thermograms show the effect of buffer containing (A) m-Cresol, (B) Phenol, (C) Phenoxyethanol 
and (D) Benzyl alcohol vs. buffer alone (control) on conformational stability of mAb-4. Thermal 
melting temperature (Tm) and thermal onset temperature (Tonset) values from triplicate experiments 










Extrinsic fluorescence spectroscopy analysis of mAb-4 conformational stability in the presence 
and absence (control) of antimicrobial preservatives. ANS extrinsic fluorescence temperature 
melts of mAb-4 in 20 mM citrate-phosphate buffer (pH 6.0) containing 100 mM NaCl with and 
without 53 mM of indicated antimicrobial preservative. Error bars represent one standard deviation 
from three independent measurements. Thermal onset temperature (Tonset) values from triplicate 












Time course of mAb-4 aggregation during storage at 50°C as monitored by SE-HPLC. Effect of 
different antimicrobial preservatives on mAb-4 is shown as (A) percent monomer loss, (B) 
increase in percent soluble aggregates, (C) increase in percent insoluble aggregates (loss of total 
area), and (D) total aggregates (soluble + insoluble).  Samples are in 20 mM citrate-phosphate 
buffer (pH 6.0) containing 100 mM NaCl with and without 53 mM of indicated antimicrobial 







Effect of antimicrobial preservatives on the deuterium uptake kinetics of six representative peptide 
segments of mAb-4 as measured by HX-MS. Error bars denote one standard deviation from three 
independent measurements. Samples are in 20 mM citrate-phosphate buffer (pH 6.0) containing 













Relative mass differences for all 140 peptide segments of mAb-4 in the presence of antimicrobial 
preservatives compared to the control (no preservatives) as measured by HX-MS. Dotted 
horizontal line represents 99% confidence limit for mass difference values for the whole dataset 
(±0.18 Da). The horizontal axis denotes the ordinal peptide numbers, sorted in ascending order 
starting from the N-terminus of the heavy chain of the antibody. Positive bars represent increased 
local flexibility in the peptide segments in the presence of antimicrobial preservatives. Negative 
values represent peptides with decreased local flexibility. Location of individual peptide segments 
is shown on the top of the figure. Each value of relative mass difference is an average of three 





Homology model of mAb-4 representing the effects of antimicrobial preservatives on local 
flexibility of the antibody relative to the control (no preservatives), as measured by HX-MS. On 
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right. Changes in the backbone flexibility of peptide segments from the CH2 domain “aggregation 
hotspot” are labelled as “primary effect” of preservatives as they show excellent correlation betwe 

























Overlay of SEC chromatograms of mAb-4 comparing pre and post thermal stress. Dotted lines 















Peptide coverage map of mAb-4 (A) heavy chain and (B) light chain. 140 peptide segments of 

















Relative local flexibility of mAb-4 in 20 mM citrate-phosphate buffer (pH 6.0) containing 100 
mM NaCl prepared in deuterium. (A) Percent flexibility of all 140 peptide segments of mAb-4 
obtained from the ratio of deuterium uptake at 30 second relative to the theoretical exchange for 















































Deuterium uptake curves for all 142 peptide segments of mAb-4 comparing HX kinetics in the 
presence of APs to control. Domain location and peptide number of the segment are shown in 
























 Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic 






























Monoclonal antibodies (mAbs) and mAb derivatives are currently the fastest growing 
segment of the biopharmaceutical drug market.176 Antibody therapy often requires relatively high 
dosing (>1 mg/kg) that can be administered either by intravenous (IV) or subcutaneous (SC) 
injection. Due to higher costs, lower patient compliance, and longer administration times 
associated with IV drug delivery by medical professionals, the self-administration of mAb drugs 
by patients at home via SC administration is being extensively investigated.1 The formulation 
development challenges for SC administration of mAbs at high concentrations (~100-150 mg/mL), 
for use in prefilled syringes and auto-injectors, include protein instability as well as injection 
volume limitations (less than 2 mL) due to high tissue backpressure or injection pain.1  
Molecular interactions that occur in high concentration formulations can also introduce 
challenges to the development and manufacturing of mAbs. As the intermolecular distance 
between individual molecules decreases at higher protein concentrations, the extent of non-ideal 
behavior increases due to intermolecular interactions between the mAbs.177,178 Such intermolecular 
interactions increase the propensity of antibody molecules to undergo reversible self-association 
(RSA) where non-covalent multimers can form at high protein concentrations and then dissociate 
upon dilution.13,14,16 The RSA of mAbs presents various pharmaceutical challenges, including the 
formation of protein aggregation precursors that can lead to the irreversible formation of 
oligomers.47,179  In addition, the RSA of mAbs gives rise to a network of associated higher order 
species that can affect the viscoelastic properties of the solution,80 resulting in increased 
viscosity,13,14,16,76 solution turbidity,93 and, under certain conditions, even phase transitions.180 The 
increase in solution viscosity also imposes manufacturing challenges including high back-pressure 
and clogging of membranes,1 as well as elevated levels of shear stress during pumping.181  
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Reversible-self association of mAbs is generally attributed to weak and transient non-
covalent interactions (e.g., hydrogen bonding, electrostatic, hydrophobic, π-π, and van der Waals 
interactions) between antibody molecules. As the protein concentration increases and the 
intermolecular distances decrease, the extent of non-covalent interactions between molecules 
rises.177,178 Not only have certain regions in the antibody structure (i.e., fragment antigen-binding 
region (Fab) and fragment crystallizable region, Fc) been shown to interact at high protein 
concentrations,182,183 such transient interactions have been shown to involve specific  amino acid 
residues and sequences within mAbs.182,184 In addition, varying solution conditions (e.g., ionic 
strength, pH, temperature, salt type, etc.) can either increase or decrease the extent of RSA of 
mAbs, depending on the distinct nature of the non-covalent interactions for an individual mAb 
formulated under specific conditions.79,185  
A variety of analytical tools have been used to characterize the RSA of proteins, and related 
effects on solution properties, including dynamic light scattering (DLS),21 composition-gradient 
multi-angle static light scattering,95,106 isothermal titration calorimetry,182 surface plasmon 
resonance,186 proton magnetic relaxation dispersion,187 nuclear magnetic resonance,188 
fluorescence resonance energy transfer,189 mass spectrometry (MS),190 self-interaction 
nanoparticle spectroscopy,191 size-exclusion chromatography,192 analytical ultracentrifugation,193 
small angle X-ray scattering,81 and atomic force microscopy.194 Most of these measurements 
provide reliable data only at low-to-moderate protein concentrations (~1-20 mg/mL). With further 
increases in protein concentration, the non-ideality of the solution, along with technical problems 
such as multiple scattering effects, compromises data reliability.195,196  NMR can provide higher 
resolution information about the site-specific nature of protein self-association, but the large size 
of antibody molecules and their complexes and the need for isotopic labeling limit the applicability 
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of NMR to examine the RSA of antibodies. Such limitations have led to the widespread use of 
solution viscosity to indirectly monitor RSA of mAbs at high protein concentrations (~20-200 
mg/mL).13,14,184 Although viscosity measurements provide an experimentally convenient method 
to monitor RSA behavior of mAbs, they do not provide site-specific information about protein-
protein interfaces.  
Hydrogen exchange mass spectrometry (HX-MS) provides an exciting opportunity to 
obtain high-resolution information about higher-order structure in antibodies.197-199 For example, 
HX-MS has been recently applied to examine the effect of various solution factors and 
physicochemical structural changes on the local flexibility of mAbs, including salts from 
Hofmeister series,137 pharmaceutical excipients,138 freeze-thaw cycles,200 methionine oxidation,165 
asparagine deamidation,201 antibody-drug conjugation,202 and deglycosylation and glycan 
modifications,157 and engineered point mutations.203 
In this study, antibody clusters were characterized by a combination of DLS and chemical 
cross-linking experiments to determine the effect of solution conditions on the extent of RSA for 
an IgG1 mAb (referred to as “mAb-C”) as a function of mAb-C protein concentration (1-10 
mg/mL). Solution viscosity measurements were then utilized to indirectly monitor the increase of 
RSA at higher mAb-C concentrations (up to 60 mg/mL protein).  We then applied a novel HX-MS 
methodology, using a stable, lyophilized formulation followed by reconstitution in D2O solutions 
that promote RSA, to map RSA-induced changes in hydrogen exchange by mAb-C (i.e., 
comparing relatively low vs. high levels of RSA at 5 vs 60 mg/mL). This HX-MS analysis revealed 
specific peptide segments at the protein interface leading to RSA of mAb-C and also identified 




3.2 Materials and Methods: 
  
 
3.2.1 Materials:  
A highly purified IgG1 mAb at 10 mg/mL, referred to as “mAb-C”, was produced by MedImmune 
LLC, Gaithersburg, MD. The antibody stock solution was dialyzed into various buffers as 
indicated below.  LC-MS grade water, 2-propanol and dibasic anhydrous potassium phosphate 
(>99.0%) and sodium chloride were obtained from Fisher Scientific (Fair Lawn, NJ).  LC-MS 
grade acetonitrile was purchased from Honeywell (Morristown, NJ).  Formic acid (≥99.0% LC-
MS-grade) was purchased from Thermo Scientific (Rockford, IL).  Monobasic anhydrous 
potassium phosphate (99.5%), sodium sulfate (>99.0%), porcine pepsin, tris (2-carboxyethyl) 
phosphine hydrochloride (TCEP), guanidine hydrochloride, deuterium oxide (99.9% D) and tris 
(hydroxymethyl) aminomethane hydrochloride (≥99.0%) were purchased from Sigma-Aldrich (St. 
Louis, MO).  The reagent bis-(sulfosuccinimidyl) 2,2,4,4, glutarate-d0 (BS
2G-d0) was obtained 
from Pierce Biotechnology (Rockford, IL).  The disaccharide α,α-trehalose dihydrate was obtained 
from Ferro Pfanstiehl laboratories (Waukegan, IL).   
 
3.2.2 Sample preparation 
As needed, mAb-C samples were dialyzed using 3.5 kDa molecular-weight-cutoff membranes 
(Slide-A-Lyzer, Thermo Scientific, Rockford, IL).  mAb-C samples were concentrated using 
Vivaspin-20 (10 kDa molecular weight cutoff) ultrafiltration columns (Sartorius Stedim, 
Gottingen, Germany). 
 
3.2.3 Dynamic Light Scattering 
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Stock samples of mAb-C were dialyzed against 40 mM potassium phosphate buffer (pH 6-8) 
containing either NaCl or Na2SO4 at concentrations ranging from 0.15 to 0.5M overnight at 4°C.  
Dialyzed samples were then diluted to 1, 2.5, 5 and 10 mg/mL using the dialysis buffer. The 
concentration of mAb-C was determined using ultraviolet absorption spectroscopy (A280 nm) using 
E1 cm 0.1% of 1.54 mL mg
-1 cm-1.204  DLS experiments were performed in triplicate at 25°C using 
the DynaPro Plate Reader (Wyatt Technology, Santa Barbara, CA).  Scattered light was analyzed 
using a backscatter detector fixed at an angle of 173°. An autocorrelation function was calculated 
using a built-in digital autocorrelator. 20μL of sample was added to each well of a 384-well plate, 
and 10μL of paraffin oil was added on top of each sample to inhibit sample loss by evaporation. 
The 384-well plate was centrifuged at 2000 rpm for 2 minutes to remove any air bubbles.  All 
mAb-C samples were kept at the temperature of interest for 10 minutes for temperature 
equilibration and then fifteen 5 second acquisitions were collected for each sample. Dynamics 
7.1.7 software was used to calculate the hydrodynamic diameter of the mAb-C samples.  The 
solution viscosity of each buffer alone (placebo) was measured using an m-VROC viscometer 
(Rheosence, San Ramon, CA) at 25°C and buffer viscosity correction was implemented in 
instrument software for calculation of the hydrodynamic diameter of mAb-C samples. 
 
3.2.4 Chemical cross-linking and SDS-PAGE analysis 
An amine-reactive cross-linker, bis (sulfosuccinimidyl) 2,2,4,4, glutarate (BS
2G), with a spacer 
arm length of 7.7 Å, was used to study reversible-self association of mAb-C. mAb-C was 
concentrated to 10 mg/mL and then dialyzed against 40 mM potassium phosphate buffer (pH 7.0) 
with and without 300 mM sodium sulfate, for 24 hours at 4°C. For the chemical cross-linking 
reaction, 10 mg/mL mAb-C in the presence and absence of sodium sulfate was incubated with 
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increasing concentrations of BS2G ranging from 5- to 40-fold molar excess to mAb-C.  The 
reaction mixtures were incubated at 4°C for 5 minutes and quenched by addition of 1 M tris 
hydrochloride.  mAb-C from the reaction mixtures was combined with 4X lauryl dodecyl sulfate 
(LDS) buffer, iodoacetamide, and filtered deionized water to obtain a final sample volume of 20 
μL containing eight micrograms of protein, 50 mM iodoacetamide, and 1X LDS buffer. For 
reducing conditions, 100 mM DTT was added to the mAb-C-LDS solution. All samples were 
heated at 75°C for 5 minutes and then analyzed using a 3%-8% tris-acetate SDS-PAGE gel (Life 
Technologies, Grand Island, NY).  
 
3.2.5 Viscosity Measurements 
Prior to solution viscosity measurements, mAb-C stock was dialyzed against 40 mM potassium 
phosphate buffer (pH 7) containing either 300 mM NaCl or Na2SO4. Dialyzed samples were 
concentrated to 60 mg/mL and then diluted with dialysis buffer to make protein concentrations 
ranging from 5 – 60 mg/mL. Solution viscosities were measured at 4°C and 25°C with an m-
VROC viscometer (Rheosence, San Ramon, CA). Samples at different concentrations of mAb-C 
were injected at a rate of 100 μL/min at a shear rate of 1420 1/s using a 1 mL glass syringe 
(Hamilton Co, Reno, NV).  Triplicate viscosity measurements were recorded over duration of 100 
seconds. Viscosity values were obtained in the units of dynamic viscosity: mPa s. 
 
3.2.6 Lyophilization of mAb-C 
Prior to freeze-drying, mAb-C samples were dialyzed against 20 mM potassium phosphate buffer 
(pH 7) with 10% (W/V) trehalose for 24 hours and then concentrated to 60 mg/mL. Half of the 
mAb-C samples were diluted in the same buffer to 5 mg/mL. The mAb-C samples at 5 and 60 
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mg/mL were filled into 3 mL FIOLAX® clear Type 1 glass vials (Schott North America, Elmsford, 
NY) with a fill volume of 500 μL. All the vials were partially stoppered by 2-leg, 13 mm 
siliconized rubber stoppers (Wheaton Industries Inc., Millville, NJ) The samples were then 
lyophilized using a LyoStar II lyophilizer (SP Scientific, Warminster, PA). Vials were subjected 
to an initial hold step at 5°C and then a freezing hold step at –40°C. During primary drying, the 
shelf temperature was maintained at –30°C for 400 minutes and then at –35°C for 800 minutes 
with the chamber pressure maintained at 100 mTorr.  Secondary drying was done by ramping the 
shelf temperature at 0.1°C/min until reaching a final shelf temperature of 25°C for 60 minutes. 
Residual moisture levels of ~0.5% (v/v) in the lyophilized mAb-C samples were determined using 
a Karl-Fischer titration unit according to vendor instructions (Mettler Toledo. LLC, Columbus, 
OH) 
 
3.2.7 Size Exclusion Chromatography (SEC) 
Lyophilized mAb-C samples were reconstituted and diluted to 0.5 mg/mL with D2O-based 40 mM 
potassium phosphate buffer containing 300 mM sodium sulfate and 10% (w/v) trehalose. All mAb-
C samples were centrifuged at 14000g for 5 minutes prior to SEC analysis. For SEC experiments, 
a 7.8 cm × 30 cm TSK-Gel BioAssist G3SWxL column (TOSOH Biosciences, King of Prussia, 
PA) column was used.  Samples were injected onto the column at a flow rate of 0.7 mL/min with 
a Shimadzu high-performance liquid chromatography (HPLC) system equipped with a diode array 
detector using a  200 mM phosphate buffer (pH 6.8) as the mobile phase. The performance of the 
column and the HPLC system was monitored using gel filtration standards (Bio-Rad, Hercules, 
CA) at the beginning and end of the experiment. The chromatograms were analyzed by integrating 
the monomer peak area detected at 214 nm. Percent aggregation in post-lyophilization samples 
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was measured relative to the total area of control samples (no lyophilization) at each protein 
concentration. To calculate the amount of insoluble aggregates, the total area of all the species 
(soluble aggregates, monomer, and fragment) in the chromatogram was calculated. The difference 
between the total peak areas of the sample and the control was used to quantify insoluble 
aggregates.  
 
3.2.8 Circular Dichroism 
Lyophilized mAb-C samples at 5 and 60 mg/mL were reconstituted to a concentration of 0.3 
mg/mL with a D2O-based 40 mM potassium phosphate buffer containing 300 mM sodium sulfate 
and 10% (w/v) trehalose at pH 7.0. The protein concentration of each sample was measured by 
absorbance at 280 nm using a previously reported value of E1 cm 0.1% of 1.54 mL mg
-1 cm-1.76 
Circular dichroism (CD) experiments were conducted on a Chirascan Plus Circular Dichroism 
Spectrometer (Applied Photophysics Ltd., Leatherhead, UK) equipped with a Peltier temperature 
controller and a four-position cuvette holder. Far-ultraviolet (UV) CD spectra of control (no 
lyophilization) and freeze-dried mAbC samples (0.3 mg/mL) were collected from 200 nm to 260 
nm using 0.1 cm path length quartz cuvettes. Control mAb-C samples were prepared in H2O-based 
40 mM potassium phosphate buffer containing 300 mM sodium sulfate and 10% (w/v) trehalose 
at pH 7.0. CD scans were collected at 10°C using a sampling time of 1 second and a bandwidth of 
1 nm. Ellipticity values obtained from the instrument were then converted to molar ellipticity by 
dividing ellipticity by protein concentration (M) and cuvette path length (m).  
 
3.2.9 Deuterated Reconstitution Buffer Preparation 
Deuterium-based reconstitution/labeling buffer contained 20 mM potassium phosphate, 300 mM 
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sodium sulfate and 10% (w/v) trehalose at pH 7. The amount of D2O in the reconstitution/labeling 
buffer was adjusted to 90 atom % by addition of H2O as described previously.
138 The pH of the 
buffer was then adjusted to 7.0.  The pH value of the solution was directly reported from the pH 
meter readout and does not include any correction for the deuterium isotope effect.205  
 
3.2.10 Hydrogen Exchange Mass Spectrometry 
Lyophilized vials containing 5 and 60 mg/mL mAb-C in 20 mM potassium phosphate and 10% 
(w/v) trehalose at pH 7.0, along with vials of the deuterium reconstitution/labeling buffer, were 
each equilibrated to 25°C on an Echotherm chilling/heating plate (Torrey Pines Scientific, Inc. 
Carlsbad, CA). A quench buffer containing 0.5 M tris(2-carboxyethyl) phosphine hydrochloride 
(TCEP), 4 M guanidine hydrochloride and 0.2 M sodium phosphate at pH 2.5 was equilibrated at 
1°C. Deuterated reconstitution buffer (500 μL) was added to the lyophilized samples to yield a 
final protein concentration of 5 and 60 mg/mL and a final formulation composition of 40 mM 
potassium phosphate, 300 mM sodium sulfate, 10% (w/v) trehalose at pH 7.0 in D2O. After 
addition of deuterated reconstitution buffer to the vials containing lyophilized protein, the vials 
were gently swirled for ~10 s until the freeze-dried cakes were reconstituted. The vials were held 
for an additional 60 s to allow foam to dissipate.  The reconstituted mAb-C samples were then 
transferred to 2 mL microcentrifuge tubes and centrifuged at 14000g for 1 minute to remove small 
amounts of insoluble aggregates present in the sample (see Table 1). Reconstituted, centrifuged 
samples of mAb-C were then incubated for four labeling times: 120, 1620, 104 and 105 s; the 
labeling period was started at the end of the dissolution step.  After labeling, the exchange reaction 
was quenched by adding 20 μL of the exchange reaction mixture to 180 μL of quench buffer 
equilibrated at 1°C. Dilution with quench buffer was maintained for both protein concentration 
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samples to keep the extent of back-exchange equal in the samples.  
A LEAP HD/X PAL (LEAP Technologies, Carrboro, NC)  was used to load quenched 
samples into the sample loop of the refrigerated column compartment containing two valves 
attached to the LC (Agilent 1200 series, Santa Clara, CA), an immobilized pepsin column, a 
peptide desalting trap, and a C18 column  as described previously.137,138 Formic acid (0.1% v/v) 
was used for digestion and desalting.  A mobile phase composed of water and acetonitrile, both 
containing 0.1% (v/v) formic acid, was use to elute the peptides.  The temperature of the 
refrigerated compartment was maintained at 1°C during the course of the experiments. Different 
volumes of sample, 90 μL for the low, and 15 μL for the high concentrations were used so that the 
total amount of protein injected into the LC was similar:  45 μg for the low, and 90 μg for the high 
concentration samples. Three independent replicates for both protein concentrations were prepared 
and analyzed.  To minimize peptide carryover in the immobilized pepsin column, the column was 
washed between samples following a cleaning procedure described previously136 except that two 
cycles of pepsin column wash were used after each injection. Deuteration was measured using a 
time-of-flight mass spectrometer (Agilent 6220, Santa Clara, CA) equipped with a standard 
electrospray ionization source operated in positive mode. 
 
3.2.11 HX-MS data processing and analysis 
 A combination of accurate mass measurements from time-of-flight MS and data obtained from 
collision induced dissociation with tandem MS on a linear quadrupole ion trap (LTQ-XL, Thermo-
Scientific) was used to identify a total of 130 peptides. Identified peptides covered 94% of the 
primary sequence of the heavy and 93% of the light chain of mAb-C.  
HDExaminer (Sierra Analytics, Modesto, CA) was used to analyze the hydrogen exchange 
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data. Peptide mass spectra from all three replicates of both protein concentrations were manually 
curated after initial processing. Deuterium uptake plots with average deuterium uptake values and 
standard deviations for each peptide were generated by using an R script program, written in-
house.  
Statistical significance was determined following the method described by Houde et al. for 
replicate differential hydrogen exchange data.  For our triplicate measurements, the 99th percentile 
of the standard deviations (s99%) was 0.28.  For differential measurements, i.e., Δm, the 99% 
confidence interval becomes 2 2
99% 99%99%CI s s  . establishing a 99% confidence limit of ±0.4 
Da for our dataset (see supplemental Figure S3).132  
Hydrogen exchange data for each peptide was mapped onto a homology model of mAb-C 
based on human IgG b12 (PDB ID: 1HZH)206 developed as described previously. 204 In some cases, 
peptides spanning the same region showed contradictory results:  some indicated significant 
differences while others did not.  At 99% confidence, false negatives are much more likely than 
false positives, peptides with significant differences “overruled” those that did not show significant 
differences.  There were no cases where overlapping peptides indicated contradictory results (i.e. 
one peptide with 0.4m   and an overlapping peptide with 0.4m   ). Pymol (Schrödinger 
LLC, Portland, OR) was used to display the HX-MS data.  
 
3.3 Results: 
3.3.1 Defining solution conditions that favor RSA 
DLS was used to measure the hydrodynamic diameter of mAb-C species under various 
solution conditions.  Figure 1 shows the effect of protein concentration (1-10 mg/mL), pH, salt 
concentration, and salt type on the size of mAb-C complexes.  A solution of primarily monomeric 
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mAb had a hydrodynamic diameter of ~9-12 nm.  The hydrodynamic diameter increased with 
increasing protein concentration, increased solution pH (Figure 1a), and increased ionic strength 
(Figure 1b).  In addition, mAb-C formulated in a solution containing sodium sulfate showed 
increased hydrodynamic diameter compared to sodium chloride (Figure 1b).  These DLS results 
are consistent with those reported previously by Esfandiary et al. for the same antibody molecule 
formulated under similar solution conditions.76,204 
To further assess the effect of salt on reversible self-association (RSA) of mAb-C, we used 
chemical cross-linking to measure the effect of sulfate on the extent of RSA at pH 7.  In the 
presence of 300 mM sodium sulfate, higher molecular weight bands at ~300 kDa and ~450 kDa 
were observed (Figure 2, top panels).  The intensity of these bands increased as the concentration 
of the cross-linker was increased from 5 to 40 molar excess over mAb-C.  In the absence of sodium 
sulfate, only a very faint band appeared at ~300 kDa and no band was observed at ~450 kDa.  
Similar results were obtained from reduced samples of mAb-C (Figure 2, bottom panels), where 
several higher molecular weight bands were observed above the heavy chain band (~50 kDa). 
The DLS and cross-linking results (Figures 1 and 2) were limited to mAb-C protein 
concentrations of ~1-10 mg/mL because higher concentrations led to experimental variability, 
non-ideal behavior or experimental artifacts (data not shown). The inability of such techniques to 
provide reliable sizing data at higher protein concentrations is consistent with previous 
reports.1,207,208 Despite analytical limitations of DLS at higher protein concentrations, the RSA-
promoting conditions identified with DLS were selected for RSA studies at high protein 
concentrations.  In order to characterize RSA at higher mAb-C concentrations (10-60 mg/mL), we 
turned to a combination of solution viscosity and HX-MS measurements, as described in the 




3.3.2 Solution viscosity as a function of protein concentration, temperature and salt 
concentration 
We used solution viscosity measurements to determine the effects of sulfate concentration, 
and temperature on RSA of mAb-C at higher protein concentrations. The solution viscosity of 
mAb-C samples increased with protein concentration and was further elevated in the presence of 
sodium sulfate and at lower temperature (Figure 3a). For example, the solution viscosity of mAb-
C at protein concentrations ranging from 5 mg/mL to 60 mg/mL at 4°C varied from 1 mPa∙s to 
~75 mPa∙s in the presence of 300 mM sodium sulfate, and from 1 mPa∙s to ~20 mPa∙s in the 
presence of 300 mM sodium chloride. The same trends were also present at 25°C, but at lower 
viscosity values (Figure 3a).   
Based on the combined results from the DLS, chemical-crosslinking and solution viscosity 
experiments, the subsequent evaluation of the effects of RSA on the local flexibility of mAb-C (as 
measured by HX-MS analysis) was performed under the following conditions: two protein 
concentrations (i.e., 5 and 60 mg/mL) were prepared in a deuterated phosphate buffer at pH 7 
containing 300 mM sodium sulfate and 10% trehalose.  Elevated solution pH and salt levels (and 
salt type) amplified the propensity of mAb-C to reversibly self-associate (as shown above) while 
the sugar was needed as a lyoprotectant (see below). The 5 mg/mL mAb-C was selected as a 
control with relatively limited RSA, whereas the 60 mg/mL mAb-C sample was chosen as a sample 
displaying more extensive RSA. Esfandiary et al. have recently shown that the same mAb can 
form a monomer-trimer-hexamer equilibrium under similar solution conditions (at 1-10 mg/mL at 
room temperature).204  Nonetheless, as shown in this work, notable differences in the extent of 




3.3.3 Development of a freeze-dried formulation for HX-MS analysis of RSA  
A conventional hydrogen exchange experiment typically begins with a five- to twenty-fold 
dilution of the protein with D2O, but in our case, such a dilution would alter the reversible self-
association of mAb-C. To maintain high protein concentration during hydrogen exchange, we 
developed an approach based on reconstitution of lyophilized protein with D2O.  To evaluate the 
effects of lyophilization and reconstitution on mAb-C we used viscosity measurements, CD, and 
SEC. mAb-C was prepared at concentrations between 5 and 60 mg/mL in phosphate buffer (pH 
7.0) containing 10% trehalose (w/v).  Samples were then freeze-dried and reconstituted and 
compared with samples that had not been freeze-dried.  
A comparison of the solution viscosity of the reconstituted mAb-C samples with control 
mAb-C samples that were not lyophilized is shown in Figure 3b. There was no difference between 
the viscosity of the control (no freeze-drying) and lyophilized/reconstituted mAb-C samples, and 
no difference in the viscosity between samples reconstituted with either H2O or D2O at both 
temperatures (4°C and 25°C). These results show that the lyophilization/reconstitution of mAb-C 
at different protein concentrations, in either H2O or D2O buffers, had no significant effect on the 
extent of RSA of mAb-C, as measured by solution viscosity. This experimental approach thus 
affords the opportunity to prepare low and high protein concentration solutions of mAb-C in D2O-
containing buffers for HX-MS analysis.   
To further ensure that freeze-drying had no notable effects on the overall structural integrity 
of mAb-C, lyophilized mAb-C samples were reconstituted with D2O-based reconstitution buffer 
and analyzed by both circular dichroism (CD) and size-exclusion chromatography (SEC). Far-UV 
CD spectra of control and lyophilized mAb-C samples are indistinguishable with minima at 217 
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nm (Figure 4), characteristic of the high beta sheet content of IgG domains.  This result indicates 
that lyophilization followed by reconstitution did not induce any changes in the overall secondary 
structure content of mAb-C.  
The aggregate content of the same samples was measured by SEC (Table 1). The amount 
of soluble aggregates and fragments present in the mAb-C samples did not change after 
lyophilization, but the amount of insoluble aggregates (loss of total area by SEC) after 
reconstitution was somewhat higher (2.1-2.7%) compared to control samples. Based on these 
results, the small amount of aggregate was removed by centrifugation prior to HX-MS experiments 
(see Methods). In addition, the overall structural integrity of mAb-C before and after lyophilization 
and reconstitution was further confirmed by HX-MS analysis as described below. These results 
indicate that lyophilization followed by reconstitution did not induce significant aggregation. 
 
3.3.4 Effects of reversible self-association (RSA) on hydrogen exchange of mAb-C 
 The RSA of mAb-C was analyzed by HX-MS by reconstituting 5 and 60 mg/mL 
lyophilized mAb-C preparations with a D2O-based reconstitution/labeling buffer.  Samples were 
incubated in D2O for varying periods of time, quenched, digested with pepsin, and the deuterium 
uptake in pepsin-generated peptides of mAb-C was measured by MS (see Methods). A total of 130 
mAb-C peptides were reproducibly generated by pepsin digestion, resulting in sequence coverage 
of 94% for the heavy chain and 93% for the light chain of mAb-C (see Supplemental Figure S1). 
Figure 5 shows representative deuterium uptake results for several different peptides as a function 
of hydrogen exchange labeling time.  Figure 5A presents results from some representative mAb-
C peptides that show no significant differences in hydrogen exchange kinetics between RSA and 
non-RSA mAb-C. In contrast, Figure 5B contains examples where RSA induced significant 
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differences in hydrogen exchange kinetics:  RSA caused both faster and slower hydrogen exchange 
in different regions of mAb-C.   As discussed in more detail below, for approximately 90% of the 
peptides, however, there were no significant differences in deuterium uptake between RSA and 
non-RSA mAb-C based on our significance criteria (see Methods).    
Figure 6 presents a global view of these data by presenting the hydrogen exchange 
differences across the 130 peptides generated in a single plot. The differences in hydrogen 
exchange between mAb-C samples at 60 mg/mL and 5 mg/mL      60 5   m t m t m t       are 
plotted on the vertical axis. The individual peptides are arranged on the horizontal axis starting 
from the N-terminal of the heavy chain and ending at the C-terminal of the light chain.  The 
peptides are numbered sequentially based on the locations of their middle residues (see 
Supplemental Table S1 for the identities and locations of the peptides). The domain locations are 
indicated by labels and alternate shading in white and grey. These plots efficiently display the 
trends in local flexibility changes between the RSA and non-RSA mAb-C. The direction of the bar 
indicates whether an individual peptide becomes more flexible (   0 Dam t  ) or less flexible (
 <0 Dam t ) upon RSA. The dashed lines in figure 6 indicate  m t  values that exceed the 
99% confidence limit of ±0.4 Da for statistically significant changes induced by RSA (see 
Methods).   
The results in Figure 6 reveal differences in hydrogen exchange in mAb-C at high vs. low 
concentrations of mAb-C, conditions shown to affect the RSA of the antibody.  Most of the mAb-
C peptides (>90%) show no significant differences in hydrogen exchange. The specific peptides 
of mAb-C that display significant decreases in hydrogen exchange   0.4 )a( Dm t   at high vs. 
low concentrations of mAb-C are located in VH and VL domains, primarily in sequences that 
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include the CDR2H and CDR2L.  For example, in the VH domain, there is a 26 amino acid 
sequence (HWVRQAPGQGLEWMGWINPHSGGTNY) that spans the CDR2H sequence of 
mAb-C and is covered by three VH domain peptides (peptide numbers 10, 13 and 18 corresponding 
to HC 35-59, HC 45-59 and HC 50-60, respectively).  These three peptides display significant 
decreases in hydrogen exchange at the 120 s time point.  The magnitude of these effects is small, 
0.5 Dam  .  In the VL domain, there is a 36 amino acid sequence covering LC 36-71 
(YQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDF), corresponding to peptide numbers 
100, 101, 102, 103, 104, 105 and 106, where significant decreases in hydrogen exchange in high 
vs. low concentrations of mAb-C were also observed.  These seven peptides showed differences 
across all of the deuterium exposure time points.   In the light chain, the magnitudes of the effects, 
0.7 Dam  , are much larger than the effects in the heavy chain. The LC 36-71 sequence in the 
VL domain spans the CDR2L sequence of mAb-C.  In summary, significant decreases in hydrogen 
exchange (i.e., increased protection against deuterium uptake) were observed upon RSA of mAb-
C in two of the six CDR regions in the mAb (i.e., the CDR2 region of the heavy and light chain).    
Interestingly, several other peptide segments from mAb-C concomitantly displayed the 
opposite effect: increased local flexibility   0.4 )a( Dm t   at the higher (vs. lower) mAb-C 
concentration (Figure 6).  For example, two peptides in the VH domain covering HC 4-29 
(GAEVKKPGASVKVSCKASGYTF, corresponding to peptide number 3 and 4) showed this 
trend.  In addition, in comparing the 60 mg/mL vs. 5 mg/mL samples of mAb-C, two peptide 
segments located in the interface of CH1 and CH2 domains covering HC 229-252 
(DKTHTCPPCPAPELLGGPSVFLFPPK, corresponding to peptide number 48 and 49) as well as 
one CH2 domain peptide covering HC 311-325 (VSVLTVLHQDWLNGK, corresponding to 
peptide 64) also showed significant increases in deuterium uptake at one or more time points.   
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Figure 7 further summarizes these HX-MS results as mapped onto a homology model of 
mAb-C (Figure 7a shows the entire mAb-C molecule and Figure 7b displays a close-up view of 
the CDR2 regions within the Fab domain).  The peptide segments in mAb-C where RSA caused 
significant decreases in hydrogen exchange   0.4 Dam t    are colored blue, while regions 
that exhibited significant increases   0.4 Dam t   are colored yellow.  The regions of mAb-C 
without significant effects (   0.4 Dam t  ) are colored in grey and regions of mAb-C lacking 
hydrogen exchange data are shown in white.  The peptides that exhibited decreased hydrogen 
exchange at high vs. low mAb-C concentration constitute the primary protein-protein interface for 
RSA of mAb-C. The peptide segments showing increased local flexibility may indicate long-range 
dynamic coupling effects of RSA in mAb-C (see Discussion). 
Finally, to further confirm that the lyophilization/reconstitution method did not adversely 
affect the structural integrity of mAb-C, we measured hydrogen exchange kinetics before and after 
lyophilization at two protein concentrations (6 and 60 mg/mL) in a subset of 35 peptides covering 
all domains of mAb-C and including all peptides that had significant differences in local flexibility 
caused by RSA (Figure 6). There were no significant differences in hydrogen exchange kinetics 
between lyophilized and control mAb-C samples at either protein concentration (see Supplemental 
Figures S4 and S5).  
 
3.4 Discussion 
The main aim of this study was to develop an HX-MS method to characterize the protein 
interfaces involved with the reversible self-association (RSA) of mAb-C directly at high protein 
concentrations (i.e., 60 mg/mL). Commonly available biophysical measurements used to monitor 
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RSA not only lack such local sequence information, but can only be performed at lower protein 
concentrations (~10 mg/ml) due to solution non-ideality (see Introduction). These analytical 
limitations were encountered with DLS and SV-AUC measurements of mAb-C under different 
solution conditions as described in this work and as reported previously.76,204  In the present study, 
we correlate solution effects on the RSA of mAb-C, as determined by DLS and chemical 
crosslinking at lower mAb-C concentrations, to solution viscosity measurements at higher protein 
concentrations. We then directly mapped the local regions of mAb-C involved at the interface of 
RSA at the higher protein concentration using HX-MS, an analytical tool that has been widely 
used to map interfaces of protein-protein interactions.209-211  
 
3.4.1 Effect of solution conditions on RSA of mAb-C 
As an initial evaluation of the RSA of mAb-C, we employed DLS and chemical cross-
linking. There was a measurable increase in the RSA of mAb-C with increasing protein 
concentration, solution pH, and ionic strength (Figures 1 and 2). These results are consistent with 
trends previously reported for the RSA of mAb-C at low protein concentrations by DLS, SV-AUC 
and CG-MALS.76 Many of these same trends were apparent at higher protein concentrations, as 
revealed by changes in viscosity, where an exponential increase in viscosity was observed ranging 
from ~1 to ~75 mPa∙s depending on the protein concentration and solution conditions (Figure 3). 
Increases in intermolecular associations between antibody molecules at high protein 
concentrations have been previously correlated to elevated solution viscosity values.13,212 This 
effect can be attributed to the antibody network formation at high protein concentration, which 
affects the packing volume fraction of the antibody and ultimately results in an increase in solution 
viscosity.80 For example, Pathak et al. demonstrated that the presence of reversibly associated 
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clusters at high protein concentrations contributed to an increase in solution viscosity.213  
Similar trends in viscosity in response to changes in solution conditions that we describe 
here for mAb-C have been reported for other IgG1 mAbs, where the extent of viscosity increased 
in a concentration-dependent manner with increasing ionic strength 76,79,81,214,215 and solution 
pH,60,76 related to elevated levels of protein RSA due to charge shielding effects.99,216,217 The 
isoelectric point (pI) range of mAb-C is basic (pI~9.1-9.4),204 and therefore, the overall surface 
charge of mAb-C is expected to be positive at neutral pH. As the pH was changed from 6 to 8, the 
tendency of mAb-C to self-associate increased possibly due to overall decrease in electrostatic 
repulsive interactions. In addition, more specific charge effects are possible, including 
protonation/deportation of histidine (His) residues upon a change in solution pH in the range of 
the pKa (~ pH 6).  From our present work, there are two histidine residues in the 26 amino acid 
sequence covering the CDR2H region (HWVRQAPGQGLEWMGWINPHSGGTNY) that 
showed significantly decreased hydrogen exchange upon RSA of mAb-C.  The probable 
involvement of His side chain residues in the RSA of this mAb was demonstrated indirectly by 
DLS studies (vs. solution pH and composition) as reported recently.76,204 The homology model 
indicates that one of these histidines is highly solvent exposed (see Figure 7c). 
As electrostatic repulsive interactions decrease when solution pH approaches pI, other non-
covalent attractive interactions such as hydrophobic and van der Waals interactions are expected 
to become more dominant allowing mAb-C monomers to self-associate to a greater extent. To 
further explore the effects of two anions, sulfate and chloride, on the extent of RSA of mAb-C, 
both hydrodynamic diameter and solution viscosity of mAb-C samples were measured in the 
presence of both the anions. Sulfate had a bigger effect on the extent of RSA of mAb-C than 
chloride (Figures 1b and 3a). In terms of ranking in the Hofmeister series of anions, divalent sulfate 
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anions have a stronger kosmotropic effect on proteins than monovalent chloride ions.218  Sulfate 
ions interact more strongly with the positively charged amino acid side chains on a protein surface 
than chloride ions,219,220 presumably resulting in enhanced charge shielding effects. Sulfate ions 
can also desolvate polar and non-polar regions of the protein surface, thus aggravating 
hydrophobic interactions by decreasing protein solubility, an effect commonly known as “salting 
out”.221,222 These ion-protein interactions correlate well with our observations of enhanced RSA 
of mAb-C in the presence of sulfate anions. Esfandiary et al. demonstrated by modeling of light 
scattering data that mAb-C formulated in the presence of 150 mM sodium sulfate at room 
temperature can assemble into monomer-trimer-hexamer mixtures, ranging from 100% monomer 
to ~ 75%-20%-5% molar ratios, as the protein concentration increases from 1 to 10 mg/mL.76,204 
 
3.4.2 Development of an HX-MS method to examine RSA  
In most HX-MS studies on protein-protein interactions, the interactions are typically non-
reversible or have relatively high affinity; therefore, HX-MS experiments can easily be carried out 
at low protein concentrations after dilution of protein stock solutions with deuterium containing 
buffers. In contrast, RSA is a concentration-driven phenomenon.  In order to study RSA of mAbs, 
HX-MS experiments need to be performed at high protein concentrations requiring a novel 
methodology to prepare high protein concentrations in deuterium containing buffers.  To this end, 
antibody solutions under RSA-promoting solution conditions at high and low protein 
concentration were lyophilized and reconstituted with a D2O based labeling/ reconstitution buffer.  
Lyophilization of proteins can cause detrimental effects on physical stability through ice 
crystal-water interfaces, cold-denaturation, solution pH change during lyophilization, and 
dehydration stress.223,224 We used a combination of CD and SEC analysis to demonstrate that the 
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lyophilization process itself did not lead to structural alterations or aggregation of mAb-C (Figure 
4 and Table 1). In addition, based on hydrogen exchange measurements of 35 key peptides from 
mAb-C (Supplemental Figure S4 and S5), we can conclude that lyophilization followed by 
reconstitution did not cause any significant changes in the local flexibility across the mAb-C 
molecule (Supplemental Figure S3). These results illustrate a potential new pharmaceutical 
application of HX-MS: evaluations of the structural integrity of protein samples before and after 
lyophilization and reconstitution. These results also demonstrate the reproducibility achievable 
with this lyophilization/reconstitution HX-MS approach. 
 
3.4.3 HX-MS mapping of the protein interface of RSA of mAb-C 
From the HX-MS analysis of mAb-C at low and high protein concentrations (Figures 5 and 
6), peptides with increased protection against deuterium uptake (i.e., slowed hydrogen exchange) 
at high mAb-C concentration are assigned as the primary interface for RSA of mAb-C. Two 
regions in VL and VH (LC 36-71 and HC 35-60) showed a significant decrease in hydrogen 
exchange at high mAb-C concentration. Both of these regions cover the CDR2 region in the heavy 
and light chain of mAb-C, respectively, which demonstrates two of the six CDRs in mAb-C are 
involved with RSA. The involvement of CDR regions, including specific aromatic/hydrophobic 
residues, in RSA of antibodies has been reported in previous studies with other antibodies.183,225,226  
More specifically with mAb-C, LC 36-71 and HC 35-60, which span CDR2L and CDR2H, 
respectively, showed significant decreases in hydrogen exchange under RSA-promoting 
conditions (Figure 7). This result indicates that the amino acid residues encompassing the CDR2 
sequence within the Fab region of mAb-C provide an interface for RSA at high protein 
concentrations. More specifically, protection in the light chain was detected in seven overlapping 
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peptides spanning CDR2L in the VL domain of mAb-C, LC 36-71 
(YQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDF).  In the heavy chain, protection was 
detected in two peptides spanning CDR2H in the VH domain, for HC 35-60 
(HWVRQAPGQGLEWMGWINPHSGGTNY). CDR loops are naturally hypervariable, provide a 
unique identity to each mAb, and are solvent exposed for high affinity binding to the antigen.  The 
sequences that became significantly protected at 60 mg/mL (i.e., upon more extensive RSA of 
mAb-C) contain numerous aromatic/hydrophobic residues. The LC36-71 sequence contains four 
aromatic residues (Y and F) and six aliphatic residues (I, L, V) and the HC 35-60 sequence has 
four aromatic (Y and W) and three aliphatic residues (I, L, V).  In addition, some of the peptide 
segments covering these sequences also contain histidine as well as charged amino acid residues 
at pH 7.  Since the addition of 300 mM sodium sulfate promotes the RSA of mAb-C, the charged 
residues may become more shielded or charge-neutralized by sulfate binding. Upon such reduced 
electrostatic repulsive interactions, the presence of aromatic and hydrophobic residues can 
potentially facilitate RSA of mAb-C at high protein concentrations. Protection from hydrogen 
exchange in the VL segment is stronger than in the VH segment suggesting that there is higher 
affinity in the VL segment. 
To the best of our knowledge, this is the first study that utilizes HX-MS to characterize 
RSA of antibodies at peptide-level resolution directly at high protein concentrations. Several 
research groups have made observations using lower resolution biophysical tools to identify 
specific regions in an antibody associated with RSA.  For example, Kanai et al. measured solution 
viscosity of purified F(ab’)2 and Fab fragments of a self-associating IgG1 mAb and concluded that 
the interface of RSA for an IgG1 mAb was in the Fab region.14  Yadav et al. swapped charged 
residues in the CDR region of a self-associating IgG1 mAb with those of a non-self-associating 
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antibody and observed a significant decrease in solution viscosity and weight average molecular 
weight (Mwc).
16  Using these same mutants, the authors of a separate study used coarse-grain 
modeling to link domain-level charge distribution in the Fab region of the antibody to RSA.227 In 
another study, substitution of aromatic residues with non-aromatic amino acids (F99A, W100A) 
in the CDR3H region of the antibody caused a considerable decrease in RSA and an increase in 
protein solubility.183,226 However, Fab-Fab interactions are not necessarily always responsible for 
such interactions between antibody molecules. For example, Nishi et al. reported that the Fc-
mediated RSA of an antibody under low ionic strength solution conditions.182  
Several groups have examined protein-protein interfaces of irreversible antibody 
aggregates (i.e., dimers and oligomers) by HX-MS. For example, Zhang et al. used HX-MS 
analysis of purified mAb aggregates to show that Fab-Fab interactions in the CDR region were 
generated as part of irreversible aggregate formation caused by heat exposure.200 In addition to 
HX-MS, antibody aggregates have been characterized using other higher resolution techniques. 
For example, Deperalta et al. used hydroxyl radical footprinting to map the interface region of an 
antibody dimer.  This work demonstrated that the protein-protein interface lies in the Fab domain 
of the antibody.228 Using alternative approaches, Paul et al. used transmission electron microscopy 
to visualize purified antibody dimers and suggested Fab-Fab interactions were responsible for 
association.229 Wang et al. used computational predictive tools to delineate aggregation-prone 
regions in variable domains of an antibody are located in or around the CDR region.152 A recent 
study by Iacob et al. showed that irreversible antibody aggregation can affect the flexibility of the 
mAb’s hinge loop region. They demonstrated decreased local backbone flexibility in the hinge 
region upon formation of a disulfide cross-linked mAb dimer.230 Interestingly, as discussed below, 
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the opposite effect (i.e., increased backbone flexibility in several regions including the hinge loop) 
was observed in our present work upon RSA of mAb-C. 
 
3.4.4 HX-MS mapping of distant dynamic effects on other regions of mAb-C upon RSA 
We also observed a significant increase in hydrogen exchange in regions in mAb-C that 
are distant from the RSA protein-protein interaction site described above (see Figure 6 and 7). 
These changes were observed in regions covering HC 4-29 (VH domain, peptide number 2 and 3), 
HC 229-252 (CH1-CH2 interface, peptide number 48 and 49) and HC 311-325 (CH2 domain, 
peptide number 64). Among these changes, an increase in local flexibility at the hinge region (CH1-
CH2 interface) of the antibody had the largest magnitude. One way to explain this significant 
increase in local backbone flexibility in the hinge region is through long-range, distant dynamic 
coupling effects that may occur upon protein-protein interactions.  
In biological systems, protein allosteric effects play a major role in cellular regulation. The 
classical model of allosteric conformational effects constitute binding of a ligand to a region or 
domain of a protein and its effect on conformation of a distal, functional region of the protein.231,232  
An emerging view of protein allostery includes a dynamic continuum in which protein-protein or 
protein-ligand interactions result in propagation of a signal through changes in protein dynamics, 
either with or without large scale conformational changes.231,232 Such alterations in protein 
dynamics as part of allosteric regulation of proteins are sometimes referred to as propagation of an 
“allosteric wave”. 233  Examples of such flexibility shifts within single protein molecule upon 
ligand binding or protein-protein interaction have been reported.234,235 Such changes in protein 
dynamic allostery can also occur upon post-translational modifications, or upon changes in 
solution pH or protein concentration.233   
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Although the distant dynamic coupling effects we observed within the mAb-C upon 
extensive RSA may lack any biological consequences, the molecular mechanism of alterations in 
local backbone flexibility upon protein-protein interactions are “allosteric-like” in that they 
resemble the molecular mechanisms of protein dynamic allostery.231,232,236  The observed localized 
changes in backbone dynamics upon RSA may potentially have important implications in terms 
of pharmaceutical properties of a mAb including storage stability, manufacturability, and 
syringeability. Since HX-MS provides increased resolution for characterizing RSA directly at high 
protein concentrations, this information could be used to design superior next-generation mAb 
molecules with lower propensity for RSA.  In terms of future work, further establishing the 
universality of such behavior among self-associating mAbs is being evaluated in our laboratories 
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2.7 ± 0.2 96.7 ± 0.3 0.5 ± 0.1 0.1 ± 0.1 
 
Effect of lyophilization and reconstitution on the aggregation profile of mAb-C as measured by 
size-exclusion chromatography (SEC). Samples of mAb-C were prepared at 5 and 60 mg/mL in 
20 mM potassium phosphate buffer (pH 7.0) with 10% (w/v) trehalose (Pre-lyophilization 
samples). After lyophilization, mAb-C samples were reconstituted with D2O-based 20 mM 
potassium phosphate buffer (pH 7.0) with 300 mM salt Na2SO4 (Post-lyophilization samples). The 
experimental data are mean and standard deviation calculated from three independent 









1 mAb-C Heavy 4-10  (VH) 
2 mAb-C Heavy 4-17  (VH) 
3 mAb-C Heavy 8-29  (VH) 
4 mAb-C Heavy 11-22  (VH) 
5 mAb-C Heavy 11-26  (VH) 
6 mAb-C Heavy 27-35  (VH) 
7 mAb-C Heavy 33-43  (VH) 
8 mAb-C Heavy 33-44  (VH) 
9 mAb-C Heavy 35-45  (VH) 
10 mAb-C Heavy 35-59  (VH) 
11 mAb-C Heavy 37-45  (VH) 
12 mAb-C Heavy 37-48  (VH) 
13 mAb-C Heavy 45-59  (VH) 
14 mAb-C Heavy 46-59  (VH) 
15 mAb-C Heavy 47-59  (VH) 
16 mAb-C Heavy 49-60  (VH) 
17 mAb-C Heavy 50-59  (VH) 
18 mAb-C Heavy 50-60  (VH) 
19 mAb-C Heavy 60-70  (VH) 
20 mAb-C Heavy 60-71  (VH) 
21 mAb-C Heavy 63-69  (VH) 
22 mAb-C Heavy 71-78  (VH) 
23 mAb-C Heavy 71-80  (VH) 
24 mAb-C Heavy 81-86  (VH) 
25 mAb-C Heavy 84-93  (VH) 
26 mAb-C Heavy 87-94  (VH) 
27 mAb-C Heavy 100-112  (VH) 
28 mAb-C Heavy 101-112  (VH) 
29 mAb-C Heavy 102-112  (VH) 
30 mAb-C Heavy 113-122  (VH) 
31 mAb-C Heavy 121-130 (CH1) 
32 mAb-C Heavy 121-140 (CH1) 
33 mAb-C Heavy 135-140 (CH1) 
34 mAb-C Heavy 135-150 (CH1) 
35 mAb-C Heavy 141-152 (CH1) 
36 mAb-C Heavy 145-174 (CH1) 
37 mAb-C Heavy 152-162 (CH1) 
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38 mAb-C Heavy 155-165 (CH1) 
39 mAb-C Heavy 164-187 (CH1) 
40 mAb-C Heavy 167-182 (CH1) 
41 mAb-C Heavy 171-182 (CH1) 
42 mAb-C Heavy 176-182 (CH1) 
43 mAb-C Heavy 188-193 (CH1) 
44 mAb-C Heavy 193-205 (CH1) 
45 mAb-C Heavy 194-201 (CH1) 
46 mAb-C Heavy 199-211 (CH1) 
47 mAb-C Heavy 219-227 (CH1) 
48 mAb-C Heavy 229-254 (CH2) 
49 mAb-C Heavy 233-252 (CH2) 
50 mAb-C Heavy 243-248 (CH2) 
51 mAb-C Heavy 246-256 (CH2) 
52 mAb-C Heavy 249-260 (CH2) 
53 mAb-C Heavy 251-260 (CH2) 
54 mAb-C Heavy 252-259 (CH2) 
55 mAb-C Heavy 261-268 (CH2) 
56 mAb-C Heavy 261-269 (CH2) 
57 mAb-C Heavy 261-271 (CH2) 
58 mAb-C Heavy 270-285 (CH2) 
59 mAb-C Heavy 271-285 (CH2) 
60 mAb-C Heavy 273-285 (CH2) 
61 mAb-C Heavy 282-284 (CH2) 
62 mAb-C Heavy 285-298 (CH2) 
63 mAb-C Heavy 308-314 (CH2) 
64 mAb-C Heavy 311-325 (CH2) 
65 mAb-C Heavy 315-341 (CH2) 
66 mAb-C Heavy 320-334 (CH2) 
67 mAb-C Heavy 342-356 (CH2) 
68 mAb-C Heavy 344-356 (CH3) 
69 mAb-C Heavy 357-366 (CH3) 
70 mAb-C Heavy 365-372 (CH3) 
71 mAb-C Heavy 365-374 (CH3) 
72 mAb-C Heavy 377-388 (CH3) 
73 mAb-C Heavy 385-398 (CH3) 
74 mAb-C Heavy 385-406 (CH3) 
75 mAb-C Heavy 385-412 (CH3) 
76 mAb-C Heavy 389-398 (CH3) 
77 mAb-C Heavy 389-406 (CH3) 
78 mAb-C Heavy 389-412 (CH3) 
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79 mAb-C Heavy 390-406 (CH3) 
80 mAb-C Heavy 399-406 (CH3) 
81 mAb-C Heavy 399-412 (CH3) 
82 mAb-C Heavy 407-412 (CH3) 
83 mAb-C Heavy 413-418 (CH3) 
84 mAb-C Heavy 417-428 (CH3) 
85 mAb-C Heavy 419-431 (CH3) 
86 mAb-C Heavy 420-436 (CH3) 
87 mAb-C Heavy 431-454 (CH3) 
88 mAb-C Heavy 432-438 (CH3) 
89 mAb-C Heavy 432-454 (CH3) 
90 mAb-C Heavy 434-454 (CH3) 
91 mAb-C Heavy 436-454 (CH3) 
92 mAb-C Heavy 437-454 (CH3) 
93 mAb-C Light 1-10 (VL) 
94 mAb-C Light 1-12 (VL) 
95 mAb-C Light 4-10 (VL) 
96 mAb-C Light 11-22 (VL) 
97 mAb-C Light 13-32 (VL) 
98 mAb-C Light 33-49 (VL) 
99 mAb-C Light 35-48 (VL) 
100 mAb-C Light 36-54 (VL) 
101 mAb-C Light 47-62 (VL) 
102 mAb-C Light 48-70 (VL) 
103 mAb-C Light 49-70 (VL) 
104 mAb-C Light 49-71 (VL) 
105 mAb-C Light 50-71 (VL) 
106 mAb-C Light 55-71 (VL) 
107 mAb-C Light 72-82 (VL) 
108 mAb-C Light 74-82 (VL) 
109 mAb-C Light 75-82 (VL) 
110 mAb-C Light 80-83 (VL) 
111 mAb-C Light 88-104 (VL) 
112 mAb-C Light 102-115 (VL) 
113 mAb-C Light 105-116 (VL) 
114 mAb-C Light 106-115 (VL) 
115 mAb-C Light 116-131 (VL) 
116 mAb-C Light 117-130 (CL) 
117 mAb-C Light 117-133 (CL) 
118 mAb-C Light 123-133 (CL) 
119 mAb-C Light 124-133 (CL) 
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120 mAb-C Light 132-146 (CL) 
121 mAb-C Light 136-143 (CL) 
122 mAb-C Light 149-172 (CL) 
123 mAb-C Light 155-172 (CL) 
124 mAb-C Light 160-172 (CL) 
125 mAb-C Light 162-172 (CL) 
126 mAb-C Light 162-178 (CL) 
127 mAb-C Light 173-179 (CL) 
128 mAb-C Light 179-184 (CL) 
129 mAb-C Light 180-194 (CL) 
130 mAb-C Light 203-214 (CL) 
 
Location of pepsin generated peptide segments (from HX-MS analysis of mAb-C) in the mAb-C 
















Hydrodynamic diameter of mAb-C under various solution conditions as measured by dynamic light 
scattering. (A) Effect of pH as a function of protein concentration. (B) Effect of salt type (NaCl and 
Na2SO4) and ionic strength. Experiments were conducted at 25°C with mAb-C samples prepared in 
40 mM potassium phosphate buffer (pH 7), containing either NaCl or Na2SO4 at 0, 0.15, 0.3 and 0.5 
M. The mAb-C samples were prepared in 40 mM potassium phosphate buffer (pH 6, 7 and 8) 
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Cross-linking and SDS-PAGE analysis of reversible self-association (RSA) of mAb-C under 
different solution conditions. The mAb-C samples were prepared in 40 mM potassium phosphate 
buffer (pH 7) in the presence and absence of 0.3 M Na2SO4. The lane in each panel marked “UN” 
represents a mAb-C control with no added cross-linker. The first and last lane of each gel contains 
molecular weight standards.  The masses are denoted on the left side gels. Subsequent lanes show 
the extent of mAb-C cross-linking in the presence of increasing concentration of BS2G cross-
linker. Top-left panel, non-reduced SDS-PAGE gel showing cross-linking of mAb-C in the 
absence of Na2SO4. Top-right panel, non-reduced gel showing cross-linking of mAb-C in the 
presence of 300 mM Na2SO4. Bottom-left panel, reduced SDS-PAGE gel showing mAb-C in the 
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absence of Na2SO4. Bottom-right panel, reduced gel of mAb-C in the presence of 300 mM Na2SO4. 






















The effect of protein concentration, temperature and salt type on solution viscosity of mAb-C 
samples either before or after lyophilization and reconstitution. (A) Effect of temperature and salt 
type on viscosity of mAb-C as a function of protein concentration. (B) Effect of lyophilization and 
reconstitution diluent (with H2O- and D2O-based buffers) on the viscosity of mAb-C as a function 
of protein concentration. Samples of mAb-C for panel A were prepared in 40 mM potassium 
phosphate buffer (pH 7.0) containing 300 mM salt (NaCl or Na2SO4). For panel B, mAb-C samples 
that were not lyophilized were prepared in 40 mM potassium phosphate buffer (pH 7.0) containing 
300 mM Na2SO4 and 10% (w/v) trehalose. Lyophilized samples were freeze-dried in 20 mM 
potassium phosphate buffer (pH 7.0) containing 10% (w/v) trehalose, and then reconstituted with 
either H2O or D2O buffers consisting of 20 mM potassium phosphate buffer (pH 7.0) and 300 mM 
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salt Na2SO4. Viscosity measurements were taken either at 4°C or 25°C, as noted. The error bars 






















Circular dichroism spectra showing the effect of the lyophilization process on the overall 
secondary structure of mAb-C. All mAb-C samples (pre and post lyophilization) were diluted to 
0.3 mg/mL with 40 mM potassium phosphate buffer (pH 7.0) containing 300 mM Na2SO4 and 
10% (w/v) trehalose for analysis at 10°C. The error bars represent one standard deviation from 











Deuterium uptake by twelve representative peptide segments from mAb-C measured at 5 and 60 
mg/mL as determined by HX-MS. (A) Six representative peptides that showed no differences in 
hydrogen exchange kinetics between low and high protein concentrations. (B) Six representative 
peptides that showed significant changes in hydrogen exchange kinetics between low and high 
protein concentrations. Domain location and peptide number of the segment are shown in 
parentheses. The error bars represent one standard deviation from three independent experiments. 










Relative differences in deuterium uptake at four exposure times as measured by HX-MS for 130 
peptide segments of mAb-C at 60 mg/mL vs. 5 mg/mL at pH 7.0. The individual peptides are 
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arranged on the horizontal axis starting from the N-terminal of the heavy chain and ending at the 
C-terminal of the light chain.  The peptides are numbered sequentially based on the locations of 
their middle residues (see Supplemental Table S1 for the identities and locations of the peptides). 
The horizontal axes of these plots denote the peptide numbers from 1 to 130.  The vertical axis is 
the difference between exchange at 60 mg/mL vs. 5 mg/ml:      60 5  –m t m t m t  .   Positive 
bars indicate an increase in deuterium uptake for a particular peptide segment at high protein 
concentration (60 mg/mL) and negative bars indicate decreased deuterium uptake for a peptide 
segment at 60 mg/mL compared to lower protein concentration (5 mg/mL). The dashed lines at ± 
0.4 Da indicate the 99% confidence limits for significant differences. White and grey shades in the 
background of the figure represent IgG domain boundaries and each domain is labeled at the top 
of the figure. Shades in blue represent CDR segments on mAb-C. Segment locations in the mAb-
C sequence and their corresponding peptide numbers can be found in the Table S1 in the supporting 
information.  An average of three independent mass measurements was used to calculate each 












Effect of concentration-dependent RSA on deuterium uptake of various segments of mAb-C as 
measured by HX-MS plotted onto homology models of mAb-C.  (A) Entire mAb, (B) view of the 
Fab domain and (C) view of the Fab domain with histidine residues in the peptide segments 
containing the CDR2H and CDR3H sequences highlighted in green color. Changes in deuterium 
uptake of particular peptide segments are colored according to the legend and are derived from the 












Pepsin peptide map of the (A) heavy chain (HC) and (B) light chain (LC) of mAb-C composed of 

















































Deuterium uptake plots as measured by HX-MS of 130 peptide segments comparing hydrogen 
exchange kinetics between 5 and 60 mg/mL mAb-C samples. Domain location and peptide number 
of the segment are shown in parentheses. The error bars represent one standard deviation from 




















Reproducibility of the HX-MS data represented by the distribution of standard deviations for the 
mass differences across all time points and segments of mAb-C from the triplicate experiments (N 












Difference plot showing the relative mass change (Δm) of 35 selected mAb-C peptide segments 
comparing lyophilized vs. unlyophilized mAb-C samples at 6 mg/mL as measured by HX-MS. 
The differences in hydrogen exchange between lyophilized and unlyophilized samples of mAb-C 
at 6 mg/mL        lyo unlyom t m t m t      are plotted on the vertical axis. The positive bars 
represent peptides that show increased in hydrogen exchange after lyophilization/reconstitution. 
Negative bars represent peptides that show decreased hydrogen exchange upon 







Difference plot showing relative mass change of 35 selected mAb-C peptide segments comparing 
lyophilized vs. unlyophilized mAb-C samples at 60 mg/mL as measured by HX-MS. The 
differences in hydrogen exchange between lyophilized and unlyophilized samples of mAb-C at 60 
mg/mL        lyo unlyom t m t m t      are plotted on the vertical axis. The positive bars represent 
peptides that show increased in hydrogen exchange after lyophilization/reconstitution. Negative 
bars represent peptides that show decreased hydrogen exchange upon lyophilization/reconstitution 






Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster 




















Protein-protein interactions play a critical role in many biological and biochemical 
processes. Like many biological processes however, protein-protein interactions can have negative 
as well as positive effects. 1-4 In vivo, cellular proteins are usually present in a very crowded, highly 
concentrated environment. 5 At such high protein concentrations, due to increases in molecular 
crowding and decreases in intermolecular distances between molecules, the extent of specific and 
non-specific protein-protein interactions driven by exposed charged and apolar regions on the 
protein surface increase. 6-8 Independent of whether a protein is in vivo or in vitro (e.g., a purified 
protein drug candidate stored in a vial), molecular crowding causes protein solutions to deviate 
from ideality, thereby affecting macromolecular interactions and potentially protein conformation. 
9 Identification of the interfaces that mediate protein-protein interactions can open new avenues 
for drug targeting and discovery, and guide protein engineers in the development of 
macromolecule candidates that are more stable and easier to administer.  
Monoclonal antibodies (mAbs) comprise a major class of biotherapeutics used for the 
treatment of many chronic conditions. 10 The subcutaneous delivery route enables patients to self-
administer 1-2 mL of injectable volume per dose. To deliver the amount of drug needed, which is 
often tens to hundreds of milligrams, in this volume, the mAbs must be formulated at very high 
protein concentrations. 2, 10 Due to decreases in intermolecular distances between protein 
molecules at high protein concentrations, attractive protein-protein interactions may overcome 
repulsive interactions, thereby favoring the formation of reversibly associating intermolecular 
protein complexes. 11, 12 Formation of large protein complexes increases the solution shear 
modulus, which can result in dramatic increases in viscosity at higher concentration, 13, 14 leading 
to formulation and manufacturing-related challenges. In addition, antibody clusters may act as 
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seeds for the formation of irreversible aggregates at high protein concentration. 15 Moreover, high 
shear stress during pumping of viscous solutions of self-associated proteins has, in some cases, 
been shown to also contribute to the formation of irreversible protein aggregates. 16 Such 
irreversible aggregates can decrease protein activity and stability, and may elicit adverse 
immunogenic reactions in patients. 17-19 In addition, parenteral administration of highly viscous 
liquids requires thicker gauge needles that may cause more painful injections. 2  
Previous work has shown that reversible self-association (RSA) between different IgG1 
mAbs can result from different binding interfaces, despite high sequence similarity between the 
mAbs. 20-22 Studies of enzymatic fragmentation of IgG1 monomers into Fab and Fc domains, 21, 23, 
24 site-specific mutations in complementarity-determining region (CDR), 25 and coarse-grained 
simulations of such protein interactions 26, 27 suggest that intermolecular reversible interactions 
between mAb molecules can be initiated by either Fab-Fab or Fab-Fc associations and to a lesser 
extent through Fc-Fc interactions. Despite providing experimental insights into how solution 
conditions modulate the rate and extent of reversible protein-protein interactions, and which major 
regions of the mAb might be involved in such phenomena, these studies offer an incomplete and 
low-resolution picture of mAb reversible self-association. A more complete understanding of the 
specific molecular mechanisms of reversible protein-protein interactions requires site-specific 
information about the surfaces that mediate such associations.  
Hydrogen exchange (HX) is a robust bioanalytical tool used to study protein dynamics and 
protein-protein interactions. 28-33 The rate of hydrogen exchange depends on the higher order 
structure of the protein: backbone amides that are fully solvated (lacking hydrogen bonding) 
undergo rapid HX while amides located in structurally protected or strongly hydrogen-bonded 
regions exchange significantly more slowly. 34-36 Thus, HX measurements can be used to map 
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protein interfaces of intermolecular protein-protein interactions because the formation of 
intermolecular contacts directly affects the solvation and hydrogen bond strengths at the protein 
interface. 33 Mass spectrometry coupled to HX (HX-MS), extends the HX technique to complex, 
multi-domain macromolecules like mAbs. 37-43 Recently, we described a novel HX-MS method to 
map protein interfaces formed between mAbs undergoing reversible protein-protein interactions 
directly at up to 60 g/L. 39  
Here, we applied this technique to investigate the molecular mechanism by which an IgG1 
mAb (mAb-J) undergoes reversible self-association, and further probed this mechanism by a 
variety of other biophysical techniques. We also mapped the interface of the reversible, 
concentration-dependent intermolecular interactions between mAb-J monomers using hydrogen 
exchange mass spectrometry (HX-MS). The results of this study augment our knowledge of how 
proteins interact with each other at high protein concentrations under crowded environments.  
 
4.2 Materials and Methods  
4.2.1 Sample preparation 
A purified IgG1 mAb, mAb-J, at a concentration of 150 g/L was obtained from MedImmune LLC, 
Gaithersburg, MD. The stock solution of mAb-J was dialyzed against the “control buffer” (20 mM 
citrate-phosphate buffer at selected pH values, containing 30 mM NaCl) with or without additional 
NaCl, arginine hydrochloride, or sugars (sucrose and trehalose) at 4°C using 3500 kDa molecular-
weight cutoff membranes (Slide-A-Lyzer, Thermo Scientific, Rockford, IL) for 24 hours. For 
static light scattering and lyophilization, additional 10% w/v trehalose was added to the samples. 
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Subsequently, after dialysis stock solutions of mAb-J were diluted using corresponding buffer 
solutions. 
4.2.2 Dynamic light scattering 
Samples of mAb-J at 10 g/L prepared in control (pH 5.0-7.0) with or without additional NaCl, 
arginine hydrochloride or sugars (sucrose and trehalose) were centrifuged at 12,000 × g for 5 
minutes before analysis. DLS was measured in triplicate using the DynaPro Plate Reader (Wyatt 
Technology, Santa Barbara, CA). Scattered light was analyzed using a backscatter detector fixed 
at an angle of 173˚. Fifteen runs of 5 second acquisitions were collected and averaged to determine 
the hydrodynamic diameter for each sample. 
4.2.3 Viscosity Measurements 
 Samples of mAb-J, ranging from 5 to 60 g/L were prepared by diluting the dialyzed stock 
with corresponding buffer solutions. Solution dynamic viscosity was measured at 25°C with an m-
VROC viscometer (Rheosence, San Ramon, CA) at a rate of 100 μL/min with a shear rate of 1420 
1 s-1. Triplicate viscosity measurements were recorded over a duration of 100 seconds.  
4.2.4 Composition-gradient multi-angle light scattering  
Dialyzed stock of mAb-J at 150 g/L in control (containing 10% w/v trehalose) with or without 
additional 100 mM NaCl and arginine was diluted with corresponding buffer solutions to prepare 
samples of mAb-J at 2 and 20 g/L. Thereafter, these samples were filtered through 0.22 μm Millex-
GV syringe filter units (EMD Millipore, Billerica, MA). A fully automated CG-MALS instrument 
with a dual syringe-pump Calypso sample preparation and delivery unit (Wyatt Technology, Santa 
Barbara, CA) was used to measure light scattering at room temperature. A Dawn Heleos II light 
scattering instrument (Wyatt Technology, Santa Barbara, CA), equipped with a 661 nm laser and 
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an Optilab Rex refractive index detector (Wyatt Technology, Santa Barbara, CA), was used to 
measure both light scattering and protein concentration. Filtered HPLC grade toluene (Fisher 
Scientific, Fair Lawn, New Jersey) was used to calibrate voltage and light scattering intensities. 
Rayleigh ratio light scattering intensities were obtained over a protein concentration range of 0.2–
20 g/L. The light scattering and concentration data were fit to a set of association models using 
Calypso software (Wyatt Technology, Santa Barbara, CA). 
To obtain a stoichiometric analysis of RSA of mAb-J under different solution conditions, 
light scattering data were fit to various association models using equation 2, a virial expansion for 
non-ideal solutions containing associating components; 






                                                           (Eq.2) 
Rθ is the excess Rayleigh ratio, M the molecular weight, i is the stoichiometry of the associated 
species (e.g., i = 2 for a dimer), Ci are the concentrations of the individual species, and C
tot is the 
total concentration. A2 is the osmotic second virial coefficient, left unconstrained during data 
fitting. A2, provides useful insights into intermolecular interactions between protein molecules. A 
negative value of A2 indicates that the overall interactions between protein molecules are attractive, 
while a positive value indicates that the overall interactions are repulsive. K in equation 2 is the 
optical constant described by equation 3 









                                                         (Eq.3) 
with n0 as the refractive index of the solvent (1.33), NA is Avogadro’s number (mol
−1), 𝑑𝑛/𝑑𝑐 is 
the refractive index increment of the protein/solvent pair (0.185 mL/g), 70, 71 and λ0 is the 
wavelength of the incident light in vacuum. Following an iterative procedure, A2 and Ci values 
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were optimized to achieve the best fit (based on χ2) between the light scattering data and various 
association models (see Table S1 for the χ2 values). A monomer-dimer-tetramer association 
equilibrium model best fit the light scattering data for mAb-J (see Table S2 for the A2 values).  
4.2.5 Lyophilization of mAb-J samples 
Stock solutions of mAb-J at 150 g/L, dialyzed against the control (containing 10% w/v 
trehalose), were diluted to 5 and 60 g/L using control buffer, and 500 μL were dispensed into 3 
mL FIOLAX® clear Type 1 glass vials (Schott North America, Elmsford, NY) with a fill volume 
of 500 μL. The vials were partially stoppered by 2-leg, 13 mm siliconized rubber stoppers 
(Wheaton Industries Inc., Millville, NJ). The samples were then lyophilized using a LyoStar II 
lyophilizer (SP Scientific, Warminster, PA) using an optimized lyophilization cycle described 
previously. 39  
4.2.6 Circular Dichroism 
Lyophilized mAb-J samples at both 5 and 60 g/L were reconstituted with D2O to a concentration 
of 0.3 g/L. CD experiments were carried out with a Chirascan Plus Circular Dichroism 
Spectrometer (Applied Photophysics Ltd., Leatherhead, UK) equipped with a Peltier temperature 
controller and a four-position cuvette holder. Far-ultraviolet (UV) CD spectra of non-lyophilized 
control and freeze-dried mAb-J samples (0.3 g/L) were collected from 200 nm to 260 nm using 
0.1 cm path length quartz cuvettes. CD scans were collected at 10 °C using a sampling time of 1 
second and a bandwidth of 1 nm. Non-lyophilized mAb-J samples were prepared in H2O-based 
control buffer. Ellipticity values obtained from the instrument were then converted to molar 
ellipticity by dividing ellipticity by protein concentration (M) and cuvette path length (m).  
4.2.7 Size-Exclusion Chromatography 
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Freeze-dried mAb-J samples at both 5 and 60 g/L were reconstituted to 0.5 g/L using D2O and 
then centrifuged at 14000 x g for 5 minutes to remove any insoluble aggregates prior to SEC 
analysis. A Shimadzu high performance liquid-chromatography system equipped with a 
photodiode array detector capable of recording UV absorbance spectra from 200 to 400 nm was 
used. A 7.8 mm × 30 cm Tosoh TSK-Gel BioAssist G3SWxL (TOSOH Biosciences, King of 
Prussia, PA) and a corresponding guard column were preconditioned with 0.2 M sodium 
phosphate, pH 6.8, and then calibrated using gel-filtration molecular weight standards (Bio-Rad, 
Hercules, CA). mAb-J species were separated at 0.7 mL min-1 based on their size. A dual 
wavelength quantification method described previously 72 was used to quantify the amounts of 
various species of mAb-J in solution. Non-lyophilized samples were prepared in H2O-based 
control buffer. To calculate the amount of insoluble aggregates in reconstituted mAb-J samples, 
the total area of all the species (soluble aggregates, monomer, and fragment) in the chromatogram 
was calculated. The difference between the total peak areas of the sample and the control was 
defined as total insoluble aggregates. 
4.2.8 Deuteration of arginine 
To remove exchangeable 1H from arginine, arginine hydrochloride was dissolved in D2O 
at appropriate concentrations and then dried at 30 ˚C for 24 hours in a VacufugeTM vacuum 
concentrator (Eppendorf, Hauppauge, NY). The process was repeated three times. After the third 
drying cycle, the deuterated arginine powder was reconstituted with D2O-based 5 mM citrate-
phosphate buffer (pH 6.0). The final pH was adjusted with deuterium chloride or deuterium oxide 
to be within 0.02 pH unit of the desired pH. The pH values were recorded without correction for 
the deuterium isotope effect. 73 
4.2.9 Hydrogen-Exchange Mass Spectrometry 
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Hydrogen exchange was initiated by adding 500 μL of D2O to vials of lyophilized mAb-J 
as described in more detail previously. 39 Labeling was thermostated to 25 °C on an Echotherm 
chilling/heating plate (Torrey Pines Scientific, Inc. Carlsbad, CA). Hydrogen exchange was 
quenched after 120, 2760, 104 and 105 seconds by adding 20 μL of the exchange reaction mixture 
to 180 μL of quench buffer containing 0.5 M tris(2-carboxyethyl) phosphine hydrochloride, 4 M 
guanidine hydrochloride, and 0.2 M sodium phosphate at pH 2.5 pre-equilibrated at 1°C. An H/DX 
PAL robot (LEAP Technologies, Carrboro, NC) was used for sample handling and injection. 
Subsequent to the quench step, samples were loaded into the sample loop of the refrigerated 
column compartment containing three valves connected to an Agilent 1260 infinity series LC 
(Agilent Technologies, Santa Clara, CA), an immobilized pepsin column, a peptide desalting trap, 
and a C18 column. The level of deuteration in each peptide was measured using an Agilent 6530 
quadrupole-time of flight mass spectrometer (Agilent Technologies, Santa Clara, CA), equipped 
with a standard electrospray ionization source operated in positive mode. A complete description 
of the hydrogen exchange methodology was previously reported. 39  
4.2.10 Hydrogen Exchange Mass Spectrometry (HX-MS) with viscosity-decreasing solutes 
A D2O-based 5 mM citrate-phosphate buffer (pH 6.0) was used to make reconstitution 
solutions containing 100 mM of deuterated arginine and 100 mM NaCl, respectively. Lyophilized 
mAb-J samples at 5 g/L were reconstituted using 500 μL of D2O-based 5 mM citrate-phosphate 
buffer (pH 6.0). Half of the lyophilized mAb-J samples at 60 g/L were reconstituted using 5 mM 
citrate-phosphate buffer (pH 6.0) containing 100 mM deuterated arginine while the other half was 
reconstituted using the same buffer containing 100 mM NaCl instead of 100 mM arginine, yielding 
a final solution composition of 25 mM citrate phosphate buffer (pH 6.0) containing 30 mM sodium 
chloride, 10 % (w/v) trehalose with or without 100 mM arginine or 100 mM NaCl. The hydrogen 
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exchange reaction was quenched after 2760 seconds. A full description of the hydrogen exchange 
process is described elsewhere. 39 
4.2.11 HX-MS data processing and analysis 
mAb-J peptic peptides were identified using accurate mass (± 10 ppm) and tandem MS 
with collision-induced dissociation on a quadrupole-time of flight mass spectrometer. A total of 
182 peptides covering 92% of the primary sequence of mAb-J were identified and used for 
analysis. HDExaminer (Sierra Analytics, Modesto, CA) was used for initial processing of the HX-
MS data. Deuterium uptake plots with average deuterium uptake values and standard deviations 
from triplicate hydrogen exchange runs for each peptide were generated using an R script, written 
in-house. A 99% confidence interval of ±0.40 Da for the differences in our dataset was calculated 
using a procedure we described previously. 39 HX-MS results were mapped onto a homology 
model of mAb-J created using the method described previously 39 based on crystal structures of an 
isolated Fc 47 and an in-silico generated KOL/Padlan structure of Fab. 46 Pymol (Schrödinger LLC, 
Portland, OR) was used to display the results 
 
4.3 Results 
4.3.1 Increases in mAb hydrodynamic diameter suggests reversible self-association 
In an initial set of experiments done to better understand the possible mechanism(s) of 
mAb-J RSA, the effects of solution properties and additives on the magnitude of RSA at relatively 
low protein concentration (1-10 g/L) were examined. All results are described relative to mAb-J 
in a control solution (20 mM citrate-phosphate, 30 mM NaCl, pH 6.0). Figure 1 shows the effects 
of charged co-solutes and sugars and changes in solution pH on the average hydrodynamic 
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diameter of mAb-J, as determined by dynamic light scattering (DLS). The average hydrodynamic 
diameter of a full length, monomeric IgG1 mAb molecule is typically 9-12 nm. 44, 45 At 10 g/L, the 
hydrodynamic diameter of mAb-J in the control solution was 17.5 nm, significantly higher than a 
typical monomeric IgG1 mAb. The large hydrodynamic diameter suggests that mAb-J undergoes 
self-association even at the relatively low concentration of 10 g/L at low ionic strength. The 
average hydrodynamic diameter of mAb-J in solution decreased (from 17.5 nm at low ionic 
strength to 12.8 nm) in the presence of an additional 100 mM NaCl. This same hydrodynamic 
diameter vs. ionic strength trend also was evident in the presence of either sucrose or trehalose 
(Figure 1A). The average hydrodynamic diameter of mAb-J decreased (from 17.5 nm to 10.8 nm) 
in the presence of 100 mM arginine. In contrast, the addition of sucrose and trehalose caused 
increases in the average hydrodynamic diameter (from 17.5 nm to 18.8 and to 19.7 nm, 
respectively; Figure 1A). Raising the pH from 5.0 to 7.0 also resulted in an increased 
hydrodynamic diameter (from 13.0 nm to 18.8 nm, Figure 1B). Taken together, these data suggest 
that the extent of mAb-J RSA, even at 10 g/L, decreases as the ionic strength increases. MAb-J 
RSA increases, however, in higher pH solutions or upon addition of sugars. Since the experimental 
limit for DLS is around 10 g/L protein concentration, which limits the investigation of association 
at higher concentrations, we then used dynamic viscosity to investigate protein-protein interactions 
at higher mAb-J concentrations. 
4.3.2 Effects of solutes on the dynamic viscosity of mAb-J solutions  
Highly associated protein will usually cause a dramatic increase in solution viscosity at 
high protein concentrations. 20, 21 Trends in mAb-J solution viscosity with increased protein 
concentration under various solution conditions are shown in Figure 2. The solution viscosity of 
mAb-J in the control buffer increased exponentially with protein concentration, an effect that can 
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be attributed to RSA between mAb monomers. Addition of NaCl or arginine to the control solution 
at concentrations up to 100 mM weakened the effect. Consistent with DLS results, the effect of 
arginine on the viscosity of mAb-J was stronger than NaCl. The effect of pH and sugars can be 
seen by comparing the solution viscosity of mAb-J at 60 g/L. As the pH of the control buffer was 
increased from 5.0 to 7.0, the viscosity of 60 g/L mAb-J increased (Figure 2D). When either 
trehalose or sucrose was added, the viscosity of the mAb-J solution increased, with the effect of 
trehalose stronger than sucrose. The solution viscosity of buffer in the absence of protein only 
increased slightly upon addition of sugars. Taken together, the viscosity results provide further 
evidence supporting the presence of concentration-dependent transient protein-protein interactions 
between mAb monomers. An increase in the ionic strength of the solution or addition of arginine 
decreased solution viscosity, while an increase in pH from 5.0 to 7.0 caused the dynamic viscosity 
of mAb-J solution to increase. These observations suggest that mAb-J intermolecular interactions 
are primarily driven by attractive electrostatic interactions.  
4.3.3 Reversible self-association of mAb-J involves a monomer-dimer-tetramer equilibrium 
The nature of mAb-J intermolecular interactions was further studied using composition-gradient 
multi-angle light scattering (CG-MALS). Static light scattering quantifies the excess Rayleigh 
ratio (R), the fractional amount of incident light that is scattered by the macromolecule per unit 
volume of the solution. Intermolecular interactions affect the magnitude of the Rayleigh ratio. If 
the relationship between R, as a function of the scattering angle (θ), and protein concentration is 
known, then the apparent molecular weight, size, and extent of self-association of the molecule 
can be determined using values of the osmotic second virial coefficient (A2) combined with 
stoichiometry estimates based various association models (as described in detail in the 
Experimental Section of the Supporting Information).  
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The mole fractions of monomeric, dimeric, and tetrameric forms of mAb-J under the 
experimental conditions were determined (Figure 3) based on fitting the static light scattering data 
to a monomer, dimer, tetramer association equilibrium model. First, for mAb-J at 20 g/L in control 
buffer containing 10% w/v trehalose, the solution had nearly-equal mole fractions of monomeric 
mAb-J (0.48) and tetrameric mAb-J (0.48) (Figure 3A). This observation suggests extensive 
protein-protein interactions, supported by an osmotic second virial coefficient (A2) value of –
9.6×10–5 mol mL g–2. In the presence of an additional 100 mM NaCl in the control buffer, the mole 
fraction of monomeric mAb-J did not decrease as steeply, reaching a value of 0.63 at 20 g/L. 
Interestingly the mole fraction of dimer was 0.27, whereas tetramer was only 0.1 under these 
conditions (Figure 3B). The value of A2 for mAb-J in the presence of additional 100 mM NaCl 
became positive, 2×10–5 mol mL g–2, in contrast to the negative value under low ionic strength 
solution conditions. The positive A2 value indicates disruption of protein-protein interactions. In 
the presence of 100 mM arginine, mAb-J was completely monomeric even at 20 g/L, suggesting 
complete disruption of attractive intermolecular interaction between mAb-J monomers over the 
concentration range tested (Figure 3C). Disruption of protein-protein interactions by arginine is 
further supported by a large, positive value of A2 (9×10
–5 mol mL g–2) for mAb-J in the presence 
of arginine.  
4.3.4 Hydrogen exchange mass spectrometry reveals association between the Fc and Fab 
 To map the interfaces responsible for protein-protein interactions, the non-associating and 
associating protein states must be compared. We chose to compare the protein concentrations 5 
g/L (~90% monomeric) and 60 g/L (less than 50% monomeric) by HX-MS analysis. To conduct 
hydrogen exchange at high protein concentration, we followed an approach we recently developed, 
39 which involves reconstituting lyophilized mAb-J with D2O-containing buffer rather than diluting 
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the solution with D2O. A combination of size-exclusion chromatography (SEC), circular dichroism 
(CD), and viscosity measurements confirms the structural integrity of mAb-J samples after 
lyophilization, as described in the Supporting Information (Figure S1, and Table S3). To maintain 
the high concentration of mAb-J during hydrogen exchange, the lyophilized samples of mAb-J 
were reconstituted with pure D2O to yield a final solution composition of 20 mM citrate phosphate 
buffer (pH 6) containing 10% w/v trehalose and 30 mM NaCl (i.e., control buffer + 10% w/v 
trehalose in D2O). To eliminate artifacts that might potentially arise from altered chemical 
exchange kinetics, the composition of the buffer was held constant while only the mAb-J 
concentration was changed. Following selected intervals of hydrogen exchange, the reaction was 
quenched by lowering the pH to 2.5, and the sample was then digested with pepsin, and analyzed 
by LC-MS (see Supporting Information).  
No significant differences were observed in the measured HX between low and high 
protein concentration for almost 95% of the peptic peptides of mAb-J (see Figure S3). Deuterium 
uptake plots for some representative peptides in this category are shown in Figure 4A. There were 
certain peptides, however, that exhibited significant protection against deuterium uptake at 60 g/L 
mAb-J. Figure 4B shows representative deuterium uptake plots for some of the peptides that 
became significantly protected. Deuterium uptake plots for all of the peptides from mAb-J are 
shown in Figure S3 and a list of all the peptides and their sequential numbering is given in Table 
S4. A global representation of all of the changes in hydrogen exchange between mAb-J at 5 and 
60 g/L is shown in Figure 5. Relative mass difference or the differences in deuterium uptake (∆𝑚) 
between mAb-J peptides from 60 and 5 g/L samples (Eq.4) are plotted on the vertical axis and 
ordinal peptide number on the horizontal axis of the plot with: 
                                                          ∆𝑚 = 𝑚60 g/L −𝑚5 g/L                                                (Eq.1) 
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These plots show the location of protected (∆𝑚 < 0 Da) and de-protected (∆𝑚 > 0 Da) regions in 
mAb-J.  
Comparison of the level of deuteration revealed various regions within mAb-J that became 
significantly protected at 60 g/L under conditions where mAb-J was substantially self-associated. 
The protected regions are located in the variable heavy chain (VH), variable light chain (VL), and 
constant domain of the heavy chain (CH3) of the antibody.  In the heavy chain of the antibody, 
these regions cover HC 92-116 (peptide numbers 42 to 47) located in the third complementarity-
determining region of the heavy chain (CDR3H) and HC 381-408 (peptide numbers 105 to 111)  
that surrounds a region in the CH3 domain. In addition, in the light chain, a segment that became 
significantly protected (LC 39-76), peptide numbers 135 to 140, spans the second CDR of the light 
chain (CDR2L) located in the VL domain of the antibody. None of the regions in mAb-J became 
significantly more flexible (higher HX) at high protein concentration. 
Thus, significant decreases in hydrogen exchange (i.e., increased protection against 
deuterium uptake) were observed upon RSA of mAb-J in two of the six CDR regions (i.e., the 
CDR2 region of the light and CDR3 region of the heavy chain) and in the CH3 domain of mAb-J. 
Figure 6 shows the protected regions mapped onto a homology model of mAb-J (for details about 
the homology model, see Materials and Methods in the Supporting Information). The segments 
that became significantly protected at high protein concentration are highlighted in yellow (Figure 
6).  A surface representation of the Fab and Fc of mAb-J is also shown in Figure 6 where protected 
segments, presumably the primary protein interface of RSA, are colored in yellow as in the ribbon 
representation. In the surface representation, the negatively-charged residues that became 
protected are colored red, the positively charged residues that became protected are blue, and 
surface exposed hydrophobic residues are colored in green. The homology model of mAb-J was 
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constructed with the in silico KOL/Padlan structure of the Fab 46 and the crystal structure of Fc 
derived from PDBID:3AVE 47 after mutations and insertion of missing residues from the mAb-J 
sequence as described in the Supporting Information. It should be noted that, while the level of 
confidence in the location and surface exposure of residues in the highly-conserved CH3 domain 
is high, the exact location and surface exposure information of the VH and VL domain residues 
may be less reliable. 
To confirm that the changes in hydrogen exchange resulted from specific interactions 
between mAb-J monomers rather than non-specific interactions arising from non-ideality at high 
protein concentrations, we compared a mAb-J control at 60 g/L to mAb-J samples at 60 g/L 
containing control buffer and either 100 mM arginine or 100 mM NaCl (Figure S4). As described 
above, arginine and sodium chloride both inhibited self-association as indicated both by decreased 
hydrodynamic diameter (Figure 1A) and reduced solution viscosity (Figure 3). The regions of 
mAb-J that became significantly protected under control solution conditions were the same regions 
that became protected at high protein concentration when compared to low concentration non-
associating control (Figure 5), confirming the validity of the analysis. Stronger protection in the 
control mAb-J sample when compared to that with 100 mM arginine reflects arginine’s more 
potent action at disrupting mAb-J RSA in comparison to 100 mM NaCl. Regions in the heavy 
chain, HC 87-93 (peptide number 41) and LC 35-38 (peptide number 132) became significantly 
more rigid upon addition of arginine at 60 g/L (see Figure S4A). These regions are at the N-
terminal of the RSA interface present in VH and VL domains of the antibody. A decrease in local 
flexibility upon addition of arginine could be attributed to allosteric effects of the arginine-
inhibited self-association. 48  
We also compared hydrogen exchange by mAb-J at 60 g/L in control buffers containing 
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either 100 mM NaCl or 100 mM arginine to a sample of mAb-J at 5 g/L in control buffer without 
any additional charged solutes. Difference plots comparing HX between these samples are shown 
in Figure S5. None of the 182 peptides analyzed in this experiment became either protected or de-
protected. These observations suggest that a solution of mAb-J containing additional 100 mM 
NaCl or 100 mM arginine at 60 g/L protein concentration behaves similarly to a dilute solution of 




MAbs may form intermolecular protein-protein interaction networks at high protein concentration. 
20, 21 These large, associated protein complexes typically cause a dramatic increase in solution 
viscosity that can introduce a number of challenges to their pharmaceutical use. This work has two 
primary goals: 1) to determine the macroscopic nature of protein-protein interactions between 
mAb-J monomers at high protein concentration; and 2) to further delineate the underlying 
molecular mechanisms that promote RSA by mapping the protein interface of interaction at high 
protein concentration.  
To investigate the nature of reversible non-covalent protein-protein interactions, their 
extent was measured indirectly by measuring the hydrodynamic diameter and dynamic viscosity 
of mAb-J solutions at varying pH values, with and without charged and uncharged solutes. The 
hydrodynamic diameter and the viscosity of mAb-J decreased as ionic strength increased. Based 
on fitting static light scattering measurements to various association models, we found that a 
monomer-dimer-tetramer equilibrium provided the best fit for mAb-J self-association. A sharp 
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decline in monomer mole fraction with increasing protein concentration and a negative A2 value 
at low ionic strength was observed. On the contrary, a slower decrease in the monomer mole 
fraction and positive A2 values in the presence of additional NaCl or arginine was observed. A 
decrease in the propensity of mAb-J to form protein-protein complexes with an increase in ionic 
strength can be attributed to electrostatic attractive interactions being the dominant contributor 
governing protein-protein interactions between mAb-J monomers. 49-51 Based on DLVO 
(Derjaguin-Landau-Verwey-Overbeek) theory, as ionic strength is increased the Debye screening 
length (the thickness of the electrical double layer surrounding the protein molecule) shortens and 
the effective charge on the mAb will decrease due to electrostatic charge screening. 52 Under such 
conditions, the strength of both repulsive and attractive electrostatic interactions decreases, thereby 
causing disruption of intermolecular protein interactions between mAb-J molecules.  
The predicted isoelectric point for mAb-J is ~7.3. Increasing the pH from 5.0 to 7.0 
promoted the extent of protein-protein interactions between mAb-J monomers. This observation 
contradicts predictions based on the electroviscous effect that describes the viscosity of dilute 
colloidal solutions as directly proportional to the electrostatic charge on the molecule. 53 According 
to the electroviscous effect, solution viscosity should decrease as the pH is moved towards the pI 
of the protein where the overall net charge on the molecule approaches its minimum. 54-56 However, 
we observed the opposite. Yadav et al 49 also observed an increase in the extent of mAb1 
association near the pI of the antibody. In another report, Yadav et al 50 showed that the mutual 
diffusion coefficient for an antibody decreased as the pH value approached the pI of the protein. 
This observation was attributed to an increase in the extent of specific protein-protein interactions 
between mAb-2 molecules near the pI. At a pH value below or above the pI, the overall net charge 
on a protein will be either positive or negative, respectively. Away from the pI, the electrostatic 
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repulsive interactions between protein molecules dominate and contributions by attractive dipolar 
interactions are weakest. At the pI, although the overall net charge on the protein reaches its 
minimum, thus decreasing global intermolecular repulsions, large numbers of charged amino acids 
can still be present at the surface. These charged side chains, if present in a specific distribution, 
can cause formation of localized charged patches on the protein surface. Charged patches on the 
protein surface can lead to spatial reorientation of protein molecules, which might initiate 
favorable dipole-dipole and charge-dipole interactions between protein molecules. 49 At high 
protein concentrations the intermolecular distances between protein molecules decrease to a few 
Angstroms. Around the pI, where intermolecular repulsive interactions reach a minimum, short-
ranged and non-specific attractive interactions between surface-exposed hydrophobic residues, 
hydrogen bonding, and van der Waals interactions can also become significant contributors to 
intermolecular protein-protein interactions. These attractive non-covalent interactions could cause 
the monomers to form protein-protein associated complexes that further cause a dramatic increase 
in solution viscosity at high protein concentrations.  
 The addition of sugars and polyols has been shown to affect protein structure and protein-
protein interactions. 57, 58 Our results (Figures 1B and 2D) showed both sucrose and trehalose 
enhanced the extent of protein-protein interactions as reflected by increased hydrodynamic 
diameter and solution viscosity of mAb-J. Sugars are preferentially excluded from the protein 
surface, causing water molecules to populate around protein domains. Accumulation of water at 
the surface produces an unfavorable increase in protein chemical potential. 59, 60 To counter such 
thermodynamically unfavorable interactions between apolar side-chains and water molecules, the 
protein structure responds by minimizing the exposed surface area, leading to lower preferential 
exclusion. Thus, sugars are often added to protein solutions to increase protein conformational 
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stability. At high protein concentrations, however, where the intermolecular distances between 
protein monomers are relatively shorter, preferential exclusion can also lead to formation of 
reversible (or potentially irreversible) protein-protein interactions because the interactions 
decrease solvent exposure, thereby lowering the extent of unfavorable preferential exclusion. 
While stabilizing, added sugars can also contribute to the formation of protein-protein complexes 
that cause an enhanced effect on the exponential increases in solution viscosity at high protein 
concentrations, as seen here. 
To map the protein interfaces of mAb-J self-association at high protein concentration, we 
used HX-MS to compare associated and non-associated mAb-J. Our results show that the observed 
reversible protein-protein interactions involve both the Fab and Fc regions of the antibody. 
Hydrogen exchange in regions covering HC 92-116 in VH domain spanning CDR3H, LC 39-76 in 
VL domain spanning CDR2L and HC 381-408 in the Fc (CH3) domain of the mAb-J significantly 
decreased (i.e., increased protection) when the concentration of mAb-J was increased from 5 to 60 
g/L. Based on this HX data, we conclude that these protein regions are the primary site of reversible 
interactions between mAb-J monomers. This is supported by control HX experiments comparing 
60 g/L mAb-J with and without viscosity-lowering additives (Figures S4 and S5) where the same 
regions in mAb-J in control buffer became significantly protected. Based on a lower resolution 
biophysical analysis, we found that adding NaCl or arginine decreased association, suggesting 
involvement of electrostatic interactions between oppositely-charged patches at the interface. The 
regions spanning CDR2L in the VL domain, LC 39-76 
(YQQLPGTAPKLLIYDNFNRPSGVPDRFSGSKSGTSASL) and the region in the VH domain of 
mAb-J that spans the CDR3H, HC 92-116 (AVYYCATVMGKWIKGGYDYWGRGTL) will each 
have a charge of +2 at pH 6.0. In contrast, the region in the Fc domain of the antibody that became 
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significantly protected, LC 381-408 (IAVEWESNGQPENNYKTTPPVLDSDGSF) will have a 
net charge of −4 at pH 6.0.  
It should be noted, however, not all of the charged side-chains at the protein interface are 
expected to be solvent exposed. To correctly predict the net surface charge at the protein interface, 
only solvent-accessible charged side-chains should be considered. Figure 6A shows a homology 
model of mAb-J with the HX-protected regions colored in yellow. Here, only the solvent 
accessible surfaces of Fab and Fc regions of mAb-J are shown in Figures 6B and 6C. Residues 
containing charged side chains at the Fab and Fc interfaces of mAb-J are colored in blue (positively 
charged) and red (negatively charged). Among all the charged side-chains, the lysine residue 
towards the N-terminal of the VH domain interface (K102) and two arginine and one lysine 
residues (R507, R514 and K519) in the VL domain interface are solvent exposed. Only one of the 
two aspartic acid residues in the VL domain (D503) has a solvent exposed side chain. In the Fc 
interface, however, all of the positively and negatively charged side chains are either fully or 
partially solvent exposed. As mentioned previously, confidence in the homology model is lowest 
in the variable regions, however, CDR loops are primarily unstructured, dynamic, and solvent 
exposed 61 thus it is reasonable to expect that the lysine and arginine side-chains will be accessible. 
The interface on the surfaces of the VL and VH domains of the antibody forms a patch with a net 
positive charge and the interface on the surface of the Fc region has a net negative charge. The 
presence of charge anisotropy between the protein interfaces of the Fab and Fc regions is consistent 
with the biophysical characterization of mAb-J RSA that suggests protein association is initiated 
by long-range electrostatic attractive interactions.  
The involvement of the CDR in the Fab region in intermolecular protein-protein 
interactions has been well documented. 21, 22, 24, 25, 39 Few reports, however, have implicated the Fc 
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region in mediating mAb RSA. 23, 26 Nishi et al. used low resolution biophysical tools to show the 
involvement of the Fc region in mediating reversible Fc-Fc interactions between mAb monomers. 
Chaudhri et al. used coarse-grained molecular dynamic simulations to probe the nature of site-site 
interactions between mAb monomers. Significant intermolecular Fab-Fc interactions were present 
in one of the two antibodies that they simulated. Ido et al, 62 using frequency modulation atomic 
force microscopy (FM-AFM), showed that mAbs self-assemble into rosette-shaped hexamers 
through lateral Fc-Fc interactions between monomers. Based on our HX measurements, mAb-J 
monomers could undergo association through Fab-Fab, Fc-Fc or Fab-Fc interactions. However, 
due to the presence of opposite charges on Fab and Fc domain interfaces of mAb-J, Fab-Fc 
mediated protein-protein interactions seem most likely.  
To the best of our knowledge, this report provides the first direct interfacial mapping of 
mAb RSA at high protein concentration with protein interfaces in both Fab and Fc region of the 
antibody. The protein sequence of the mAb-J Fc interface is conserved between all antibodies of 
IgG1 subclass. Thus, the negatively-charged patch would be present in all IgG1s. In contrast, the 
corresponding interface in the Fab region spans the CDR2L and CDR3H regions of this specific 
antibody. Amino acid sequences of the hypervariable regions or the CDR regions differ greatly 
between different mAbs. A special case of specific orientation and distribution of charged, 
aliphatic and aromatic amino acids in the Fab region interface of mAb-J might contribute 
significantly to initiating favorable interactions between Fab and Fc domain interfaces of mAb-J. 
Another observation of interest was the more potent action of arginine compared to NaCl 
on decreasing the size of mAb-J complexes and the viscosity of the mAb-J solutions. Our results 
showed arginine caused a greater decrease in hydrodynamic diameter and solution viscosity than 
NaCl, as measured by DLS, viscosity, and CG-MALS (Figures 1A, 2AB, and 3, respectively). 
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Analysis of the static light scattering data showed that arginine completely disrupts the interactions 
between mAb-J monomers, and that its effect is stronger than the effect of NaCl, which still allows 
formation of dimers and tetramers of mAb-J. These results suggest that, although the interactions 
between mAb-J monomers are dominated by electrostatic attraction, there may also be additional 
secondary contributions by other short range non-covalent interactions, such as van der Waals 
interactions, hydrogen bonding, π-π stacking interactions and hydrophobic interactions. These 
observations collectively suggest that arginine’s effect is not limited to only electrostatic charge 
shielding and disruption of charge-charge attractive interactions.  
Arginine’s potent effect on protein-protein interactions has been previously reported by 
other researchers. 63-65 In addition to its charge-charge interactions with the ionizable side-chains 
of amino-acids, arginine has also been shown to interact favorably with the apolar and aromatic 
amino-acids. 63 Kita et al. and Arakawa et al. 66, 67 suggested that arginine penetrates the protein 
solvation shell to interact with specific amino acid side chains in the protein. Shukla et al. 
performed molecular dynamics simulations that suggested formation of favorable interactions 
between arginine co-solute and aromatic and charged side-chains present on the protein surface. 65 
Formation of favorable cation-π interactions between the guanidinium side chain of arginine and 
aromatic side chains of tryptophan, tyrosine, and phenylalanine and formation of salt bridges with 
charged side-chains of amino acids on the protein surface help to explain the more potent action 
of arginine in suppression of protein-protein interactions. 68  
In addition to possessing surface-exposed oppositely charged amino acids at protein 
interfaces in the Fab and Fc regions of the mAb-J, the patches also contain surface-exposed 
hydrophobic residues. The interaction interfaces in the VL and VH domain together contain a 
tyrosine, a phenylalanine, a valine, and an isoleucine residue that are fully or partially surface-
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exposed in the homology model. The protein interface in the Fc domain contains a tyrosine, a 
tryptophan, and a valine residue that are surface exposed. These surface-exposed aliphatic and 
aromatic residues at protein interfaces might be involved in mediating short-range non-covalent 
van der Waals and hydrophobic interactions. The effect of arginine on short-range non-covalent 
interactions in associating mAb systems is a topic currently being further evaluated in our 
laboratories. 
Our proposed model for mAb-J RSA is shown in Figure 7. Because mAb-J associates 
through Fab-Fc interactions at high protein concentrations, depending upon the kinetics of 
association, the associated species might be tetramers or the association could potentially extend 
to the formation of either linear fibrous complexes or rosette-shaped protein complexes. Higher-
order associated complexes formed at high protein concentrations would increase the shear 
modulus of the mAb solutions, causing a dramatic increase in solution viscosity.  
In conclusion, our experiments show that mAb monomers can form reversibly-associated 
protein complexes mediated through Fab-Fc interactions. We also demonstrated that, although 
mAb-J intermolecular interactions are primarily driven by electrostatic attractive interactions, 
other short-ranged non-covalent forces may also play a role in mediating complex formation at 
high protein concentrations. Our results contribute to a better understanding of the nature of mAb 
RSA at high protein concentrations. This study further supports the notion that HX-MS can 
substantial aid protein engineering and candidate selection efforts directed toward the development 
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4.6 Tables and Figures 
Figure 4.1 
 
Effects of additives and pH on the hydrodynamic diameter of mAb-J as measured by dynamic light 
scattering. (A) Addition of incremental amounts of NaCl and 100 mM arginine to the control buffer 
and (B) addition of sugars and the effect of pH on the hydrodynamic diameter of mAb-J. All 
measurements were taken at 25°C. For panel A, mAb-J was prepared at 10 g/L in control solution 
(20 mM citrate-phosphate buffer containing 30 mM NaCl at pH 6.0) containing either additional 
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NaCl (30, 60 and 100 mM) or 100 mM arginine. For panel B, additional 10% (w/v) sucrose and 
trehalose were added to the control solution with the pH adjusted to (5.0, 6.0 and 7.0). The error 





















Concentration-dependent effects of additives and pH on the dynamic viscosity of mAb-J solutions. 
Effects of (A) NaCl and (B) arginine on solution viscosity as a function of mAb-J concentration. 
Effects of (C) 10% (w/v) sucrose and trehalose and (D) pH on solution viscosity of mAb-J 
solutions at 60 g/L protein concentration. All measurements of solution viscosity were taken at 
25°C. In panels A, B and C, all samples of mAb-J were prepared in the control solution containing 
additional amounts of NaCl, arginine, or sugars. In panel D, mAb-J samples were prepared in the 
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control with pH adjusted to (5.0, 6.0 and 7.0). The error bars represent one standard deviation from 






















Effects of additives on the reversible self-association of mAb-J monomers based on analysis of 
static light scattering showing the mole fractions of monomeric (black squares), dimeric (red 
circles), and tetrameric (blue triangles) mAb-J species over a protein concentration range of 0.2-
20 g/L in (A) control solution, (B) control solution + NaCl, and (C) control solution + arginine. In 
Panel C, the mole fractions of both dimer and tetramer are superimposed at zero. Samples of mAb-
J were prepared in the control solution containing 20 mM citrate-phosphate buffer, 30 mM NaCl, 
10% (w/v) trehalose at pH 6.0 with or without additional 100 mM NaCl or arginine. Panel A, B 
and C show mean of triplicate measurements at 25°C and error bars represent one standard 










Representative deuterium uptake plots for 8 peptide segments of mAb-J. Black squares and red 
circles represent HX-MS experiments at low (5 g/L) and high (60 g/L) protein concentrations, 
respectively. The data in panel A are representative of peptides that showed no significant 
differences in hydrogen exchange kinetics between the two concentrations of mAb-J. Peptide 
segments shown in panel B are representative of peptide segments that showed significant 
protection (slowed HX) at high protein concentration. The domain location and peptide index 
number are shown in parenthesis at the top of each plot. Error bars represent one standard deviation 
from three independent HX measurements. (For deuterium uptake plots of all peptide segments of 









Differential deuterium uptake by 182 peptides at 4 different hydrogen exchange times comparing 
high (60 g/L) and low (5 g/L) concentrations of mAb-J at pH 6.0. Peptides are numbered in order 
from N terminus of the heavy chain to the C terminus of the light chain on the horizontal axis of 
the plots (see Table S4 for exact locations). The vertical axis is difference in HX between high vs. 
low protein concentrations, ∆𝑚(𝑡) = 𝑚60(𝑡) − 𝑚5(𝑡). Positive bars show peptide segments with 
faster HX at high protein concentration and negative bars indicate peptide segments with slower 
HX at high protein concentration. The dashed horizontal bars at ± 0.40 Da are the 99% confidence 
intervals. Vertical dashed lines separate boundaries of different domains of mAb-J (domains are 
listed on the top of the plot). The locations of the CDR segments are shaded in blue. Some peptides 
span more than one domain thus the boundaries are approximate. An average of three independent 















Locations of significant protection at high protein concentration mapped onto a homology model 
of mAb-J. The protected regions are colored yellow. A zoomed in surface representation of Fab 
and Fc domains of mAb-J is presented in the inset panels to the right. Surface exposed, positively 
and negatively charged residues are highlighted in blue and red, respectively, surface exposed 
hydrophobic residues are colored in green. Segments with no significant difference in HX between 







A model of mAb-J reversible self-association illustrating two possible morphologies that an 
associated mAb network could form at high protein concentrations resulting in elevated solution 
viscosity. On the left, the Fab domain of the antibody is shown in orange and the Fc is green. On 
the right homology model of mAb-J with protein interfaces of RSA colored in yellow are arranged 












Post-lyophilization biophysical characterization of mAb-J. (A) Circular dichroism (CD) spectra 
showing the effect of lyophilization process on secondary structure of mAb-J.  (B) Size exclusion 
chromatography (SEC) chromatograms comparing pre and post lyophilization mAb-J samples. (C) 
Solution dynamic viscosity measurements comparing pre- and post-lyophilization mAb-J samples 
to test the effect of lyophilization on mAb-J protein-protein interactions. Samples of mAb-J were 
prepared in control buffer containing 10% (w/v) trehalose. Error bars in panel B and C represent 





















Peptic peptide coverage map of mAb-J (A) heavy chain and (B) light chain. 182 peptide segments 




























































Deuterium uptake plots for 182 peptide segments of mAb-J comparing HX kinetics between 5 and 
60 g/L mAb-J samples (orange and red, respectively). Domain location of the peptide is given in 
parentheses. Error bars represent one standard deviation from three independent HX experiments. 




















Difference plots showing HX differences after 2760 seconds of hydrogen exchange for 182 
peptides. The plots compare mAb-J samples at 60 g/L in control containing 10% (w/v) trehalose 
with mAb-J samples at 60 g/L containing additional (A) 100 mM arginine and (B) 100 mM NaCl, 
∆m(t) = m60,no additive(t) − m60,arginine/NaCl(t). (Refer to the caption for Figure 5 for a more 








Difference plots showing relative mass differences at 2760 second exchange time-point for 182 
peptides. The plots compare mAb-J samples at 60 g/L in control containing (A) no additional 
charged additives, (B) 100 mM arginine and (C) 100 mM NaCl with mAb-J samples at 5 g/L 
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containing no additional charged additives, ∆m(t) = m60,arginine/NaCl(t) − m5,no additives(t). 








































 Monoclonal antibodies (mAbs) are one of the major classes of biopharmaceutical agents. 
However, like other protein drugs, antibodies are also prone to physical and chemical degradation. 
During their manufacture, storage and transport, antibodies encounter various external stresses 
such as heat stress, shaking, various different kinds of interfaces, administration devices, etc. These 
stresses affect both conformational and colloidal stability of antibodies and make them predisposed 
to undesirable degradation like protein aggregation, fragmentation, loss of potency and increased 
potential for immunogenicity upon administration in patients. With the recent trend of formulating 
antibodies at high protein concentrations for subcutaneous administration by patients at home, 
physical phenomenon such as reversible self-association and high viscosity have also become 
significant challenges. Transient protein-protein interactions at high protein concentrations not 
only may cause issues related to process engineering and drug delivery (e.g., high solution 
viscosity), but also have been shown to lead to increased levels of protein aggregation over time. 
Analytical tools that can provide reliable and high resolution data at high protein concentrations 
can greatly help protein engineers and protein formulators to design mutant antibodies with 
enhanced physiochemical properties that remain stable and pharmaceutically well behaved at high 
protein concentrations.                                     
Hydrogen-exchange mass spectrometry (HX-MS) provides an excellent opportunity to 
study protein-protein interactions at residue level resolution. Other physical phenomena such as 
solution non-ideality, viscosity, multiple-scattering etc. do not affect mass spectrometry operations 
and results, therefore, mass spectrometry can prove as an excellent partner for hydrogen exchange 
(HX) to study protein interactions at high protein concentrations. Recent work has also shown 
applicability of HX-MS to probe possible interactions between protein local flexibility and long 
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term physical stability. Majumdar et al1 and Manikwar et al2 tested the effect of certain 
destabilizing and stabilizing excipients on the local flexibility of a reporter peptide region in the 
CH2 domain of an IgG1 mAb that showed correlations with accelerated and longer term physical 
stability profile of that mAb.  
This dissertation further explored the utility of HX-MS as an analytical tool for potentially 
predicting mAb physical stability by drawing strong correlations between the local flexibility of 
the reporter peptide region in the CH2 domain and mAb aggregation propensity and thermal 
stability. We also developed a novel HX-MS methodology to study transient protein-protein 
interactions between mAb monomers at high protein concentrations (i.e., reversible self-
association). In this pursuit, we studied two different IgG1 mAbs (mAb-C and mAb-J) and mapped 
the protein interfaces of their reversible self-interactions. 
 
5.2 Chapter summaries and future work 
5.2.1 Chapter 2 
Chapter 2 of this dissertation examines the effect of various phenolic antimicrobial 
preservatives on an IgG1 class of monoclonal antibody (mAb). The pharmaceutically relevant 
antimicrobial preservatives (APs) m-cresol, phenol, phenoxyethanol and benzyl alcohol were 
chosen. They all are relatively hydrophobic molecules, and the extent of hydrophobicity, with m-
cresol being the most hydrophobic followed by phenol, phenoxyethanol and the least hydrophobic 
being benzyl alcohol. The thermal stability of the mAb was measured using DSC and extrinsic 
fluorescence spectroscopy. SEC was used to study the effect of APs on mAbs aggregation 
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propensity under thermal stress conditions over time. Local dynamics of mAb were then measured 
using HX-MS.  
The criteria behind choosing the APs tested in this study was their degree of 
hydrophobicity. All the APs that were tested in this study showed a destabilizing effect on the 
mAb. The most hydrophobic AP, m-cresol, showed the biggest effect on mAb physical stability 
of as well as aggregation propensity, followed by phenol, phenoxyethanol and the least 
destabilizing AP, benzyl alcohol. Each of these APs also caused changes in the local flexibility of 
the mAb. A trend of small increases in flexibility was observed with all of the APs, however, 
majority of such changes were not significant. Deuterium uptake values for all mAb-4 peptides at 
all four time-points were normalized to their peptide lengths and added to get a global deuterium 
uptake value for each AP. The difference between the global deuterium uptake values of the APs 
and control strongly correlated with the physical stability data and hydrophobicity of the APs.  
These global increases in flexibility could indicate towards a mechanism of mAb destabilization 
that is not centralized to any one domain. However, a peptide segment in the CH2 domain (HC 
237-254) showed significant increase in local flexibility upon addition of APs and this increase in 
local flexibility showed an excellent correlation to the mAb physical stability and aggregation 
propensity trends in the presence of APs. Interestingly, increase in mAb local flexibility in HC 
237-254 also correlated with the level of hydrophobicity of the tested phenolic APs.  
 The utility of tracking the flexibility differences in the CH2 region hotspot peptide segment 
(HC 237-254) using HX-MS has been demonstrated previously1-4. This study in addition to 
strengthening this argument also showed that increasing levels of physical destabilization induced 
by excipients correlated with flexibility trends in the aggregation hot-spot peptide segment which 
further demonstrates the utility of HX-MS in conducting quantitative analysis of physical 
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destabilization in the presence of excipients for mAbs. Pharmaceutical excipients are usually 
categorized into various categories and experiments using various excipients to further explore the 
utility of HX-MS to predict long term stability in their presence are currently being conducted in 
our laboratories. A high-throughput HX-MS method to screen various formulation combinations 
or pharmaceutical excipients involving global deuterium uptake as well as the aggregation hot-
spot regions in the antibody structure may be a promising addition to the formulation development 
toolkit. In addition to physical stability, mAbs can also undergo degradation through chemical 
destabilization. Investigation of local flexibility shifts within the antibody structure upon chemical 
modification of specific amino-acids, and correlations to differences in conformation stability and 
changes in the aggregation propensity upon long term storage of the mAb, will help to develop a 
better understanding of mAb degradation pathways and mechanisms.  
 
5.2.2 Chapter 3 
Protein-protein interactions can have serious implications towards the pharmaceutical 
product stability and immunogenicity profile of therapeutic protein products5,6. High protein 
concentration formulations are necessary to develop for subcutaneous delivery of mAbs.  At high 
protein concentrations, however, due to the presence of solvent exposed patches of hydrophobic 
residues or asymmetrically charged residues on protein surfaces, certain mAbs molecules undergo 
transient protein-protein interactions and form oligomeric networks. Transient protein networks at 
high protein concentrations can cause significant increases in protein solution viscosity which in 
turn causes challenges related to process development, drug delivery and protein aggregation 
overtime. High-resolution characterization and mapping of such transient antibody reversible self- 
interactions can be a significant challenge as most of the classical techniques like NMR and X-ray 
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crystallography fail to provide reliable data for antibodies in pharmaceutical dosage forms due to 
various analytical limitations. This chapter describes a novel HX-MS methodology to study local 
flexibility and protein reversible self-associations at high protein concentrations. The extent of 
antibody reversible self-interactions was measured using low-resolution biophysical tools such as 
DLS, chemical-crosslinking and cross-linking. The IgG1 mAb tested in this study showed increase 
in self-association propensity with increase in pH (i.e., solution pH approaching the pI value of the 
mAb), ionic strength and with decrease in temperature. These observations collectively indicated 
towards a reversible self-associating system initiated by hydrophobic interactions.  
To map the protein interface of mAb self-association, mAb-C at 60 mg/mL was compared 
to 5 mg/mL (associating sample vs non-associating sample) using HX-MS. Significant protection 
in deuterium uptake was observed in certain peptides segments in the VH and VL domain, primarily 
within sequences spanning the CDR2L and CDR2H regions of the antibody. Both of these regions 
were found to be rich in hydrophobic amino-acids upon closer examination of the primary 
sequence of the antibody. Three histidine amino-acids were also a part of the interface of sequence 
adjacent to the interface. These observations showed good correlations with the biophysical 
characterization studies of the mAb reversible self-association and its dependence on solution pH. 
Interestingly, certain peptide segments showed significant increase in local flexibility under self-
associating conditions. Increase in the local flexibility of peptide sequences in the VH and CH2 
domains of the antibody at high protein concentration was regarded as distant dynamic coupling 
effects of antibody reversible self-association. 
 The data presented in this study was later used as a guide for designing mutant versions of 
mAb-C by other researchers where they were able to design molecules with enhanced 
physiochemical properties, decreased association potential and lower viscosity at high protein 
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concentrations7. Molecular dynamics (MD) docking studies and computer simulations of protein 
self-associations to understand how certain protein primary sequences influence the extent of 
protein-protein interactions will further extend our knowledge concerning such phenomenon. 
Correlations between HX-MS observations and MD simulations will help in explaining 
correlations between local flexibility of the interfaces, nature of amino-acid makeup and affinities 
of associations. 
 
5.2.3 Chapter 4 
The work presented in chapter 3 was extended in chapter 4 to explore the reversible self-
association behavior of a monoclonal antibody that showed a completely distinct mechanism of 
transient protein associations. The IgG1 mAb, “mAb-J”, showed increased propensity of self-
association and reversible oligomerization upon decrease in solution ionic strength and at solution 
pH near the pI of the mAb (~7.4), indicating an electrostatic attractive interactions driven self-
association. Previous studies have experimentally shown that mAbs reversibly-self associate 
through either Fab-Fab or Fc-Fc contacts points between patches of exposed charged or 
hydrophobic amino-acids8-12. Similarly to chapter 3, low and high protein concentrations of mAb-
J were identified (5 and 60 mg/mL) using DLS, CG-MALS and viscosity measurements. Both low 
and high protein concentration samples were then subjected to HX-MS analysis and the protein 
interface of association was mapped at a residue level resolution. Significant protection in 
deuterium uptake was observed in two continuous interfaces in the VH and VL domains (spanning 
CDR3H and CDR2L loops) and CH3 domain in the Fc fragment of mAb-J. Both, CDR3H and 
CDR2L interfaces in the Fab domain contained several exposed positively charged amino-acids 
and the overall charge on the interface was positive, however, the Fc domain interface was 
285 
 
negatively charged with several exposed negatively charged amino-acids. This observation 
correlated very well with the low-resolution characterization of mAb-J self-association and 
indicated towards an association even involving Fab-Fc interactions driven by electrostatic 
attractive interactions. Interestingly, no distant dynamic coupling effects, where certain regions of 
mAb-J showed increased local flexibility under association promoting conditions, were observed 
which may potentially be related to the more extensive network of interactions via the Fab-Fc 
mechanism of RSA of this mAb. 
 The results from this chapter, experimentally present the first case of Fab-Fc interactions 
driven reversible self-association of an IgG1-mAb. This also was the first example of experimental 
mapping of Fab-Fc interactions at a peptide level resolution. Site-specific mutagenesis studies 
geared towards mutating residues in the interface to develop stable mutants of mAb-J with superior 
physicochemical and rheological properties at high protein concentrations should be planned for 
the future. Similarly, to chapter 3, MD simulations and docking studies can strengthen the 
correlations between HX-MS studies and low-resolution biophysical characterization studies of 
transient self-association events. More user-friendly and easy to use HX-MS methodologies to 
study mAb local flexibility and protein-protein interactions will be a great addition and 
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